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Chapter 1: Introduction- Setting the scene 
It is now widely recognised that prevalence of type 2 diabetes is on the rise to 
a pandemic proportion. The World Health Organisation (WHO) estimates that 
there is 422 million people with diabetes (WHO, 2016a) and the global 
prevalence of diabetes was 8.5% in 2014 (mainly due to rise in type 2 
diabetes) and reduced physical activity and poor diet is implicated as the most 
likely explanation (WHO, 2016b). Traditionally, physical activity and physical 
fitness has been linked with health; earliest evidence of exercise for health 
promotion stems from ancient China in 2’500 BC (Hardman and Stensel, 
2003). Conversely, the widely available evidence also supports the conclusion 
that physical inactivity is one of the most important public health menace facing 
the 21st century and, may even be the most significant (Blair, 2008).   
Furthermore, the worldwide demographics has changed; with increased life 
expectancy and ageing population, comes its own chronic health issues and 
economic implications (Phillips, 2012). Supporting this, Knoops et al., reported 
that 580 million people worldwide are over 60 years and this figure is expected 
to increase to 1000 million by 2020 (Knoops et al., 2004) and  to 2.1 billion by 
2050 (United Nation, 2017). Worryingly, one of the significant and most 
visually apparent changes with ageing is decreased muscle mass and function 
loss and historically, this concept has been supported by various researchers 
(Evans and Lexell, 1995; Narici and Maffulli, 2010). This undesirable loss of 




muscle mass due to ageing is termed ‘Sarcopenia’ (Rosenberg, 1997)(see 
section 1.1). Various theories (including some putative) have been put forward 
to explain the cause of sarcopenia: 1) Genetic predisposition; 2) Alteration in 
muscle protein turnover; 3) changes in hormones and cytokines (such as 
androgens, insulin, growth hormone, insulin like growth factor-1 (IGF-1) and 
interleukin-6 (IL)-6); 4) Loss of innervation to the muscle; 5) Impaired 
vascularisation of the muscles; 6) Increased oxidative stress; 7) Poor nutrition 
and 8) Physical inactivity (Phillips, 2012). Irrespective of operational definitions 
and causative theories, what is clear however is that, there is high prevalence 
of low muscle mass and poor muscle strength with ageing (Kalyani, Corriere 
and Ferrucci, 2014). It is now clear that with ageing, the prevalence of chronic 
diseases such as diabetes, obesity and cardiovascular diseases increase and 
further, approximately one-third of adults aged over 65 years have diabetes 
(46% undiagnosed)(Kalyani and Saudek, 2010). Moreover, up to 70% of 
adults with diabetes have difficulties in carrying out activities of daily life, more 
evidently lack of lower extremity mobility limitations, and diabetes is 
highlighted as a significant risk factor for most geriatric syndromes (Kalyani 
and Saudek, 2010). Consequently, to improve public health, it is paramount to 
understand the factors responsible for the functional disability (and 
mechanisms of sarcopenia) in older population, especially with diabetes 
(Kalyani and Saudek, 2010).  
Continuing with the earlier theme, insulin resistance (IR) is noted to be more 
prevalent in older compared to younger individuals and is further associated 




with frailty (a geriatric condition of physiological vulnerability to stressors) 
leading to disability and mortality (Fried et al., 2001; Bandeen-Roche et al., 
2006). Moreover, hyperglycaemia (noted in IR state) is strongly linked to the 
development of frailty and incident mobility limitations, potentially mediated by 
loss of muscle mass (Kalyani et al., 2012). Evidence from large cross-sectional 
and longitudinal studies report accelerated loss of muscle mass in individuals 
with persistent IR (i.e. people with diabetes)(Park et al., 2007, 2009; Kuo et 
al., 2009; Volpato et al., 2012; Kalyani et al., 2013; Leenders, Verdijk, van der 
Hoeven, et al., 2013). Emerging evidence suggests type 2 diabetes 
accelerates skeletal muscle loss, possibly due to mechanisms specific to 
diabetes per se. Crucially, muscle specific insulin resistance due to disuse 
atrophy (common in old age and frailty) appears to drive further muscle loss 
independent of other mechanisms known to cause muscle insulin resistances. 
However, molecular mechanism explaining this observed complex relationship 
is still poorly understood. So, further mechanistic research is needed to 
evaluate these molecular processes and pathways (see section 1.3 for 
details). 
On a separate note, the paradigm that testosterone increases skeletal muscle 
mass is well established (Bhasin et al., 1996a) and on the contrary, its 
deficiency causes decreased appendicular skeletal muscle, decreased lean 
tissue and increased body fat (Boxer et al., 2005). Furthermore, testosterone 
deficiency is common in diabetes and is partly explained by insulin resistance 
(Grossmann et al., 2008). Conversely, insulin resistance in men is associated 




with reduced Leydig cell testosterone production (Pitteloud, Hardin, et al., 
2005). Yet, the causality of this relationship between low testosterone and 
metabolic disease (type 2 diabetes and metabolic syndrome) is complex, with 
hypogonadism-induced obesity and obesity-induced hypogonadism acting bi-
directionally effecting the disease pathology (Daniel M Kelly and Jones, 2013). 
As with disuse muscle atrophy and insulin resistance, the molecular 
mechanisms explaining the interplay between hypogonadism (low 
testosterone) and insulin resistance is still poorly understood. Hence, further 
research investigating these complex networking is warranted.  
1.1 Sarcopenia: its current burden and effects on ageing population: 
Ever since Rosenberg first coined the term ‘sarcopenia’ in 1989, it has been 
the topic of much interest to researchers and also one among the largest public 
health issues facing the ageing population world-wide today (Rosenberg, 
1989). The European Sarcopenia Working Group (ESWG) defines sarcopenia 
as a “syndrome characterised by progressive loss of muscle mass and 
strength with a risk of adverse outcomes” (Cederholm, 2009). Prevalence of 
sarcopenia is estimated at 30% in population over 60 years and rises to more 
than 50% in those over 80-year-old (Gweon, Sung and Lee, 2010). 
Furthermore, it is estimated that about 1 in 4 elderly people will have a serious 
fall each year due to sarcopenia (Doherty, 2003). Moreover, skeletal muscle 
acts as a major organ for glucose uptake (Kraegen et al., 1990) and 
contributes significantly to basal energy expenditure (Radegran, 1999). It is 




not surprising that sarcopenia is defined as a geriatric syndrome (i.e., a 
complex condition arising in ageing population which is very common and 
costly to manage) (Cederholm, 2009). Hence to reduce the risk of falls in 
elderly and to preserve the strength of the muscle necessary for daily activities, 
it is paramount that we aim to improve the incidence of sarcopenia (Doherty, 
2003). 
1.1.1 Ageing and Protein metabolism: 
1.1.2 Aetiology and mechanism of skeletal muscle loss in ageing: 
The aetiology of skeletal muscle loss due to ageing is a complex phenomenon 
and involves changes in central and peripheral nervous system and also 
alterations in hormonal, nutritional, immunological and physical activity (Narici 
and Maffulli, 2010). It has been reported that changes both in systemic and 
cellular properties plays a vital role in onset of sarcopenia. These systemic 
changes include increase in oxidative stresses, production of pro-inflammatory 
cytokines and decreased production in anabolic hormones and eventually 
these leads to cellular changes such as myocyte apoptotic signalling, altered 
protein synthesis and/ or turnover and impaired satellite cell function (Buford 
et al., 2010). So mechanistically, sarcopenia can be attributed to 1) decreased 
muscle protein synthesis (MPS) and 2) increased muscle protein breakdown 
(MPB) (Altun et al., 2010). 
 




1.1.3 Nutrition intervention and skeletal muscle metabolism in aging population: 
1.1.3.1 Signalling pathways involved in muscle protein metabolism: 
Mammalian target of rapamycin (mTOR) is the major system for stimulation of 
MPS. This system senses four important stimuli or pathways responsible for 
the regulation of MPS, which are: 1. Insulin and insulin-like growth factor-1 
(IGF-1) through IRS (Insulin receptor substrate) and PI3K 
(Phosphatidylinositol-3) pathway; 2. Amino acids through PI3K pathway, 3. 
Energy metabolism through AMPK (AMP activated protein kinase) pathway 
and 4. Resistance exercise through PLD (Phospholipase D) pathway 
(Wackerhage and Ratkevicius, 2008). Conversely, ubiquitin proteasome 
pathway (UPP) plays a major role in the regulation of MPB (Lecker, Goldberg 
and Mitch, 2006), supplemented by other system such as calcium activated 
(ATP–independent) proteolytic process and caspase-3 enzyme responsible 
for the initial cleavage of muscle myofibrils and actomycin (Glover, Yasuda, M. 
A. Tarnopolsky, et al., 2010). 
1.1.4 Nutrition and muscle protein metabolism: 
Oral nutrition supplement remains a mainstay strategy to oppose the muscle 
loss in elderly (Milne, Avenell and Potter, 2006). Milne et al., concludes 
following his meta-analysis of 55 trials that showed positive weight change can 
be attained by giving oral protein and energy supplements to older people in 
the setting of hospitalised patients, long-term care patients and for elderly 




living at home (Milne, Avenell and Potter, 2006). Furthermore, Gweon et al., 
reported that protein consumption of 0.08-0.8 g/kg body weight was 
associated with increased muscle protein fractional synthesis rate (FSR) in 
elderly and healthy young subjects (Gweon, Sung and Lee, 2010). It has been 
demonstrated that consumption of 1.2 -1.6g of protein per kg of body weight – 
or protein ingestion in excess of 12% of total calorie intake-can reduce the loss 
of muscle mass and older adults who consumed highest amount of protein lost 
least amount of muscle weight compared to adults consuming lowest amount 
of protein during a 3-year study (Houston et al., 2008). 
  




1.2 Human skeletal muscle disuse atrophy: effects on muscle protein synthesis, 
breakdown and insulin resistance - a qualitative review 
1.2.1 Background: 
The ever-increasing burden of an ageing population and pandemic of 
metabolic syndrome worldwide demands further understanding of the 
modifiable risk factors in reducing disability and morbidity associated with 
these conditions. Disuse skeletal muscle atrophy (sometimes referred to as 
“simple” atrophy) and insulin resistance are ‘non-pathological’ events resulting 
from sedentary behaviour and periods of enforced immobilisation e.g., due to 
fractures or elective orthopaedic surgery. Yet, the processes and drivers 
regulating disuse atrophy and insulin resistance and the associated molecular 
events remain unclear – especially in humans. The aim of this review is to 
present current knowledge of relationships between muscle protein turnover, 
insulin resistance and muscle atrophy during disuse, principally in humans. 
Immobilisation lowers fasted state muscle protein synthesis (MPS) and 
induces fed-state ‘anabolic resistance’. While a lack of dynamic 
measurements of muscle protein breakdown (MPB) precludes defining a 
definitive role for MPB in disuse atrophy, some proteolytic “marker” studies 
(e.g., MPB genes) suggest a potential early elevation. Immobilisation also 
induces muscle insulin resistance (IR). Moreover, the trajectory of muscle 
atrophy appears to be accelerated in persistent IR states (e.g., Type II 
diabetes), suggesting IR may contribute to muscle disuse atrophy under these 




conditions. Nonetheless, the role of differences in insulin sensitivity across 
distinct muscle groups and its effects on rates of atrophy remains unclear. 
Multifaceted time-course studies into the collective role of insulin resistance 
and muscle protein turnover in the setting of disuse muscle atrophy, in 
humans, are needed to facilitate the development of appropriate 
countermeasures and efficacious rehabilitation protocols. 
1.2.2 Human Skeletal Muscle Tissue: 
Skeletal muscle tissue represents the largest protein/ amino acid (AA) 
reservoir in the human body (Bonaldo and Sandri, 2013). Skeletal muscles are 
not only crucial for locomotion but also represent the body’s largest 
metabolically active tissue, glucose disposal site and fuel reservoir for other 
organs in fasting and pathological conditions (i.e., hepatic supply of amino 
acids for gluconeogenesis). Loss of muscle mass occurs with many common 
illnesses (Evans, 2010) including cancers (Stephens et al., 2010), renal/heart 
failure (Gordon, Kelleher and Kimball, 2013), sepsis (Gordon, Kelleher and 
Kimball, 2013), muscle genetic diseases (Sandri, 2010) and 
neurodegenerative disorders (Verdijk et al., 2012). Muscle atrophy also occurs 
in otherwise healthy individuals under situations of reduced neural input - such 
as during immobilisation e.g. due to leg casting for fractures (Phillips, Glover 
and Rennie, 2009a), bed-rest, spinal cord injury (Castro et al., 1999) and 
during 'ageing' (i.e. sarcopenia) (Evans and Lexell, 1995). The main 
environmental determinants of muscle mass in adulthood are exogenous 




essential amino acids (AA) (needing to be acquired through dietary protein 
intake), Newton’s gravity and locomotion (DeFronzo and Tripathy, 2009). 
Indicative of this, lack of energy intake during starvation (Rennie et al., 2010), 
inactivity (Wall, Dirks and Van Loon, 2013), spaceflight (Vandenburgh et al., 
1999) or limb immobilisation (Phillips, Glover and Rennie, 2009b) all lead to a 
reduction in muscle cross sectional area, an associated loss of function, and 
muscle insulin resistance. Crucially, loss of muscle mass is associated with 
greater morbidity and mortality (Sasaki et al., 2007), reduced independence, 
especially in older populations (Leenders, Verdijk, Van Der Hoeven, et al., 
2013) and this is accelerated in type 2 diabetes (Leenders, Verdijk, van der 
Hoeven, et al., 2013) 
1.2.3 Overview of disuse atrophy, countermeasures and muscle metabolism: 
Disuse atrophy is often referred to as “simple atrophy” in that atrophy is 
intrinsic to the muscle(s) specifically exposed to disuse; that is, disuse atrophy 
is not a systemic condition. Countermeasures for disuse atrophy are limited 
but include forms of mechanical loading (Wilkinson et al., 2008) such as 
exercise/ electrical stimulation (Wall et al., 2012), passive physiotherapy 
(Fowles et al., 2000) and harnessing the adjunct anabolic effects of protein 
nutrition (T. A. Churchward-Venne et al., 2012). Ascertaining an 
understanding of the mechanisms of disuse atrophy - particularly in relation to 
the regulation of muscle protein synthesis (MPS) and breakdown (MPB) - is 
important for designing countermeasures or rehabilitation protocols (Reggiani, 




2015). Furthermore, despite accumulating evidence that physical inactivity 
plays a causative role in development of non-communicable diseases such as 
obesity, insulin resistance, type 2 diabetes and dyslipidaemia (Atherton et al., 
2016), the mechanistic role of muscle insulin resistance (IR) in driving muscle 
atrophy in the context of ‘simple disuse’ remains unclear (Atherton et al., 
2016). This review will focus on identifying different models of human disuse 
atrophy, the degree of muscle and strength loss and the regulation of muscle 
protein turnover and muscle IR. Future translational studies to mitigate disuse 
atrophy will rely upon robust evidence being present in humans of active 
mechanisms (often of putative mechanisms that have been pre-identified in 
animals). As such, this review will focus mainly on current evidence from 
clinical studies. 
1.2.4 The impacts of experimental disuse on muscle mass and strength loss in 
humans: 
A plethora of clinical studies have investigated the degree of muscle loss in 
humans exposed to disuse. The most frequent employed models to study 
disuse atrophy in humans are unilateral limb suspension (ULLS) using a knee 
brace or cast, and bed rest; other scenarios include spinal cord injury and 
spaceflight. In terms of muscle mass, the observed rate of decline in muscle 
size (cross sectional area (CSA)) for each day of ULLS in knee extensors was 
~0.40% and ~0.36% for plantar flexors following 42 d of unloading (Hackney 
and Ploutz-Snyder, 2012). Other studies have demonstrated losses of muscle 




strength and mass early on in disuse, i.e. 5 d of cast immobilisation lead to 
~3.5% reductions in quadriceps CSA and ~9% in strength (Dirks et al., 2014). 
This had progressed to ~8% reductions in CSA and ~23% reductions in 
strength by 14 d (Wall, Dirks and Van Loon, 2013). Additionally, Suetta et al. 
reported ~10% reductions in myofibre area and ~13% decreases in strength 
after just 4 d progressing to ~20% reductions in myofibre area and strength 
after 14 d of ULLS (Suetta et al., 2012, 2013). A further study reported 
decreases in mid-thigh CSA of 11% following 28 d of bed rest (Brooks et al., 
2008). Lastly, a study by Castro et al., showed muscle CSA to be ~45% less 
compared to able-bodied controls 6-weeks after complete spinal cord injury 
(Castro et al., 1999). Adding to the above constellation, Gibson et al., studied 
men who were immobilised following tibial fracture (thus having 6- weeks of 
casting) and reported reductions in quadriceps CSA of ~17% (Gibson et al., 
1987). Furthermore, Alkner et al., reported that 90 d bed rest led to ~10% and 
~16% reductions in quadriceps and triceps surae mass after 29 d, with rates 
of weekly loss slowing during the last 2 months to roughly half that observed 
during the first month (Alkner and Tesch, 2004). Finally, muscle CSA 
decreased by ~5% (de Boer et al., 2007; Glover, Yasuda, M. A. Tarnopolsky, 
et al., 2010) at 14 d and 10%, at 23 days (23 d), i.e. 0.5% a day following ULLS 
(de Boer et al., 2007). Collectively, these studies indicate a varying degree of 
rates of disuse muscle atrophy, depending on the duration and nature of 
immobilisation but also measurement techniques i.e. MRI/DXA/ultrasound/ 
myofibre CSA; however, it appears atrophy occurs more rapidly in first 3-14 d 




of unloading and eventually reaching a nadir where further loss of muscle 
occurs at a slower rate despite continued unloading of muscle (Bodine, 2013). 
Differences in the rate of muscle atrophy have also been observed according 
to different muscle and fibre types as well as the mode of immobilisation. For 
example, after prolonged disuse (~180 d of space flight), loss of fibre size and 
force was reported in the soleus and gastrocnemius muscles with the order of 
atrophy (greatest-least) being: soleus type I> soleus type II > gastrocnemius 
type I > gastrocnemius type II (Fitts et al., 2010). Similar effects of disuse on 
fibre type following 35 d of bed rest was reported in the vastus lateralis (VL) 
muscle, i.e. the loss of fibre CSA was greater in type 1 than type II fibres 
(Brocca et al., 2012). Conversely, muscle fibre type specificity has not been 
observed in other studies (Bamman et al., 1998; Trappe et al., 2008; Hvid et 
al., 2010) where duration of immobilisation was shorter (<14 d). It is notable 
that; these studies have mainly focused on a single muscle with muscle biopsy 
taken from a single site in the periphery of the muscle. This is relevant because 
muscles do not atrophy uniformly across the entire length of a single muscle 
(Miokovic et al., 2012), with differential atrophy across different muscles being 
observed following 27-60 d head-down-tilt bed rest. The investigators also 
reported that the posterior calf muscles atrophied faster than the knee 
extensor muscles (Vastus Lateralis) and ankle flexors (Tibialis anterior). In 
another study where multiple muscles were examined using MRI over 43 d 
disuse in the form of ankle immobilisation, the greatest rate of muscle loss was 
observed in soleus and medial gastrocnemius muscle followed by lateral 




gastrocnemius and tibialis anterior (Psatha et al., 2012). The aetiology driving 
distinct fibre type, and individual muscle atrophy susceptibility is poorly 
defined.  
1.2.5 Regulation of skeletal muscle mass in ambulated and unloaded human muscle: 
1.2.5.1 Ambulated regulation of MPS and MPB: 
Skeletal muscle mass is regulated by the balance between MPS and MPB. 
Nutrients (i.e., AA) and nutrient derived hormones (i.e., insulin) play a crucial 
role in regulating the balance between MPS and MPB. In ambulated humans, 
intake of dietary protein stimulates MPS due to the essential amino acids 
(EAA) components of proteins (Atherton and Smith, 2012). These anabolic 
responses are dose-dependent and saturable; at a maximal stimulus, rates of 
MPS increase ~200-300% for a period of approximately 2 h following ~20 g 
protein (Cuthbertson et al., 2005; Atherton and Smith, 2012). In contrast, 
insulin released following intake of dietary protein and/or CHO, is neither 
necessary nor sufficient to stimulate MPS (Greenhaff et al., 2008). Reflecting 
this, the anti-catabolic effects of insulin upon MPB was not recapitulated via 
AA infusions when insulin concentrations were clamped at 5 µU.ml-1 (post 
absorptive) (Greenhaff et al., 2008). Instead, insulin concentrations of just 15 
IU/ml (3× post absorptive) are sufficient to maximally suppress MPB (Wilkes 
et al., 2009). This anti-catabolic effect of insulin acting on MPB was confirmed 
in a recent systematic review and meta-analysis of 44 human studies, which 
concluded insulin did not significantly affect MPS but has a crucial role in 




reducing MPB (Abdulla, Smith, Philip J. Atherton, et al., 2015). Therefore, 
while EAA’s stimulate MPS, insulin suppresses MPB (and stimulates muscle 
glucose uptake). On the basis, EAA and insulin are so vital in maintaining 
muscle metabolic homeostasis, failure of these mechanisms inevitably leads 
to skeletal muscle atrophy and IR. 
1.2.5.2 Impact of Disuse on MPS and anabolic pathways: 
Disuse of human skeletal muscle alters muscle metabolism dynamics 
(Mallinson and Murton, 2013). For instance, early work by Gibson et al., 
showed that young men exposed to ULLS exhibited ~30% slower rates of 
fasted state MPS compared to the contralateral non-immobilised limb (Gibson 
et al., 1987). Subsequent studies confirmed reductions in MPS; for instance, 
~50% reductions in MPS following 2- weeks of bed rest (Ferrando et al., 1996; 
Paddon-Jones et al., 2004) and ULLS with braces/casting (Elisa I Glover et 
al., 2008). In further agreement with this, Kortebein et al., reported ~30% 
reductions in post-absorptive MPS during a 24 h period in older adults after 10 
d of bed rest (Kortebein et al., 2007). Crucially, blunting of MPS in response 
to muscle unloading is not restricted to fasted periods. Glover et al., reported 
that ULLS led to ~27% reductions in postprandial rates of MPS at both low and 
high doses of AA infusions (Elisa I Glover et al., 2008). Similarly, Drummond 
et al., reported that 7 d of bed rest blunted fed state MPS following EAA 
ingestion (Drummond et al., 2012). Similarly, 14 d of ULLS led to a ~30% 
reduction in MPS after ingestion of 20 g dietary protein (Wall et al., 2013). On 




this basis, available evidence strongly supports the notion that skeletal muscle 
atrophy in humans during a period of disuse is driven by blunting of both 
postabsorptive and postprandial MPS (Rennie et al., 2010; Wall et al., 2013). 
The mTOR (mechanistic target of rapamycin) pathway is the major signal 
transduction network “hub” involved in the regulation of mRNA translation. Cell 
and rodent based research suggests this system senses important stimuli 
responsible for the regulation of MPS i.e. 1) insulin and insulin-like growth 
factor-1 (IGF-1) through IRS (insulin receptor substrate) and PI3K 
(Phosphatidylinositol-3) pathways (Wackerhage and Ratkevicius, 2008); 2) AA 
through leucyl-tRNA/Rag-mTORc1 pathways (Wackerhage and Ratkevicius, 
2008), 3) Energy stress through AMPK-eukaryotic elongation factor (AMP 
activated protein kinase/ eEF2) pathway (Wackerhage and Ratkevicius, 
2008), and 4) mechanical stress e.g. through mechano-sensory pathways 
(Wackerhage and Ratkevicius, 2008). However, the impact of these factors in 
the regulation of MPS in human remains unclear. For example, under 
ambulated conditions, one of the mTOR upstream effector, the class III PI3K 
hVps34 (human vacuolar protein sorting-34) was shown to be inhibited in 
amino acid starved state (basal condition) and increased activity of this protein 
appears to be concomitant with increased S6K1, suggesting it to be key player 
in mTOR signalling pathway (Dickinson and Rasmussen, 2011). Furthermore, 
intake of dietary protein typically leads to increase in phosphorylation status of 
class III PI3K hVps34 (Dickinson and Rasmussen, 2011), mTOR and its 
downstream substrates regulating mRNA translation, such as p70S6K 




(Drummond et al., 2012). However, in response to disuse, blunted 
phosphorylation of mTOR and p70S6K was shown after 2- weeks of 
immobilisation while, no significant increases in phosphorylation of mTOR and 
p70S6K were noted after immobilisation (Wall et al., 2013). In contrast, others 
have reported no decreases in Akt/mTOR signalling despite reductions in MPS 
(de Boer et al., 2007; Wackerhage and Ratkevicius, 2008). It is worthwhile 
noting that peak stimulation of signalling proteins (mTOR and p70S6K) occurs 
1 to 2 h after protein intake while many studies have muscle biopsies taken 3 
to 6 h after protein intake when the response would be attenuated or perhaps 
absent (Glover, Yasuda, M. A. Tarnopolsky, et al., 2010; West et al., 2011; 
Drummond et al., 2012; T. a Churchward-Venne et al., 2012). Further studies 
are needed with frequent biopsy sampling to fully determine a role for 
deactivation in mTORC1-related signalling networks (or indeed other putative 
mechanisms) regulating depressions in post-absorptive and post-prandial 
MPS. 
1.2.5.3 Impact of Disuse on MPB and catabolic pathways: 
In contrast to the recognised deficits in MPS during immobilisation, the role of 
MPB in disuse atrophy is less clear. This is partly confounded by the technical 
and clinical challenges in measuring in vivo rates of MPB (e.g. arterio-venous 
balance methods to measure rate of appearance i.e. breakdown and pulse 
chase stable isotope approaches to measure fractional breakdown rates) 
(Kumar et al., 2009; Atherton and Smith, 2012; Atherton et al., 2016). In the 




only study to our knowledge to measure this, Symons et al., demonstrated no 
increase in MPB in his study of healthy young volunteers exposed to 21 d of 
microgravity setting using a bed rest model (Symons et al., 2009). Although 
not directly quantifying MPB, Wall et al., reported that muscle free tracer 
enrichment over 4-hour (4 h) post prandial period was >3 fold higher after 
immobilisation (Wall et al., 2013). Since MPS has consistently been shown to 
be reduced with immobilisation, a likely explanation is that MPB is actually 
reduced (rather than increased) and hence the less unlabelled phenylalanine 
efflux was diluting the muscle free labelled tracer (L-(ring-2H5)) phenylalanine 
pool (Wall et al., 2013). Alternatively, an accumulation of free tracer could 
simply be explained by established “anabolic resistance” i.e. where a failure of 
AA incorporation into the muscle lead to its accumulation (Elisa I Glover et al., 
2008; Phillips, Glover and Rennie, 2009b; Rennie et al., 2010; Wall et al., 
2013). Nevertheless, regardless of the driving force behind muscle atrophy 
(i.e., disuse, ageing, cancer, organ failure), blunted postabsorptive and 
postprandial MPS (Figure 1-1) (anabolic resistance) seem to be the major 
drivers of disuse atrophy – rather than increases in MPB. Nonetheless, more 
work is needed across the time-course of unloading to verify this. 





Figure 1-1- Diagrammatic representation of the main mechanisms involved in disuse skeletal muscle atrophy in 
humans. Immobilisation/ disuse reduces both postabsorptive and post prandial muscle protein synthesis (MPS) via 
the mammalian target of rapamycin (mTORC1) and Akt signalling. The role of MPS, muscle protein breakdown (MPB) 
and insulin resistance (IR) in simple disuse atrophy remain poorly defined in humans. So, the role of insulin resistance 
and MPB in the setting of disuse atrophy needs further evaluation. Inflammation probably leads to IR. Recently, 
reactive oxygen species (ROS) has been implicated in development of muscle atrophy in disuse setting, but the 
mechanism in human remains putative. Solid arrow shows positive association and broken arrow shows putative 
association. See text for more details. 
In terms of the molecular regulation of MPB, the ubiquitin proteasome system 
(UPS) (Lecker, Goldberg and Mitch, 2006) supplemented by lysosomal and 
calcium activated calpain (ATP–independent) and caspase dependent 
cleavage of actinomyosin complexes (Glover, Yasuda, M. a Tarnopolsky, et 
al., 2010) are the major catabolic pathways in muscle. The identification of the 
“atrogenes” as genes that are uniformly upregulated irrespective of the atrophy 
stimulus (e.g. denervation, disuse, thermal injury) has received much attention 
as key drivers of atrophy programming (Bodine, Latres, et al., 2001; Jones et 




al., 2004; Milan et al., 2015). This led to members of the Forkhead Box (Fox) 
O family (Fox1, 3 and 4) being identified as downstream targets of Akt pathway 
and as the main transcription factors regulating MAFbx/atrogin-1 expression 
(Sandri et al., 2004). In terms of disuse atrophy, mRNA expression of two E3 
ubiquitin ligases was initially found to be crucial in immobilisation, unloading 
and denervation induced muscle atrophy (Bodine, Stitt, et al., 2001). These 
genes, MuRF-1 (Muscle Ring Finger-1) and MAFbx/atrogin-1 (Muscle Atrophy 
F-box), are expressed in skeletal muscle at low levels but rapidly induced in 
response to unloading (Bodine, Stitt, et al., 2001). In humans, after 5 d (Dirks 
et al., 2014) and 2 weeks (Jones et al., 2004) of immobilisation, MAFbx and 
MuRF1 mRNA were reported to be elevated. Nonetheless, while their 
expression is thought to be regulated by transcription factors such as FOXO1, 
FOXO3a (Sandri et al., 2004) and NF-kB (p50 and Bcl-3)(Wu, Kandarian and 
Jackman, 2011), no increase in mRNA expression in FOXO’s were noted after 
4 or 14 d of immobilisation (Suetta et al., 2012). De Boer et al., reported the 
expression of MuRF-1 but not MAFbx mRNA was increased after 10 d of ULLS 
(Jones et al., 2004; de Boer et al., 2007), while both had decreased by 21 d 
(de Boer et al., 2007). Furthermore, increases in UPP components (particularly 
UBE2E) were up-regulated 48 h following instigation of ULLS (Urso et al., 
2006). In contrast, a recent study by Brocca et al., found that muscle atrophy 
following ULLS found no change in mRNA expression of ubiquitin-proteasome 
and autophagy systems (Brocca et al., 2015). Some work has been done in 
relation to autophagy (and calpain-signalling) in relation to human disuse 




(Jones et al., 2004). Autophagy is responsible for removing unfolded, 
damaged and dysfunctional proteins and organelles via the formation of 
autophagosomes for degradation by lysosomes (Sandri, 2010). Interestingly, 
up regulation of autophagy markers such as Beclin-1 suggested increased 
autophagosome formation and hence a higher activity of the macro-autophagy 
by 24 d of bed rest; nonetheless, other autophagy markers such as P62, 
LC3II/I ratio and cathepsin-L were not up-regulated (Brocca et al., 2012). While 
details of the pathways discussed above are outside the scope of this review, 
the readers are referred to reviews by Bonaldo (Bonaldo and Sandri, 2013) 
and Sandri (Sandri, 2010). What is clear however is that without more clinical 
studies with time-course acquisition, including dynamic measures of MPB in 
tandem with molecular markers spanning different proteolytic systems, no firm 
conclusions can be made surrounding the mixed results regarding whether 
existing molecular data suggest MPB is increased, decreased or unchanged 
in response to disuse in humans. 





Figure 1-2- Diagrammatic representation of the overlap between insulin signalling pathway, reactive oxygen species 
(ROS), inflammatory cytokine such as NF-kB and ubiquitin-proteasome system in insulin resistant (IR) states 
particularly diabetes: In IR state, PI3K activity is decreased, leading to decreased activity of Akt, which in turn release 
the inhibition of FOXO and caspase-3 resulting in elevation of  muscle ring finger-1 (MuRF-1) and muscle atrophy F-
box (MAFbx/atrogin-1) finally leading to increased proteolytic activity. Also, ROS and low-grade inflammation via NF-
kB pathway led to muscle atrophy. See text for more details. 
 
In addition to the anabolic and catabolic pathways described above, emerging 
evidence indicates that disturbed redox signalling may also be an important 
regulator of MPS and MPB in muscle disuse atrophy (Powers, Smuder and 
Judge, 2012; Zuo and Pannell, 2015). Oxidative injury has been shown to 
occur in muscle fibres during periods of disuse in locomotor skeletal muscles 
(Min et al., 2011) and in non-load bearing muscle such as the diaphragm 
during prolonged mechanical ventilation (Kavazis et al., 2009). After 35 d of 




bed rest, vastus lateralis muscle showed ~18% muscle fibre atrophy and 
increased protein carbonylation (Dalla Libera et al., 2009). Furthermore, an 
inverse linear relationship was observed between normalised levels of protein 
oxidation and muscle fibre CSA (Dalla Libera et al., 2009). An analysis of gene 
expression showed upregulation of pathways involved in the oxidative stress 
response (increase in mRNA for stress response gene heme oxygenase-1) 
following 48 h of unilateral lower leg suspension (ULLS) (Reich et al., 2010). 
Conversely, in a limb immobilisation human model with ~5.7% muscle and 
11.8% muscle fibre loss after 14 d of immobilisation, no increase in lipid 
peroxidation and protein oxidation in vastus lateralis was observed (Glover, 
Yasuda, M. a Tarnopolsky, et al., 2010). Although information on oxidative 
stress and potential mechanisms explaining proteolysis in disuse human 
muscle is still sparse (Pellegrino et al., 2011), these findings support the 
extensive evidence available from animal studies that oxidative stress inhibits 
MPS (Powers, Smuder and Criswell, 2011) and increases muscle MPB (via 
increased gene expression of key proteins involved in the proteolytic pathways 
such as autophagy, calpains and proteosomes; activation of both calpain and 
caspase-3 and possibly by modification of myofibrillar proteins which 
enhances their susceptibility to proteolytic processing)(Powers, Smuder and 
Criswell, 2011). Interaction between ROS and insulin signalling pathway has 
also been described, i.e. ROS may regulate Insulin growth factor-1 (IGF-1) 
signalling either positively or negatively depending on the amount of ROS 
produced (Papaconstantinou, 2010). Low levels of endogenous ROS due to 




their reversible oxidative inhibition of protein tyrosine phosphatases induces 
phosphorylation of tyrosine residue on the insulin receptor and its substrates 
triggering IGF-1 signalling (Bashan, Kovsan and Kachko, 2009). In contrast, 
the IGF-1 signalling pathway is inhibited by higher levels of ROS and recent 
evidence suggests ROS down regulates the IGF-1 cascade and induces 
insulin resistance (Bashan, Kovsan and Kachko, 2009) (Figure 1-2). For 
detailed discussion of the signalling pathways linking ROS and muscle 
atrophy, the interested reader is referred to recent reviews on oxidative stress 
and disuse muscle atrophy (Pellegrino et al., 2011; Powers, Talbert and 
Adhihetty, 2011; Powers et al., 2014; Zuo and Pannell, 2015). 
1.2.5.4 Impact of disuse on muscle IR and links to muscle mass in persistent IR states 
Insulin-mediated glucose uptake is also blunted with muscle disuse (Mikines 
et al., 1991; Biensø et al., 2012); that is, unloaded muscle becomes IR. This 
IR can be observed at a whole-body level following bed-rest, but is most 
apparent at the muscle level across the physiological range of insulin 
concentrations under clamp conditions (Mikines et al., 1991). Recently, a one 
week bed-rest study in young males by Dirks et al, revealed reduced muscle 
mass (~1.4 kg lean tissue and ~3% quadriceps CSA) and whole-body insulin 
sensitivity (~29%) (Dirks et al., 2016). Thus, disuse lowers MPS, induces 
anabolic resistance to nutrients and impairs insulin-mediated muscle glucose 
uptake - even in healthy adults (Fink, 1983).  




The role of IR in driving muscle atrophy however is poorly defined. Evidence 
from large cross-sectional and longitudinal studies report accelerated loss of 
muscle mass in individuals with persistent IR (i.e., people with diabetes), 
perhaps pointing to mechanistic links. For instance, declines in muscle mass 
were inversely related to duration of diabetes or HbA1c (Park et al., 2007, 
2009; Kalyani et al., 2013) and attenuated with insulin sensitisers (Kuo et al., 
2009). Human muscle tissue accounts for 80% of glucose uptake after food 
ingestion and insulin resistance (HOMA-IR) is associated with reduced 
quadriceps muscle strength (Kalyani et al., 2013; Leenders, Verdijk, van der 
Hoeven, et al., 2013), power (Kalyani et al., 2013) and muscle mass 
(Leenders, Verdijk, van der Hoeven, et al., 2013) in humans. Approximately a 
50% more rapid decline in knee extensor strength has been observed in older 
patients with type 2 diabetes compared with patients without diabetes over a 
3 year period, suggesting that decreased muscle strength may be accelerated 
in type 2 diabetes (Park et al., 2007). In a further study (Volpato et al., 2012) 
it is reported that the differences in walking speed, muscle strength, power and 
muscle quality between individuals with and without diabetes were 
independent of co-existing peripheral motor neuropathy or peripheral vascular 
disease, suggesting a direct effect of diabetes per se on muscle performance. 
These findings are important because in catabolic conditions such as 
diabetes, atrophy in combination with reduced activity decrease quality of life 
and increase mortality (Zinna and Yarasheski, 2003). Yet, despite clear 
evidence linking accelerated muscle loss in diabetes compared to non-




diabetes, studies investigating the direct effect of immobilisation on muscle 
protein turnover in patients with diabetes compared to those without diabetes 
are scant. Furthermore, clear distinction between Type 1 and Type 2 diabetes 
needs to be made when investigating patients with diabetes. This is because 
Type 1 diabetes is a condition with severe depletion of energy stores and 
reduced mitochondrial function resulting in accelerated muscle protein loss 
(Hebert, Clinic and Sw, 2010), which can be reversed by insulin replacement 
(Workeneh and Bajaj, 2013). In contrast, muscle loss, whilst accelerated in 
type 2 diabetes, is unaffected by insulin treatment (Workeneh and Bajaj, 
2013), possibly due to IR. Hence, skeletal muscle mass loss, whilst common, 
appears to occur less predictably and to varying degree in Type 2 diabetes 
compared with Type 1 diabetes (Workeneh and Bajaj, 2013). Collectively, 
these data are consistent with the notion that diabetes causes muscle mass 
loss possibly due to mechanisms driving muscle IR, however there is lack of 
data regarding the effects of immobilisation or disuse on muscle mass in 
individuals with diabetes.  
The mechanistic regulation of muscle IR in driving muscle atrophy in the 
setting of ‘simple disuse’ remains vague (Atherton et al., 2016). Early human 
studies by Shulman et al, showed that, under steady state plasma 
concentration of both glucose and insulin, mimicking postprandial conditions, 
the mean rate of muscle glycogen synthesis accounted for most of the whole 
body glucose uptake and virtually all of non-oxidative glucose metabolism in 
both healthy and diabetic subjects (Shulman, 2000), with defects in muscle 




glycogen synthesis playing a major role in causing insulin resistance in type 2 
diabetes (Shulman, 2000). This may be explained by defects in the insulin 
receptor substrate (IRS)-1/ phosphatidylinositol (PI) 3-kinase pathway, leading 
to reduced glucose uptake and utilisation in insulin target tissues (Draznin, 
2006). Free fatty acids induce muscle IR by inhibiting glucose 
transport/phosphorylation and reductions in both the rate of muscle glycogen 
synthesis and glucose oxidation (Roden et al., 1996). Additionally, many other 
mechanisms have been postulated to explain free fatty acid-induced muscle 
IR, including the Randle cycle, oxidative stress, inflammation and 
mitochondrial dysfunction (Martins et al., 2012). Full details regarding above 
mechanisms escape the scope of this article and readers are referred to a 
review by Martins et al., (Martins et al., 2012). With regard to disuse induced 
muscle atrophy, following (7 d) bed-rest healthy volunteers showed reduced 
glucose infusion rate and leg glucose extraction (after bed rest) along with 
reduced muscle GLUT4, hexokinase II, protein kinase B/Akt1, and Akt2 protein 
levels, and a tendency for reduced 3-hydroxyacyl-CoA dehydrogenase activity 
(Biensø et al., 2012). Further in the same study, the ability of insulin to 
phosphorylate Akt and activate glycogen synthase was reduced post bed-rest 
(Biensø et al., 2012); but whether this observation is causative or a 
consequence of immobilisation is not clear. However, a substantial decline in 
glucose uptake within 24 h  of immobilisation would argue against a causative 
effect (Atherton et al., 2016). Recently, Vigelsø et al. (Vigelsø et al., 2016), 
showed an inverse association between the increase in muscle pyruvate 




dehydrogenase complex (PDC) activation and leg lactate release during 
contraction after 2 weeks unilateral lower limb immobilisation, suggesting PDC 
as a potential key regulator of immobilisation induced muscle IR. Overall, the 
above data suggests that muscle disuse results in development of whole body 
and muscle specific IR, fuelling the argument that lack of muscle contraction 
per se may be the main physiological driver for this dysregulation, however a 
mechanistic explanation for this still remains unclear (Atherton et al., 2016). 
1.2.5.5 Summary: 
Disuse muscle atrophy causes many undesirable complications. There seems 
to be complex interplay of numerous mechanisms contributing to the aetiology 
of disuse muscle atrophy. During muscle disuse, both post-absorptive and 
post-prandial MPS is suppressed, with little evidence to support there being 
an increase in ‘bulk’ protein MPB. Moreover, animal models show increased 
(2.5 times) rate of muscle protein turnover and are also very sensitive to 
disuse, while exhibiting marked fibre-type-dependant differences in rates of 
muscle protein turnover (type I fibres being twice as great as type II fibres) 
when compared to humans. Due to these inherent species-specific 
differences, pre-clinical findings cannot easily be reconciled with nor 
extrapolated to humans. So, further research quantifying MPS and MPB and 
their temporal relationship during disuse in humans is warranted. There is 
strong evidence that type 2 diabetes accelerates muscle loss, possibly due to 
mechanisms innate to diabetes. Crucially, muscle IR secondary to disuse 




appears to drive the procession of disuse muscle atrophy independent of other 
mechanisms known to cause muscle IR. Nonetheless, the mechanistic role of 
muscle IR driving this atrophic response is poorly defined. Because, common 
proteolytic mechanisms may exist across ‘simple muscle atrophy’ and other 
catabolic conditions (e.g. type 2 diabetes, inflammation, cachexia etc.), these 
two process can rarely be seen as being mutually exclusive (Atherton et al., 
2016). Further, many questions remain unanswered especially the molecular 
regulation of MPS and MPB and muscle insulin resistance. This whole area of 
research has potential implications for the wider clinical community as similar 
metabolic processes occur during cancer cachexia, metabolic syndromes 
including type 2 diabetes, ageing (i.e., sarcopenia), sepsis and many 
neurodegenerative disorders. Henceforth, further translational research is 
necessary before this knowledge can be effectively applied in developing 
targeted strategies to prevent this in the setting of disuse muscle atrophy.  
  




1.3 Testosterone: Effects on skeletal muscle protein and Glucose metabolism: 
1.3.1 Physiology of testosterone: 
Although, testosterone has been a focus of scientific society for almost 150 
years due to its distinct biological effects, particularly sexual and physical 
effects. However, it still remains inspiration to new research, particularly its 
effects on human skeletal muscle physiology (Freeman, Bloom and McGuire, 
2001). Testosterone (17-hydroxy-4-androstene-3-one) is a 0.288kD C19 
steroid hormone synthesised from cholesterol via a series of enzymatic 
process catalysed by specific enzymes (Mendelson, Dufau and Catt, 1975). 
Biologically synthesised testosterone has a powerful androgenic and anabolic 
effects (Kadi, 2008) and is mainly produced in Leydig cells of testes and small 
amounts is also produced in adrenal glands and other peripheral tissues 
(Freeman, Bloom and McGuire, 2001). The later, site of testosterone 
production is mainly spillover from the process of other hormones synthesis 
such as cortisol and aldosterone in the adrenal glands and estradiol in the 
ovaries respectively (Conley and Bird, 1997). The above two process explains 
how the adrenal gland and the ovaries can produce testosterone despite the 
absence of Leydig cells in these tissues (Vingren et al., 2010). 
1.3.2 Hypothalamic-Pituitary-Gonadal Axis: 
The signal for gonadal testosterone synthesis and release originates from 
specialised neurons in hypothalamus, which produce and release 




gonadotrophin releasing hormone (GnRH) (Kim, 2007). GnRH released 
directly in to the hypothalamic-hypophyseal portal vein, travels to anterior 
pituitary gland and stimulates the production and release of luteinising 
hormone (LH) and follicle-stimulating hormone (FSH) from the gonadotrophs 
(Kim, 2007). LH and FSH then enters the systemic circulation and are 
transported to the gonads. In the gonads, LH stimulates testosterone 
production in the Leydig cells of men and the theca cells of women. Binding of 
LH to a G-protein-coupled membrane receptor activates cyclic adenosine 
monophosphate-dependent protein kinases (protein kinase A), which in turn 
stimulates the rate limiting step in the testosterone production (Miller, 1988). 
As with any steroid hormones, testosterone cannot be stored in the cells they 
are produced and are released immediately in the blood stream following the 
their synthesis (Vingren et al., 2010). However, in women testosterone is 
further processed in to estradiol in the granulosa cells adjacent to the theca 
cells (Vingren et al., 2010). Interestingly, FSH does not appear to have direct 
effects on testosterone synthesis in men, however it is important in stimulation 
of steroid binding protein synthesis in the liver. Similarly, in women, FSH 
stimulates the synthesis of pregnenolone in the granulosa cells and steroid 
binding protein synthesis in the liver (Vingren et al., 2010). The signaling 
pathway from FSH is similar to that induced by LH in the theca and Leydig 
cells and the pregnenolone synthesised in the granulosa cells travels to theca 
cells, where it is further processed to testosterone (Vingren et al., 2010). 
Eventually, p450 aromatase produced due to FSH stimulation is responsible 




for conversion of testosterone to estradiol in the granulosa cell. This complex 
signaling cascade from hypothalamus to the gonads leading to production and 
secretion of testosterone (and estradiol) is coined as the ‘hypothalamic-
pituitary-gonadal axis’ (Figure 1-3) (Harris, 1951).  
 
Figure 1-3- The mammalian hypothalamic pituitary gonadal axis. At puberty, pulsatile secretion of gonadotrophic 
releasing hormone (GnRH) stimulates the anterior pituitary to release the gonadotrophic hormones, luteinising 
hormone (LH), and follicle-stimulating hormone (FSH). These acts on the gonads to promote gamete formation and 
the production of gonadal steroid hormones, which form feedback loops to regulate GnRH, LH, and FSH release. 
Kisspeptin (Kiss1) neurons act as a principal relay for steroid feedback on GnRH secretion. In females, high levels of 
estrogens and progesterone stimulate kisspeptin neurons of the AVPV to induce the preovulatory surge of GnRH/LH, 
whereas they inhibit KISS1 expression in the arcuate nucleus (ARC). In the male, GnRH and gonadotrophic hormone 
release are negatively regulated by circulating testosterone, partly through the activity of kisspeptin neurons of the 
ARC. POA, preoptic area; AVPV, anteroventral periventricular nucleus; ME, median eminence. (adapted from 
(d’Anglemont de Tassigny and Colledge, 2010) 
 
 




1.3.3 Effects of testosterone on skeletal muscle protein turnover: 
Accumulating evidence suggests that testosterone produces muscle 
hypertrophy by enhancing fractional muscle protein synthesis (Urban et al., 
1995; Brodsky, Balagopal-F and Sreekuhl4ran, 1996). Furthermore, Urban et 
al (1995) states that testosterone stimulates the expression of IGF-1 and 
downregulates IGF binding protein-4 in the muscle. So, this reciprocal 
changes caused by testosterone between IGF-1 and its binding protein 
provide a potential mechanism for enhanced anabolic signal (Bhasin, 
Woodhouse and Storer, 2001). Conversely, suppression of endogenous 
testosterone production by administration of gonadotropin-releasing hormone 
(GnRH) analogue in young men resulted in marked decrease in the rate of 
whole-body muscle protein synthesis, in muscle strength and in fat oxidation 
together with increase in muscle adiposity (Mauras et al., 1998). In addition, 
manipulation of the circulating testosterone level in addition to administering 
GnRH analogue showed existence of positive relationship between 
testosterone concentration and fat-free mass, muscle strength and size 
(Bhasin, Woodhouse and Storer, 2001). Moreover, attenuated physiological 
response to a period of 12 week strength training was noted in volunteers 
receiving GnRH analogue in a randomised double blind placebo controlled 
study (Kvorning et al., 2006). Overall, the above studies support the prevailing 
notion that testosterone has profound anabolic effects on the human skeletal 
muscle protein synthesis.  




1.3.3.1 Mechanisms of testosterone action on skeletal muscle: 
The evidence exploring molecular mechanisms of testosterone action on 
skeletal muscle is still poorly understood (Mudali and Dobs, 2004). However, 
an early study (Griggs et al., 1986) reported that muscle RNA was significantly 
elevated suggesting the possibility of testosterone acting via hormone receptor 
situated on muscle nuclei. Further, it is postulated that, testosterone appears 
to stimulate IGF-1 expression both directly and indirectly; resulting in muscle 
protein synthesis and growth, and also may counter the inhibitory effects of 
myostatin, cytokines and glucocorticoids (Mudali and Dobs, 2004). 
1.3.3.2 Effects of testosterone on lean body mass (LBM) and muscle protein 
synthesis (MPS): 
Early animals (increase in nitrogen retention in castrated animals) (Kochakian, 
Tilloston and Endahl, 1956) and human studies has shown that anabolic 
steroids, particularly testosterone administration increases lean body mass 
(LBM) and has a features of typical dose response curve (Forbes, 1985). 
Furthermore, in a study of healthy men receiving pharmacological dose 
(3mg/kg/week) of testosterone enanthate over 12 weeks showed ~20% mean 
increase in muscle mass estimated by creatinine excretion and MPS rate 
estimated by measuring (13C) Leucine incorporation increased by ~27% mean 
in all 9 subjects (Griggs et al., 1989). Supporting this, significant increase in 
MPS (estimated by rate of incorporation of stable isotope in to quadriceps 
muscle during primed infusion of L-[1-13C]leucine) following administration of  




similar dose (3mg/kg/week) of testosterone was reported in 6 male patients 
with myotonic dystrophy (Griggs et al., 1986). In a further study, 6 healthy old 
men receiving testosterone to increase their testosterone concentration equal 
to that of healthy young men reported significant increase in quadriceps and 
hamstring muscle mass and also in fractional synthetic rate of muscle protein 
(stable isotope infusion technique) (Urban et al., 1995).  Since then, few other 
studies in healthy hypogonadal men have reported increase in fat free mass 
~5kg (~9.9%) (by underwater weight and D2O) (Bhasin et al., 1996a); ~7% (by 
bioelectrical impedance) (Katznelson et al., 1996); ~15% (by DEXA scan) 
(Brodsky, Balagopal-F and Sreekuhl4ran, 1996); ~2% (by DEXA scan) (Wang 
et al., 1996); ~3kg (by DEXA scan) (Snyder et al., 2000) and ~2.7kg (by DEXA 
scan) (Wang et al., 2000) following administration of various preparation of 
testosterone. Interestingly, Borst et al., reported ~4 kg increase in fat free mass 
in 60 older hypogonadal men receiving testosterone (125mg/week) in 
combination with finasteride (type II 5α-reductase inhibitor) highlighting the 
musculoskeletal effects of testosterone without the side effects of prostatic 
enlargement (in finasteride group) (Borst et al., 2014). Collectively, these 
studies support the prevailing notion that, testosterone has significant anabolic 
effects both on skeletal muscle mass (lean body mass or fat free mass) and 
MPS both at physiological and pharmacological doses.  
 
 




1.3.3.3 Effects of testosterone on muscle protein breakdown (MPB): 
Despite a multitude of studies conducted over last few decades to look at 
effects of testosterone on muscle mass and MPS (as summarised in 1.3.3.2) 
there is still a lack of understanding of influence of testosterone on muscle 
protein breakdown. None of the above studies (as summarised in 1.3.3.2) 
measure muscle protein breakdown. The observed increase in muscle mass 
and protein synthesis in aforementioned studies may indicate that muscle 
protein breakdown was not increased (Rooyackers and Nair, 1997). In a 
recently concluded study involving 57 hemodialysis patients (35% patients 
having low testosterone concentrations), the testosterone concentration was 
independently and positively correlated with lean body mass (measured by 
bioimpedance method) suggesting that hypogonadism (low testosterone 
concentration) may be associated with increased muscle breakdown (Cobo et 
al., 2017). However, further studies with direct measurement of MPB are 
needed to clarify this issue. 
1.3.4 Effects of testosterone on skeletal muscle glucose disposal and insulin 
resistance: 
There is now plethora of evidence to support the concept that testosterone 
plays a paramount role in regulating lean muscle mass and body fat 
composition, especially in men (Daniel M Kelly and Jones, 2013). 
Furthermore, testosterone deficiency is associated with increased fat mass 
(particularly truncal), decreased insulin sensitivity, impaired glucose tolerance, 




elevated triglycerides and cholesterol and low HDL-cholesterol. 
Aforementioned factors are extremely prevalent in metabolic syndrome (MetS) 
and type 2 diabetes, leading to increased cardiovascular risk (Daniel M Kelly 
and Jones, 2013). Moreover, testosterone deficiency is associated with 
decreased lean body mass, and relative muscle mass is inversely related to 
insulin resistance and development of pre-diabetes (Srikanthan and 
Karlamangla, 2011). Given the knowledge that, up to 70% of body’s insulin 
sensitivity is accounted by muscle tissue, testosterone deficiency may lead to 
insulin resistance via anabolic and/ or metabolic processes in the muscle 
(Pitteloud, Hardin, et al., 2005). Worryingly, little is known about the influence 
of testosterone on insulin action (and molecular mechanisms involved) in 
skeletal muscle and subsequently, the effects on carbohydrate metabolism 
and risk of developing type 2 diabetes (Daniel M Kelly and Jones, 2013).  
1.3.5 Molecular mechanisms of testosterone action on skeletal muscle glucose 
metabolism: 
Early animal studies, has long established that castrated rats muscle has 
decreased glycogen storage levels in levator ani and perineal muscles and 
testosterone replacement induces significant increase in glycogen content 
(Leonard, 1952; Apostolakis, Matzelet and Voigt, 1963; Bergamini, Bombara 
and Pellegrino, 1969). Similarly, notable rise in muscle glycogen synthesis 
(due to increased testosterone-induced glycogen synthase activity) is 
observed following testosterone replacement in castrated rats compared to 




their untreated controls leading to reduced blood glucose (Ramamani, 
Aruldhas and Govindarajulu, 1999). Indeed, testosterone replacement 
normalised glycogen phosphorylase activity in castrated rats resulting in 
reduced breakdown of muscle glycogen avoiding elevation in blood glucose 
(Bergamini, 1975). Conversely, the rate of glycogenesis was shown to be 
reduced in rat skeletal muscle following testosterone administration and 
increased glycogen content is postulated as possible reason than decreased 
glycogenolysis (Bergamini, 1975). In addition to aforementioned role of 
testosterone in skeletal muscle glucose uptake, action on few key enzymes 
involved in glycolysis is also postulated (Daniel M. Kelly and Jones, 2013). 
Elevated activity of phosphofructokinase and hexokinase is also reported in 
cultured rat skeletal muscle cells (Sato et al., 2008). Supporting this, Bergamini 
et al., reported a maximal 40% increase in hexokinase activity in castrated rats 
12 h after administration of testosterone compared to their untreated controls 
(Bergamini, Bombara and Pellegrino, 1969). Indeed, in a recent study of 
testicular feminised (TfM) mouse (wherein affected animal has low 
endogenous testosterone levels and non-functional androgen receptor (AR)) 
showed significantly reduced expression of hexokinase-2 in the skeletal 
muscle compared to their wild type (McLaren et al., 2012). Interestingly, in the 
same study, testosterone replacement did not alter hexokinase-2 expression 
postulating involvement of AR-mediated mechanisms (McLaren et al., 2012). 
Collectively, these animal studies support the argument that testosterone 
plays a very important role in glucose uptake (via insulin independent 




mechanisms) especially in skeletal muscle and may explain the possible 
mechanism via which glucose disposal is impaired in testosterone deficient 
states.  
1.3.6 Insulin action on skeletal muscle glucose homeostasis- in health and persistent 
insulin resistance state (Type 2 diabetes): 
Skeletal muscle and adipose tissue glucose uptake via insulin are mainly 
mediated by GLUT4 glucose transporter isoform. In normal resting state, 
majority of GLUT4 molecules reside inside the membrane vesicles in the cell, 
following stimulation by insulin (via insulin receptors, activation of cascades 
involving insulin receptor substrate-1 (IRS1) and other signaling pathways) 
they migrate to cell membranes (Bryant, Govers and James, 2002). So, 
diminished GLUT4 expression correlates with reduced insulin sensitivity 
(Daniel M. Kelly and Jones, 2013) and in patients with type 2 diabetes, defects 
at the level of insulin receptor, IRS-1 and GLUT4 expression is observed 
(Pessin and Saltiel, 2000).  
1.3.7 Effect of testosterone on skeletal muscle insulin sensitivity and resistance: 
In relation to androgen (testosterone) action on glucose control, both GLUT4 
and IRS-1 were up-regulated in cultured skeletal muscle cells and adipocytes 
following testosterone treatment at low dose and short incubation periods 
(Chen et al., 2006). Likewise, IRS-2 mRNA expression was elevated in cells 
isolated from male human skeletal muscle biopsies following testosterone 




treatment (Salehzadeh et al., 2011). Furthermore, GLUT4 expression and 
translocation was elevated in cultured skeletal muscle cells of neonatal rats 
after treatment with testosterone (Sato et al., 2008). Additionally, testosterone 
increased the phosphorylation of Akt and protein kinase C (PKC), a pivotal 
step in the insulin signaling cascade for regulation of GLUT4 translocation 
(Sato et al., 2008). Crucially, these effects were opposed by 
dihydrotestosterone (DHT) inhibitors, implying that local conversion of 
testosterone to DHT and activation of AR is an important step in skeletal 
muscle glucose uptake (Sato et al., 2008). Interestingly, patients with Kennedy 
disease (a neuromuscular disorder encompassing a genetic polymorphism 
with excessive CAG repeat in exon 1 of AR) leading to relative insensitivity of 
AR (Stanworth et al., 2008, 2011). Furthermore, validating AR-mediated 
mechanisms, men with Kennedy disease have an increased risk of developing 
type 2 diabetes, which indeed strongly supports the link between impaired 
androgen status and type 2 diabetes (Stanworth et al., 2008, 2011; Zitzmann, 
2009). Crucially, elevated GLUT4 expression in AR-deficient (TfM) mouse 
following testosterone treatment suggested an AR-independent mechanism in 
action (McLaren et al., 2012). Collectively, these studies reinforce the notion 
that testosterone via various (insulin dependent) mechanisms improves 
glucose handling by skeletal muscles. Lack or failure of these beneficial 
actions (pathways) may promote muscle specific insulin resistant state, 
contributing to development of Type 2 diabetes.   
 




1.3.8 Effects of testosterone and RET on skeletal muscle and glucose metabolism 
Emerging evidence shows that prevalence of type 2 diabetes is on the rise to 
a pandemic proportion (WHO, 2016a). Insulin resistance (IR) is noted to be 
more prevalent in older compared to younger individuals and is further 
associated with frailty leading to disability and mortality (Fried et al., 2001; 
Bandeen-Roche et al., 2006). Ageing and exercise training related changes in 
glucose handling and insulin resistance involve several tissues, but skeletal 
muscle metabolic changes leads to particularly large impact on whole body 
glucose metabolism (Tsintzas et al., 2013). Further, age related decline in 
skeletal muscle mass and strength (sarcopenia)(Mitchell et al., 2012) is 
associated with increases muscle insulin resistance (Cleasby, Jamieson and 
Atherton, 2016). 
On a different note, aging is associated with insulin resistance and a decline 
in testosterone secretion (Morley et al., 1997; Harman et al., 2001; Feldman 
et al., 2002). Recent meta-analysis showed that testosterone replacement 
therapy increases muscle mass in elderly men by increasing insulin-like 
growth factor-1 (IGF-1) expression, regulating forkhead box O (FOXO1), 
peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-
1), and p38 mitogen-activated protein kinases (MAPK), and also stimulates 
hypertrophy via intracellular androgen receptor signaling cascade dependent 
upon Erk and mammalian target of rapamycin (mTOR) (Neto et al., 2015). 
Interestingly, Pitteloud et al. (Pitteloud, Mootha, et al., 2005), reported that 




men with hypogonadal testosterone levels are twice as insulin resistant as 
their eugonadal counterparts, confirming a positive co-relation between 
Testosterone level and insulin sensitivity across full spectrum of glucose 
tolerance. So, testosterone therapy in men with persistent insulin resistant 
state (T2DM) and hypogonadism increases insulin sensitivity, increases lean 
mass, and decreases subcutaneous fat (Dhindsa et al., 2016). 
Furthermore, accumulating evidence shows that Resistance Exercise Training 
(RET) improved glycemic control and insulin sensitivity in adults with T2DM 
(Gordon et al., 2009). Moreover, RET increases insulin sensitivity of muscle 
by a coordinated increase in insulin-stimulated microvascular perfusion and 
molecular signaling at the level of TBC1D4 and glycogen synthase in muscle 
and in addition securing improved glucose delivery and uptake in to the muscle 
(Sjøberg et al., 2017). Remarkably, RET has also been indicated in inducing 
significant endogenous hormonal (testosterone, GH, IGF-1) release (Fink, 
Schoenfeld and Nakazato, 2018).  
There is still a paucity of evidence showing cumulative anabolic effect of 
Testosterone therapy and RET on muscle mass and strength (Bhasin et al., 
1996b) and glucose metabolism (Jensen et al., 2018). 
 
 




1.4 Beta-Hydroxy-Beta-Methylbutyrate (HMB) and Glucose metabolism: 
1.4.1 Leucine: 
In relation to HMB and protein metabolism, it is not only the amount of protein 
intake which is important but also the quality of protein for positive effect on 
muscle protein synthesis. To support this argument Tang et al, reported that 
whey protein was superior to soy and casein in young healthy males in his 
study (Tang et al., 2009). Furthermore, different protein types have various 
profiles of essential amino acids (EAA), branched-chain amino acids (BCAA) 
and leucine. Accumulating evidence shows that leucine is not only a substrate 
for protein synthesis but also stimulate mTOR signalling pathway involved in 
protein anabolism (Katsanos et al., 2006). Supporting the above argument in 
a separate study Paddon-Jones et al reported that iso-caloric ingestion of 15g 
EAA with 15g whey protein against 15g whey protein alone showed more 
stimulation of MPS in the former group compared to later (Paddon-Jones et 
al., 2006). 
 
Figure 1-4: Structure of amino acid Leucine (Aristoy and Toldrá, 2004) 
 
 




1.4.2 Beta-Hydroxy-Beta-Methylbutyrate (HMB): 
Beta-Hydroxy-Beta-Methylbutyrate (HMB) is a metabolite of leucine (Figure 
1-4) one of the essential branched chain amino acids (Vukovich et al., 2001b). 
The benefits of dietary supplement of HMB to boost anabolic processes has 
been at the realm of scientific society for long time. Accumulating literature 
suggest that, HMB particularly enhances protein metabolism by stimulating 
MPS and attenuating MPB (Eley, Russell and Tisdale, 2008). HMB also plays 
a vital role in skeletal muscle myogenesis by expressing myoD and stimulate 
muscle anabolism by activating Akt pathway, which is critical in initiating MPS 
signalling (Kornasio et al., 2009). Furthermore, a recent study by Wilkinson et 
al., showed that oral consumption of 3.42g of free-acid HMB in healthy young 
male stimulated MPS and attenuated MPB (-57%) measured by Arterio-
Venous (A-V) balance (Wilkinson et al., 2013). This conceivable idea that, 
HMB can be a potent anabolic nutraceutical has interested commercial arena 
as well.  
1.4.3 HMB and carbohydrate metabolism: 
Accumulating evidence has shown that Beta-Hydroxy-Beta-Methylbutyrate 
(HMB) has positive impact on skeletal muscle protein metabolism such as 
enhancing muscle protein synthesis and suppressing muscle protein 
breakdown (Wilkinson et al., 2013, 2018; USU et al., 2019). However, 
published data, to date on carbohydrate metabolism and HMB 
supplementation is controversial, suggesting either null, negative or positive 




effects. Further, these studies were limited to younger individuals (Vukovich et 
al., 2001a) and were pre-clinical or animal studies (Kreider et al., 2000). 
Interestingly, related research in this area used calcium form of HMB which is 
deemed to have poor bioavailability and systemic clearance compared to free 
acid gel form (Fuller et al., 2011). Given the paucity of evidence regarding the 
effects of HMB supplementation on glycaemic parameters and insulin kinetics 
in humans (young and old), this study will attempt to explore this unchartered 
territory.  
So, combined exercise and nutraceutical interventions seems to have the 
potential to reverse some of the catabolic state associated with human skeletal 
muscle disuse atrophy and to positively influence glucose metabolism, 
however mechanisms underlying these processes are poorly defined and 
needs further exploration.  




1.5 Aim of the thesis: 
As summarised in the introduction section, disuse of human skeletal muscle 
(due to immobility, cancer, ageing etc.,) causes lot of undesirable effects 
leading to derangement of metabolic processes. Furthermore, ageing is a very 
complex process leading to loss of skeletal muscle mass and strength 
(sarcopenia) and inversely related to testosterone levels which together may 
have more detrimental effects of these metabolic process leading to morbidity 
and mortality. Further, available evidence to date on carbohydrate metabolism 
and HMB supplementation is controversial. So, molecular mechanism 
underlying the above process (involving ageing and muscle loss) and the 
counter measure (exercise, diet and rehabilitation) to abate this processes is 
largely unknown, hence: 
1. Firstly, we aim to investigate the effects of single leg immobilisation on 
muscle mass, muscle protein turnover and glucose uptake in healthy 
young men. We hypothesize hypothesise that in healthy young men, 
single leg immobilisation impairs skeletal muscle insulin resistance and 
causes muscle mass loss.  
2. Secondly, we aim to investigate the role of endogenous and exogenous 
testosterone (T) therapy in regulating resistance exercise-induced 
modulation of glycaemia control in young and older men, respectively. 
We hypothesise that testosterone suppression in young men blunts and 
supplementation in old men improves glycaemic control, respectively.  




3. Finally, we aim to investigate the effects of Beta-Hydroxy-Beta-
Methylbutyrate (HMB) on carbohydrate metabolism in young and old 
healthy men. We hypothesise that HMB improves glycaemic control.  




Chapter 2: General Methods 
This chapter will briefly discuss various methods and procedures commonly 
used across all the studies discussed below. Individual methodology relevant 
to specific chapters will be described in detail separately. 
2.1 Muscle Biopsies: 
Muscle biopsies are performed using conchotome biopsy technique as 
described by Dietrichson and colleagues (Dietrichson et al., 1987). After 
sterilising the skin over vastus lateralis of the quadriceps muscle, the skin and 
deep tissue is anaesthetised using 5ml of 1% Lidocaine. After 2-10 minutes a 
0.5 to 1cm skin incision will be made through the skin, subcutaneous tissue 
and muscle fascia. Using the conchotome about 200-300mg of muscle tissue 
will be taken. This will be immediately washed in ice cold 0.9% saline before 
blood, visible fat and connective tissue are removed. Immediately after this the 
muscle tissue will be frozen in liquid nitrogen before stored in -80 C until 
further analysis is conducted on the samples. 
2.2 DXA- Derived muscle mass: 
To analyse the total body muscle and fat mass before and after the study, DXA 
(64752, GE Medical Systems-Lunar Prodigy, US) was used to determine total 
FFM, legs LM, total fat percentage (TFP), total fat mass (TFM), FFM index 
(FFM divided by height squared (FFM·height-2), and appendicular FFM (fat 




free mass of arms and legs in kilograms divided by square of height in metres). 
Participants were asked to attend overnight fasted having not performed any 
heavy physical activity 24 h prior to scanning. For the DXA scan, participants 
wore loose comfortable clothing with no metal or plastic zippers, buttons or 
snaps.  Prior to use on participants, a QA block phantom is used to calibrate 
the system, to ensure optimal measurement. In addition, spine phantoms are 
run bi-monthly to assess the reproducibility and accuracy of the system over 
time. 
2.3 Oral Glucose tolerance test (OGTT) and Glucose Assay: 
All participants completed a 2 h OGTT using 75 g unflavoured dextrose 
dissolved in water during the study. Venous blood samples were obtained at 
before and every 15 min (0, 15, 30, 60, 75, 90, 105, and 120 min) after 
dextrose ingestion to be assayed for glucose and insulin levels. 
2.4 Glucose, Insulin and c-peptide analysis: 
Blood glucose was analysed using glucose analyser machine (YSI 2300 STAT 
PLUS, UK) and plasma insulin and C-peptide concentrations were measured 
using high-sensitivity insulin enzyme linked immunosorbent assays (Insulin: 
DRG Instruments GmbH, Marburg, Germany; C-peptide: EZHCP-20K, 
Millipore, US) according to the manufacturer’s protocol. 
  




Chapter 3: The effects of single leg immobilisation on muscle 
mass, muscle protein turnover and glucose uptake in healthy 
young men: 
3.1 Overview: 
Background and Aims: To determine the short term (4 d) impacts of 
unilateral knee brace- mediated immobilisation model, in relation to muscle 
mass, protein turnover and glucose uptake.  
Methods: 9 Healthy young men (22±2 y, BMI 24±1 kg/m2) underwent 4 d 
immobilisation wherein one leg was immobilised and other leg remained 
ambulant (control). Muscle mass via ultrasound derived vastus lateralis (VL), 
muscle thickness (MT) and maximal voluntary contraction (MVC) via 
dynamometer and thigh lean mass (TLM) via DEXA were collected in both 
legs at baseline and after 4 d of immobilisation. After a baseline blood and 
saliva sample, subjects consumed 3 mL/kg of 70% deuterium oxide (D2O) with 
additional saliva samples collected throughout the study. Bilateral VL muscle 
biopsies were collected on day 4 (at t=-120, 0, 90, and 180 min) to determine 
4 d integrated MPS, estimated MPB, and acute fasted/fed MPS using a primed 
constant infusion of L-[ring-13C6]-phenylalanine, with cellular muscle anabolic 
and catabolic as well as glucose signaling quantified via immuno-blotting.  




Results: After 4 d, the immobilised leg showed a decrease in TLM (Pre: 7477 
± 423g, Post: 7352 ± 427g (P <0.01)), MT (Pre: 2.67 ± 0.17cm, Post: 2.56 ± 
0.17cm (P <0.05)) and strength (Pre: 264 ± 23 N.m, Post: 229 ± 12 N.m (P 
<0.05)) with no change in control. 4d integrated MPS was decreased in 
immobilised vs control legs (Control: 1.55 ± 0.07 %.d-1, Immobilised: 1.29 ± 
0.06 %.d-1 (P<0.01), whilst FBR remained unchanged (Control: 1.44 ± 0.18 
%.d-1, Immobilised: 1.73 ± 0.12 %.d-1)). Only the control leg increased acute 
MPS in response to feeding (Fasted: 0.043 ± 0.004 %.h-1, Fed: 0.065 ± 0.006 
%.h-1 (P<0.01)) with no change in immobilised (Fasted: 0.034 ± 0.005 %.h-1, 
Fed: 0.049 ± 0.005 %.h-1). There was no change in markers of anabolic and 
catabolic signalling with immobilisation. GLUT4 levels significantly reduced in 
immobilised group (p<0.05) compared to control group. Plasma insulin 
concentration during IV EAA/ Dextrose clamp showed significantly higher 
(p<0.05) compared to basal values.  
Conclusion: Disuse atrophy acutely is driven by decline in MPS rather than 
increase in MPB and seems to induce insulin resistance. Pro-anabolic 
strategies may circumvent these catabolic effects. 
  





From a health perspective, skeletal muscle is a critical, but somewhat 
underappreciated, tissue. Beyond its role in generating contractile force for 
movement, skeletal muscle is the primary site of postprandial glucose 
disposal, contributes largely to circulating lipid oxidation, accounts for a large 
portion of resting metabolic rate, and is vitally important with advancing age. 
Reduced physical activity or muscle disuse results in muscle atrophy, which 
can lead to impaired functional capacity, the onset of insulin resistance, as well 
as an increased risk for morbidity and mortality. Periods of muscle disuse are 
unavoidable due to a variety of situations such as hospitalisation, homebound 
sickness, or orthopedic injuries. In fact, people will likely experience multiple 
bouts of skeletal muscle disuse during their lifetime from which some might fail 
to fully recover. Thus, muscle disuse is a significant and continuing problem 
resulting loss of muscle mass, strength/function, and metabolic health 
(particularly insulin-induced glucose disposal). Understanding the etiology of 
muscle disuse atrophy is essential if we are to develop effective strategies to 
combat this process, reduce healthcare costs, as well as improve human 
health and independence. The mechanism(s) causing muscle atrophy remain 
a subject of debate, which has been recently discussed in a Crosstalk article 
(Phillips and Mcglory, 2014; Reid, Judge and Bodine, 2014). The major 
question that remains to be addressed is which process – muscle protein 
synthesis (MPS) or muscle protein breakdown (MPB) – is predominantly 
affected with skeletal muscle disuse leading to atrophy in humans? The 




current study will assess both MPS and MPB but will also discuss muscle 
glucose uptake following single leg immobilisation. 
3.3 Aim of the study: 
Our overall aim is to define the molecular mechanisms causing disuse atrophy 
in young men and the effects of single leg immobilisation on muscle mass, 
protein turnover and glucose uptake. 
3.4 Materials and Methods: 
3.4.1 Inclusion Criteria: 
1) Healthy males, between the ages of 18 and 30 y 
2) BMI between 18.5 and 30.0 kg/m2 
3) Able and willing to provide informed consent 
3.4.2 Exclusion Criteria: 
1) The use of anti-inflammatory and/or analgesic medication, whether it is 
prescription or not 
2) A history of neuromuscular disorders or muscle/bone wasting diseases 
3) Any acute or chronic illness, cardiac, pulmonary, liver, or kidney 
abnormalities, uncontrolled hypertension, insulin-dependent or insulin-
independent diabetes, or the presence of any other metabolic disease 
– all of which will be determined via a medical history screening 
questionnaire  




4) The use of any medications known to affect protein metabolism 
(glucocorticoids, nonsteroidal anti-inflammatory medication, or 
prescription strength acne medication, etc.)  
5) A (family) history of thrombosis 
6) The use of anticoagulant medications 
7) Consumption of tobacco-containing products 
8) Excessive alcohol consumption (>21 units/week) 
9) History of bleeding diathesis, platelet or coagulation disorders, or 
antiplatelet/anticoagulation therapy 
3.4.3 Sample Size Calculations:  
The sample size calculation is based on data from Wall et al.(Wall et al., 2016), 
who used a similar study design to assess rates of muscle protein synthesis 
in the postprandial state following lower limb immobilisation. They observed 
lower postprandial muscle protein synthesis rates in the immobilised when 
compared with non-immobilised leg (0.020±0.007 vs. 0.044±0.010 %/h, 
respectively). Based on this observed difference, we will require 5 participants 
in the current study to ensure a power of 95% and a significance level of 5% 
(see Figure 3-1 below for details).To account for subject dropouts, we recruited 
9 participants for the study. 





Figure 3-1: Sample Size Calculation 
3.4.4 Conduct of the studies: 
A schematic representation of the experimental design can be seen in Figure 
3-2. Nine young, healthy males (mean ± SEM: age, 22 ± 1 y; body mass index, 
24 ± 1 kg.m-2) volunteered to take part in this study. Volunteers were initially 
screened by medical questionnaire, with exclusions for history of any 
neuromuscular disorder or muscle/bone wasting disease, acute or chronic 
metabolic, respiratory or cardiovascular disorder, or any other signs of ill 
health. All participants were performing activities of daily living or recreation 
upon entry to the study, but were not routinely undertaking heavy, structured 




exercise. Participants did not use tobacco-containing products or consume 
excessive alcohol (> 21 units per week). The experimental procedures were 
approved by the Hamilton Integrated Research Ethics Board (HiREB #2192) 
and conformed to the Declaration of Helsinki. Written informed consent was 
obtained from all participants prior to their participation. 
This study involved a bilateral leg protocol, with one leg randomly assigned to 
be immobilised and the other consequently used as a co-temporal 
contralateral control. Upon inclusion, participants were asked to visit the 
laboratory on two separate occasions, both of which followed an overnight fast. 
On the first visit, participants had the thigh lean mass of both legs measured 
using dual-energy X-ray absorptiometry (Lunar iDXA; GE Medical Systems, 
Mississauga, ON), before ingesting a bolus dose of D2O (3 mL.kg-1) for the 
measurement of integrated MPS rates. A saliva and blood sample was 
obtained prior to and 2 h following D2O consumption for measurement of 
deuterium enrichment in body water. Mid-thigh vastus lateralis CSA was 
assessed using B-mode ultrasonography (Vivid Q, GE Medical Systems, 
Horten, Norway). During the first assessment, a mark was made with 
permanent marker 50% of the distance between the greater trochanter of the 
femur and the lateral epicondyle of the knee, identified by palpation. A thick 
layer of acoustic gel was applied on the leg at the area of measurement and 
care was taken to avoid depressing the muscle belly during image acquisition. 
Maximal voluntary isometric contraction torque (MVC) of each leg was 
assessed using Biodex dynamometer (Biodex System 3; Biodex Medical 




Systems, Shirley, New York) at an angle of 60°. Thereafter, a knee brace (X-
Act ROM; DonJoy, Dallas, TX, USA) was fitted to the immobilisation 
randomised leg and fixed at an angle of 60° of knee flexion. Participants 
continued to wear the knee brace as described for a duration of 3 full days, 
collecting a saliva sample each day, before returning to the laboratory for their 
second visit exactly 4 d after the first visit. Upon arrival for visit 2, participants 
had their knee brace removed, DXA thigh lean mass measured, Ultrasound 
scan and a further saliva sample was obtained. Participants were transported 
between stations in a wheelchair to prevent weight bearing in the immobilised 
leg prior to undergoing the infusion trial described below. 
 
Figure 3-2: Schematic representation of study Design 
Participants reported to the laboratory in the overnight fasting state (at least 
10 h fasted). The knee brace was removed, and participants remained in a 
supine position on a laboratory bed for the entire duration of the infusion trial. 
A catheter was placed in an antecubital vein for amino acid and dextrose 




infusions. A second catheter was inserted into an antecubital vein of the 
contralateral arm and placed under a heated blanket for arterialised blood 
sampling. After obtaining a baseline blood sample (t = -210 min), a primed 
constant infusion of L-[ring-13C6]-phenylalanine (0.4 mg/kg prime; 0.6 
mg/kg/h infusion) was initiated for the assessment of MPS. Additional blood 
samples were collected at multiple time points: t = -180, -120, -100, -80, -70, -
60, -50, -40, -30, -20, -10, 0, 20, 40, 60, 80, 100, 110, 120, 130, 140, 150, 160, 
170 and 180 mins. At t = -120 min, a saliva sample was collected, and the first 
muscle biopsies were taken from both the immobilised and control leg for 
measurement of integrated MPS. Further muscle biopsies were collected from 
both legs at t = 0 min to determine basal MPS based on L-[ring-13C6]-
phenylalanine incorporation. After collecting the muscle biopsies, primed 
constant infusions of amino acids (34 mg/kg prime; 102 mg/kg/h infusion; 
PRIMENE 10%, Baxter Corporation, Mississauga, Ontario, Canada) and 
dextrose (blood glucose clamped at 7.0-7.5 mM) was started to mimic a 
postprandial state for the remainder of the infusion trial. During the 
postprandial state, the L-[ring-13C6]-phenylalanine infusion rate was 
increased to 0.86 mg/kg/h to account for unlabelled phenylalanine entering the 
free amino acid pool and prevent dilution of the precursor pool. At t = 90 and t 
= 180 min, muscle biopsies were collected from the immobilised and control 
legs. After the final biopsies, participants were provided with juice and a snack, 
the dextrose infusion was gradually decreased, and other infusions were 
stopped. Plasma glucose was monitored for another 30 min in order to prevent 




hypoglycaemia. Blood samples were collected in EDTA containing tubes and 
centrifuged at 1800 g for 10 min at 4°C. Aliquots of plasma were frozen in 
liquid nitrogen and stored at -20°C. Biopsies were collected from the middle 
region of the m. vastus lateralis, approximately 15 cm above the patella and 3 
cm below entry through the fascia, using the percutaneous needle biopsy 
technique. Muscle samples were dissected carefully, freed from any visible 
non-muscle material, immediately frozen in liquid nitrogen, and stored at -80°C 
until further analysis. A schematic representation of the infusion trial can be 
seen Figure 3-3 
 
Figure 3-3  Schematic representation of Infusion trial 
 
3.4.5 Measurement and measurements instruments: 
During the screening visit, body height (m) and mass (kg) were measured to 
calculate BMI (kg/m2). Systolic and diastolic blood pressure (mmHg) were 
assessed using an automated blood pressure monitoring device. On day 0 
and at the end of the study, body composition (i.e., fat (%), appendicular lean 




mass (kg), and lean body mass (kg)) were determined by dual-energy X-ray 
absorptiometry (DXA). Ultrasound was used to assess thigh muscle thickness 
and CSA, and a Biodex dynamometer was used to quantify maximal isometric 
strength in both the immobilised and control legs. 
Baseline saliva and blood samples were collected on day 0 immediately before 
and 2 h after ingesting D2O to determine deuterium enrichments in the body 
water and protein-bound (albumin) pool, respectively. Additional blood 
samples were taken every 15 min during the 2h amino acid infusion. One 
saliva sample was collected every morning afterwards (day 1- 3) to measure 
the decay of deuterium enrichment in the body water. On the last day of the 
study (day 4) participants collected a final saliva sample and had their muscle 
biopsies taken from both the immobilised and control legs (muscle biopsies 
from the infusion trial will be used). This method allows for the determination 
of muscle protein synthesis rates over the entire duration of the immobilisation 
trial by measuring the incremental incorporation of deuterium-labelled alanine 
into the muscle protein-bound pool and assesses whether daily MPS rates 
differ between the control and immobilised leg. Comparisons can then be 
made between the chronic measurements of muscle protein synthesis (using 
the D2O method) and the acute measurements of muscle protein synthesis 
(using 13C6-Phe method) in response to a transient period of immobilisation. 
During the infusion trial (day 4), a primed constant infusion of 13C6-Phe in 
combination with repeated plasma sampling and muscle biopsy collection to 




determine both basal and postprandial MPS rates using the precursor-product 
method were used.  
All muscle biopsy samples were collected under sterile conditions, using the 
conchotome biopsy technique (Dietrichson et al., 1987) with 1% w·v-1 lidocaine 
as local anaesthetic. Any fat tissue and connective tissue was rapidly 
dissected out and muscle was washed in ice-cold phosphate-buffered saline 
(PBS) and frozen in liquid nitrogen or liquid-nitrogen cooled isopentane, before 
storage at -80°C. 
Dextrose was infused according to a protocol adapted from DeFronzo et al. 
(DeFronzo, Tobin and Andres, 1979) until a steady-state blood glucose 
concentration of 7-7.5 mM was obtained. To measure glucose concentrations 
over the course of the dextrose infusion, serial blood sampling was performed 
every 5-minutes and analysed with the YSI STAT 2300.  
Muscle biopsies were collected (as described above) from the immobilised and 
non-immobilised leg on day 4 during the infusion trial at t=-120, 0, 90, and 180 
min. Myofibrillar protein were extracted to determine myofibrillar protein-bound 
2H-alanine (only t=-120), 13C6-Phe, 2H8-Phe, and 15N-Phe enrichments by 
gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-
IRMS). The saliva samples were analysed for 2H enrichments by cavity 
ringdown spectroscopy. Plasma samples were analysed for 13C6-Phe, 2H8-
Phe, and 15N-Phe enrichments. Fractional synthetic rates of muscle protein 
synthesis were calculated by dividing the increment in muscle protein-bound 




2H-alanine or 13C6-Phe enrichment between two muscle biopsies (or plasma 
albumin) over time by the average enrichment in total body water or plasma. 
Myofibrillar protein breakdown rates were determined by measuring the 
dilution of the muscle intracellular amino acid pool upon cessation of tracer 
incorporation. 
3.4.6 Body water and protein bound alanine muscle fraction enrichment 
Body water enrichment was measured as previously described (Daniel J. 
Wilkinson et al., 2014). Saliva was heated in a vial at 100°C, then cooled 
rapidly on ice and the condensate transferred to a clean vial ready for analysis. 
Deuterium enrichment was measured on a high-temperature conversion 
elemental analyser connected to an isotope ratio mass spectrometer (TC/EA-
IRMS Thermo Finnigan, Hemel Hempstead, UK). For isolation of myofibrillar, 
sarcoplasmic, and collagen fractions, 30–50 mg of muscle was used. The 
muscle was homogenised in ice-cold homogenisation buffer [50mM Tris·HCl 
(pH 7.4), 50mM NaF, 10mM ␤-glycerophosphate disodium salt, 1mM EDTA, 
1 mM EGTA, and 1mM activated Na3VO4 (allfrom Sigma-Aldrich)] and a 
complete protease inhibitor cocktail tablet (Roche, West Sussex, UK) at 10 
µl/µg tissue. Homogenates were rotated for 10 min, and the supernatant was 
collected by centrifugation at 1000 g for 15 min at 4°C. The pellet was re-
suspended in 500 μL mitochondrial extraction buffer (MEB), dounce 
homogenised and the supernatant removed after centrifugation at 1000g for 5 
min at 4 °C. The myofibrillar pellet was solubilised in 0.3 M NaOH and 




separated from the insoluble collagen by centrifugation, and the myofibrillar 
protein was precipitated with 1 M perchloric acid. The protein was then 
precipitated, acid hydrolysed, and the free amino acids were purified and 
derivatised as their n-methoxycarbonyl methyl esters (MCME). Incorporation 
of deuterium into protein bound alanine was determined by gas 
chromatography-pyrolysis-isotope ratio mass spectrometry (GC-pyrolysis-
IRMS, Delta V Advantage; Thermo Finnigan, Hemel Hempstead, UK) 
alongside a standard curve of known dl-Alanine-2,3,3,3-d4 enrichment to 
validate measurement accuracy. MPS, FGR and FBR were calculated as 
previously described (Gharahdaghi et al., 2019). The incorporation of L-[ring-
13C6]-phenylalanine was determined by gas chromatography–combustion-
isotope ratio mass spectrometry (Delta plus XP; Thermofisher Scientific, 
Hemel Hempstead, United Kingdom) with Muscle intracellular phenylalanine 
enrichment was measured by gas chromatography-mass spectrometry (Trace 
DSQ; Thermofisher Scientific) following precipitation of the sarcoplasmic 
fraction and purification of the aqueous supernatant using Dowex H+ resin as 
described above, with AAs converted to their tert-butyldimethylsilyl derivatives. 
The fractional synthesis rates (FSR) of the myofibrillar proteins was calculated 
using the precursor-product relationship as previously described (Bukhari et 
al., 2015). 
3.4.7 Immunoblotting for muscle signalling pathway activity  




Immunoblotting was performed as previously described (Atherton et al., 2010) 
using the sarcoplasmic fraction isolated from MPS preparation. Sarcoplasmic 
protein concentrations were analysed using a NanoDrop ND1000 
spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE-US) and 
sample concentrations adjusted to 1µg/µl in 3x Laemmli buffer to ensure 
equivalent protein loading onto a Criterion XT Bis-Tris 12 % SDS-PAGE gel 
(Bio-Rad, Hemel Hempstead, UK) for electrophoresis for 1h at 200 V. 
Separated proteins were transferred onto a PVDF membrane for 45 min at 
100 V, then blocked in 5 % low-fat milk in Tris-buffered saline and 0.1 % 
Tween-20 (TBST) for 1h at room temperature. Membranes were then 
incubated at 4OC over-night in 5 % milk diluted in TBST primary antibody 
solutions. Afterwards membranes were washed 3 x 5 min with TBST and 
incubated for 1h at room temperature in their respective HRP conjugated 
secondary antibody, anti-rabbit (Cell Signalling Technologies) 1:2000 5 % low-
fat milk in TBST, anti-mouse (Cell Signalling Technologies) 1:2000 5 % low-
fat milk in TBST. Membranes were washed 3 x 5 min in TBST and incubated 
for 5 min in enhanced chemiluminescence reagent (Millipore, Watford, UK) 
and visualized using a Chemidoc XRS. Bands were quantified using ImageLab 
software and normalised to total loaded protein visualised by Coomassie 
brilliant blue staining [29]. Primary antibodies against p-AKT Ser473 (1:2000, 
#4060), Pan-AKT (1:2000, #4685), p-TSC2 Thr1462 (1:2000, #3611), TSC2 
(1:2000, #4308), p-mTOR Ser2448 (1:2000, #2976), mTOR (1:2000, #2972), 
p-p70S6K1 Thr389 (1:2000, #9234), p70S6K1 (1:2000, #2708), p-S6RP 




Ser235/236 (1:2000, #2211), S6RP (1:2000, #2217), p-4e-BP1 Thr37/46 
(1:2000, #2855), 4e-BP1 (1:2000, #9644), p-eIF4E Ser209 (1:2000, #9741), 
eIF4E (1:2000, #9742) were from Cell Signalling Technologies. Fed (90 min) 
data was normalised to control mean and transformed using Y= (log(1+Y)). 
  





Mainly, muscle mass, MPS, MPB, some biomarkers related to protein 
metabolism and glycemic control will be discussed below (in relation to this 
thesis). 
3.5.1 Muscle mass, VL Thickness and Strength: 
 
Figure 3-4: Pre and post measures in control and immobilised legs of A) Thigh Lean Mass B) VL muscle 
thickness C) Peak torque. ** P<0.01, * p<0.05 
At baseline there was no significant difference in DXA derived TLM, VL MT or 
strength, between legs. Over the 4 d study period the control leg showed no 
change in TLM (Pre: 7476 ± 475 g, Post: 7501 ± 477 g), MT (Pre: 2.69 ± 0.18 
cm, Post: 2.65 ± 0.17 g) or strength (Pre: 253 ± 16 N.m, Post: 260 ± 15 N.m). 
The immobilised leg showed a decrease from baseline in TLM (Pre: 7477 ± 
423 g, Post: 7352 ± 427 g (P <0.01)) (Figure 3-4A), MT (Pre: 2.67 ± 0.17 cm, 
Post: 2.56 ± 0.17 g (P <0.05)) (Figure 3-4B), and strength (Pre: 264 ± 23 N.m, 



































































3.5.2 Integrated MPS, Fractional growth and breakdown rates: 
 
Figure 3-5: Over the 4 d study period in control and immobilisation legs A) muscle protein synthesis %.d-
1 B) fractional growth rate %.d-1 C) fractional breakdown rate %.d-1 D) correlation between the change in 
MPS vs  change in VL MT. ** P<0.01,  * P <0.05. 
Post 4 d study period integrated MPS was decreased in the immobilised vs 
the control leg (Control: 1.55 ± 0.07 %.d-1, Immob: 1.29 ± 0.06 %.d-1 P<0.01) 
(Figure 3-5A). Likewise, the FGR was decreased in the immobilisation leg 
(Control: 0.08 ± 0.12 %.d-1, Immob: -0.38 ± 0.11 %.d-1 P<0.05) (Figure 3-5B), 
whilst the FBR remained unchanged (Control: 1.44 ± 0.18 %.d-1, Immob: 1.73 



































































in MPS (P=0.03, r2 = 0.05)(Figure 3-5D) and was not correlated with the 
change in FBR (P=0.17, r2 = 0.29). 
3.5.3 Acute muscle protein synthesis: 
 
 
Figure 3-6: A) acute fasted and fed MPS rates in control and immobilised legs B) the absolute decrease 
in integrated or acute muscle protein synthesis %.d-1 assuming 2/3 of the day is spent fasted and 1/3 
fed). Correlation between change in fasted to fed muscle protein synthesis vs C) change in fasted to fed 
P-RPS6 and D) change in fasted to fed P-4EBP1 **P<0.01 
After 4 d of immobilisation, there was an overall trend for decreased MPS 
(effect of immobilisation P=0.07) yet fasted and fed rates of acute MPS 
































































































































increased MPS in response to feeding (Fasted:  0.043 ± 0.004 %.h-1, Fed: 
0.065 ± 0.006 %.h-1 (P<0.01)) with no change in immobilisation (Fasted: 0.034 
± 0.005 %.h-1, Fed: 0.049 ± 0.005 %.h-1) (Figure 3-6A). The absolute decrease 
in MPS %.d-1 from integrated or acute MPS were similar (Integrated: -0.26 ± 
0.05 %.d-1, Acute: -0.27 ± 0.12 %.d-1 (assuming 2/3 of the day is spent fasted 
and 1/3 fed) (Figure 3-6B). The change in MPS was not correlated with either 
the change in RPS6 or 4EBP1 phosphorylation from fasted to fed states 
(Figure 3-6C&D). Overall, markers of both anabolic and catabolic markers 
were similar between control and immobilised leg, with no effect of 
immobilisation on markers of MPB (Table 3-1). 




Table 3-1: Muscle anabolic and catabolic signalling in control and immobilisation legs. *Significantly 
different to fasted, * P <0.05 
 
3.5.4 Glucose related biomarker and Insulin levels: 
Levels of GLUT4 were significantly reduced in immobilised group (p<0.05) 
compared to control group. No changes in the levels of AS160 and PGC1b 
were noted compared to control and immobilised group (Figure 3-7).  Plasma 
insulin concentration during IV EAA/ Dextrose clamp showed significantly 
(p<0.05) higher compared to basal values (Figure 3-8). 
 
  Fasted Fed 
P-mTOR S2448 C 0.60 ± 0.16 0.61 ± 0.09 
I 0.56 ± 0.17 0.52 ± 0.09 
P-4EBP1 T37/46 C 0.67 ± 0.08 0.72 ± 0.06 
I 0.84 ± 0.10 0.84 ± 0.09 
P-AKT S473 C 0.67 ± 0.08 1.02 ± 0.17 
I 0.60 ± 0.07 1.12 ± 0.21* 
P-RPS6 S235/236 C 0.52 ± 0.21 1.78 ± 0.19* 
I 0.57 ± 0.17 1.62 ± 0.34* 
P-eIF4E S209 C 0.66 ± 0.09 0.66 ± 0.10 
I 0.78 ± 0.10 0.59 ± 0.07 
P-eIF4B S422  C 0.69 ±0.05 0.88 ± 0.15 
I 0.59 ± 0.10 0.77 ± 0.13 
P-eEF2 T56 C 0.68 ± 0.06 0.67 ± 0.04 
I 0.65 ± 0.06 0.71 ± 0.04 
Calpain 1 C 0.69 ± 0.04 0.74 ±0.04 
I 0.78 ± 0.04 0.77 ± 0.03 
MAFbx C 0.63 ± 0.13 0.74 ± 0.15 
I 0.76 ± 0.08 0.72 ± 0.11 
Ubiquitin C 0.69 ± 0.04 0.70 ± 0.03 
I 0.76 ±0.06 0.64 ± 0.03 





Figure 3-7: Baseline Control (C) vs Immobilised (I)– Quantification of western blots of (A) GLUT4, (B) AS160 & (C) PGC1-β. * significant different from control (p<0.05). 
Measured by paired t test. n=8





Figure 3-8: Insulin response to IV EAAs/ Dextrose – Plasma insulin concentrations. *Greater than 
basal p<0.05, ** p<0.01. 
3.6 Discussion:  
Burgeoning problem of persistent state of insulin resistance, such as Type 2 
diabetes and ageing, and its association with sarcopenia is a growing concern 
(Nilwik et al., 2013; Perry et al., 2016). Hence, there is a great need amongst 
scientific field to understand the effects of human skeletal muscle disuse 
atrophy and its effects on MPB, MPS and glycemic control. Many situations 
such as hospitalisation, recovery from illness, injury etc., results in a period of 




physical inactivity that is associated with the accelerated loss of muscle mass 
and muscle strength (Kouw et al., 2019). This muscle atrophy is clearly 
noticeable in prolonged period of immobilisation (Trappe et al., 2008; Fitts et 
al., 2010). But emerging evidence suggests these process happening at much 
earlier in the periods of skeletal muscle disuse (Wall et al., 2014; Kilroe et al., 
2020). Furthermore, short successive periods of immobility called as “catabolic 
crisis” have been proposed to contribute to the persistent age-related skeletal 
muscle loss and strength (Alley et al., 2010; Wall, Dirks and Van Loon, 2013; 
Kouw et al., 2019).  
There is an overabundance of clinical studies, using different immobilisation 
models, that have investigated the degree of muscle loss in humans exposed 
to disuse (Rudrappa et al., 2016). The most frequent employed models to 
study disuse atrophy in humans are unilateral limb suspension (ULLS) using 
a knee brace or cast, and bed rest; other scenarios include spinal cord injury 
and spaceflight. In terms of muscle mass, the observed rate of decline in 
muscle size (cross sectional area (CSA)) for each day of ULLS in knee 
extensors was ~0.40% and ~0.36% for plantar flexors following 42 d of 
unloading (Hackney and Ploutz-Snyder, 2012). Other studies have 
demonstrated losses of muscle strength and mass early on in disuse, i.e. 5 d 
of cast immobilisation lead to ~3.5% reductions in quadriceps CSA and ~9% 
in strength (Dirks et al., 2014). This had progressed to ~8% reductions in CSA 
and ~23% reductions in strength by 14 d (Wall, Dirks and Van Loon, 2013). 
Supporting the above findings, we herein, report loses of ~11% in as little as 




4 d of unilateral immobilisation using knee braces. Additionally, Suetta et al. 
reported ~10% reductions in myofibre cross sectional area and ~13% 
decreases in strength after just 4 d progressing to ~20% reductions in myofibre 
area and strength after 14 d of ULLS (Suetta et al., 2012, 2013). Likewise, we 
report a significant decline in DXA derived muscle loss of 1.7%; correlated with 
significant decline in MT of 4%. Hence, our data adds to current literature 
suggesting that muscle loss occurs rapidly at onset of immobilisation.  
It is reported that, disuse skeletal muscle atrophy results from both decreased 
protein synthesis and increased protein breakdown, resulting in net skeletal 
muscle mass loss (Huang and Zhu, 2016; Rudrappa et al., 2016). Early studies 
using amino acid tracers revealed that immobilisation results in a decline in 
both fast and fed-state MPS likely inducing a state of anabolic resistance (de 
Boer et al., 2007; Elisa I. Glover et al., 2008; Wall et al., 2013). But, these 
studies possibly showed only a ‘snap shot’ of protein balance (Atherton et al., 
2015). Hence, measures to evaluate integrated MPS is important, so D2O 
provides an effective tool at quantifying this bye encapsulating anabolic and 
catabolic responses over the entire measurement periods (Daniel J Wilkinson 
et al., 2014; Brook et al., 2015; Mcglory et al., 2019). Herein, we combined 
integrated D2O MPS measures along with acute AA tracer to capture not only 
early integrative changes in MPS but also acute feeding responses. We show 
that VL MPS is significantly depressed over 4 d of ULLS and that this was 
correlated with loss of VL MT, providing further evidence that declines in MPS 
are predominant in muscle mass loss. Interestingly, we show that by day 4 this 




is primarily a result of impaired feeding responses and a tendency for overall 
reduced muscle protein synthesis in fasted/fed states; the earliest observation 
of immobilisation induced anabolic resistance. Additionally, not only we 
showed similar declines in daily integrative MPS (i.e., from our D2O measures) 
but also in daily acute MPS (i.e., from our acute measures). These findings 
further support the argument that MPS can alone explain declines in muscle 
mass, in the absence of bulk rise in MPB.  
Furthermore, the role of MPB remain unclear in setting of disuse muscle 
atrophy. Moreover, increased markers of MPB during early stages of disuse 
has been indicated in a possible role in causation (Urso et al., 2006; Dirks et 
al., 2014). Emerging evidence suggests that calpains plays an important role 
in dysregulation of proteolysis seen in muscle atrophy and further, abnormally 
activated calpain results in muscle atrophy via its downstream effects on 
ubiquitin-proteasome pathway (UPP) and Akt phosphorylation (Huang and 
Zhu, 2016). In contrast, our study showed no changes to calpain mediated 
pathway in setting of skeletal muscle disuse. Interestingly, increased calpain-
dependent protein degradation seen in calcium-treated skeletal muscle could 
be associated with reduced HSP90 and hence Akt activation (Huang and Zhu, 
2016). But, in our study no increase in Akt was noted. Further, we showed 
rates of MPS combined with the net change in muscle mass per day (FGR) to 
calculate FBR. Studies has shown that, using these validated equations fairly 
accurate estimation of FBR can be obtained (Hector et al., 2018; Gharahdaghi 
et al., 2019). Herein, we calculated no overall increase in FBR with single leg 




immobilisation. Interestingly, changes in FBR were not correlated with 
declines in muscle mass and no change in key markers of MPB. Above finding 
suggests the notion that reduced MPS rather than increased MPB may be a 
major contributor in muscle mass loss during immobilisation.  
Insulin-mediated glucose uptake is also blunted with muscle disuse (Mikines 
et al., 1991; Biensø et al., 2012); that is, unloaded muscle becomes IR. This 
IR can be observed at a whole-body level following bed-rest, but is most 
apparent at the muscle level across the physiological range of insulin 
concentrations under clamp conditions (Mikines et al., 1991). Recently, a one 
week bed-rest study in young males by Dirks et al, revealed reduced muscle 
mass (~1.4 kg lean tissue and ~3% quadriceps CSA) and whole-body insulin 
sensitivity (~29%) (Dirks et al., 2016). Thus, disuse lowers MPS, induces 
anabolic resistance to nutrients and impairs insulin-mediated muscle glucose 
uptake - even in healthy adults (Fink, 1983). Furthermore, it is accepted that 
the GLUT4 glucose transporter is a major mediator of glucose removal from 
the circulation and a key regulator of whole-body glucose homeostasis and 
mainly expressed on adipose tissue and skeletal muscles (Huang and Czech, 
2007). In addition, Blakemore et al. reported that, the concentration of GLUT4 
protein were significantly reduced (50%) in immobilised limb after 1 week and 
it persisted for 6 weeks (Blakemore et al., 1996). In support of this observation 
our study showed significantly (p<0.05) reduced GLUT4 in immobilised leg 
compared to control (non-immobilised leg). Accumulating evidence has shown 
that peripheral insulin resistance (hyperinsulinemia)  develops immediately 




after immobility (such as post-surgery immobilisation) and might be associated 
with perturbations in insulin stimulated GLUT4 pathway (Thorell et al., 1999). 
Likewise, in our study, we noted significant increase in plasma insulin level 
post immobilisation suggesting development of peripheral insulin resistance.   
In conclusion, 4 d single leg immobilisation in young men induces significant 
skeletal muscle atrophy driven by sustained reduction in MPS. MPB does not 
seem to play any major role in muscle atrophy, as evidenced by lack of 
changes in catabolic markers and no increase in FBR, albeit a calculated 
measure with its own limitations. That being said, we showed decreased in 
integrated MPS accompanied by anabolic resistance possibly driven by 
development of peripheral insulin resistance (supported by reduced GLUT4 
activity). So, development of effective counter measure is warranted to 
overcome this cascade of catabolic processes triggered by muscle disuse 
atrophy. 
  




Chapter 4: The role of endogenous and exogenous testosterone 
(T) therapy in regulating resistance exercise-induced 
modulation of glycaemia control in young and older men, 
respectively: 
4.1 Overview: 
Insulin resistance has assumed paramount importance as a risk factor for 
many metabolic diseases, coincident with the established pandemic of 
obesity, worldwide. The main behavioral strategies to overcome insulin 
resistance remain diet and exercise. However, the “andropause”, so-called 
due to age-related testosterone (T) depletion has been associated with 
impaired glycaemia control – leading to investigations of the role of T in 
regulating insulin sensitivity. Recently, T therapies have been evaluated in 
humans with variable effects, such that the role and efficacy of T therapy in 
relation to glycaemia control across age remains unclear. The aim of this study 
was therefore to investigate the mechanistic and therapeutic role of T therapy 
during 6- weeks of supervised resistance exercise training (RET), in relation 
to insulin sensitivity in groups of healthy younger and older men. We 
hypothesised T is a key factor in regulating exercise-induced improvements in 
glycaemia control.  




Methods: Healthy non-hypogonadal men were recruited (n=34; ‘younger 
group’~18-30y and ‘older group’ ~60-75y; all BMI≤30kg.m-2, serum T>230 
ng·dl-1) with the aim of determining the role of: i) endogenous suppression of 
T in relation to RET-induced improvements in glycaemia control, and ii) 
provision of exogenous T therapy adjuvant to short-term RET in older men. 
Thus, young men were assigned in a randomised double-blinded fashion to 
receive injection of either: placebo (YP; saline, n=8) or the GnRH analogue, 
Goserelin acetate 3.6mg (Zoladex) (YZ; n=8). Instead, older men received 
placebo (OP; saline, n=9) or Testosterone esters 250 mg (OT; n=9). All 
subjects underwent 6- weeks whole body RET (3-sets, 8-10 reps at 80% 1-
RM) with 75g oral glucose tolerance testing (OGTT baseline, after injection 
and after RET)  
Results: Provision of Goserelin significantly reduced serum T in YZ (vs. YP), 
while the OT group elicited marked enhanced serum T (both P<0.05) that were 
sustained throughout RET. Over 6-weeks of RET, both the OT group 
(1367±572 mU-1.2h-1, P=0.03) and YP group (2381±1013 mU-1.2h-1, 
P=0.009) showed decreased insulin area under curve (AUC), respectively. 
Further, measures of C-Peptide highlighted decreases in OT compared to OP 
(OT: 601±46 ng.ml-1 vs. OP: 830±77 ng.ml-1, P=0.02), with a decreasing trend 
in YP compared to YZ (551±57 ng.ml-1 vs. 789±116 ng.ml-1, P=0.08). 
Additionally, Cederholm index of peripheral insulin sensitivity in YP showed an 
increase from OGTT before and after RET (61.7±4.7 vs. 74.5±3.7 
mg⋅L2⋅mmol⋅L−1⋅mU−1⋅min−1, P<0.05), and in OT, showed a significant 




increase from baseline to OGTT after RET (57.3±5.1 vs 68.6±5.3 
mg⋅L2⋅mmol⋅L−1⋅mU−1⋅min−1, P<0.05). Finally, Matsuda index of insulin 
sensitivity in YP yielded significant increases based on fold-change from 
baseline OGTT to OGTT after RET (9.9±2.4 vs 12.8±3.2, P<0.05). 
Conclusions: T therapy (OT) and non-suppressed endogenous T (YP), 
enhanced insulin sensitivity (supported by reduced c-peptide) in older and 
young men, respectively, coupled with RET. We conclude: i) endogenous T is 
an important mediator of exercise-induced improvements in insulin sensitivity, 
and ii) T therapy adjuvant to pre/re-habilitation exercise may be of value to 
overcome the burgeoning trend of worsening insulin resistance with aging. 
4.2 Aim of the study: 
To investigate the mechanistic and therapeutic role of T therapy during 6-
weeks of supervised resistance exercise training (RET), in relation to insulin 
sensitivity in groups of healthy younger and older men. 
4.3 Materials and Methods: 
4.3.1 Ethics and study participants: 
This study was approved by The University of Nottingham Faculty of Medicine 
and Health Sciences Research Ethics Committee (G11082015 SoMS 
MSGEM), was conducted according to the declaration of Helsinki, and was 
pre-registered at clinicaltrials.gov (NCT02152839). Before entry into the study, 
participants provided written informed consent to participate after all 




procedures and risks were explained to them. All participants performed 
activities of daily living and were recreationally active but had not partaken in 
RET within the previous 12 months. Participants were screened by medical 
questionnaire, physical examination, routine blood chemistry and a resting 
electrocardiogram. Participants who presented with metabolic, respiratory or 
cardiovascular disorders or who were prescribed medication (e.g., beta-
adrenergic blocking agents, statins, anti-inflammatory drugs) and any other 
medications which could influence T metabolism were excluded. Of the pre-
screened volunteers, eighteen older (O) and sixteen younger (Y) non-
hypogonadal healthy normotensive (<140/90) volunteers males with morning 
normal serum T concentrations were assigned in a random double-blinded 
fashion to receive bi-weekly either: Old placebo, OP (saline, n=9) or Old 
Testosterone, OT (Sustanon 250-mg, n=9) injections in older groups and one 
off either: Young Placebo, YP (n=8) or young GnRH analogous (Goserelin, so 
called Zoladex, YZ) (3.6-mg, n=8) injections in younger groups over 6-weeks 
of whole-body supervised RET. All participants involved in the study were 
monitored throughout the study for any negative side effects of T injections. 
No adverse events were reported during or after completion of the study. 
4.3.2 Conduct of study: 
Following baseline measurements of maximal voluntary contraction (MVC) 
and 1-repetition maximum (1-RM; on separate days); regardless of group 
assignment, all participants were further characterised at baseline. This 




involved collection of fasting blood, oral glucose tolerance test (OGTT), muscle 
ultrasound (Mylab 70; Esaote Biomedica, Italy) of the m. vastus lateralis 
muscle (VL) and a dual-energy X-ray absorptiometry (DXA; Lunar Prodigy II, 
GE Medical Systems, Little Chalfont, UK) scan. Finally, injection of T or P in 
older groups and Z or P in younger groups was administered by an un-blinded 
research technician. The fully supervised RET protocol then commenced and 
continued for the next 6-weeks. A detailed schematic of the study protocol is 
depicted in Figure 4-1. 
Figure 4-1: Schematic of study protocol 
4.3.3 Resistance Exercise Training (RET) procedures and strength assessments: 
Participants in both groups performed the same whole-body RET including 
leg-extension, leg-press, leg-curl, lat-pull-down, shoulder-press and bench-
press (all 3-sets of 8-10 reps at 80% 1-RM)) (Sundell, 2011) 3-times· weeks -




1 non-consecutively for 6-weeks. Individuals’ 1-RM (Dohoney et al., 2002) was 
re-assessed every 2-weeks before the corresponding training session to 
maintain intensity with progression. 
4.3.4 DXA-derived muscle mass: 
To analyse the total body muscle and fat mass before and after the study, DXA 
(64752, GE Medical Systems-Lunar Prodigy, US) was used to determine total 
FFM, legs LM, total fat percentage (TFP), total fat mass (TFM), FFM index 
(FFM divided by height squared (FFM·height-2), and appendicular FFM (fat 
free mass of arms and legs in kilograms divided by square of height in metres). 
Participants were asked to attend overnight fasted having not performed any 
heavy physical activity 24 h prior to scanning. For the DXA scan, participants 
wore loose comfortable clothing with no metal or plastic zippers, buttons or 
snaps.  Prior to use on participants, a QA block phantom is used to calibrate 
the system, to ensure optimal measurement. In addition, spine phantoms are 
run bi-monthly to assess the reproducibility and accuracy of the system over 
time. 
4.3.5 Metabolic and biochemical measurements: 
4.3.5.1 Oral Glucose tolerance test (OGTT) and Glucose Assay: 
All participants completed a 2 h OGTT using 75 g unflavoured dextrose 
dissolved in water 3 times (OGTT1: before injection; OGTT2: ~5 d after first 
injection; OGTT3: after 6-weeks RET) during the study. Venous blood samples 




were obtained at before and every 15 min (0, 15, 30, 60, 75, 90, 105, and 120 
min) after dextrose ingestion to be assayed for glucose and insulin levels.  
4.3.5.2 Glucose, Insulin and C-peptide analysis:  
Blood glucose was analysed using glucose analyser machine (YSI 2300 STAT 
PLUS, UK) and plasma insulin and C-peptide concentrations were measured 
using high-sensitivity insulin enzyme linked immunosorbent assays (Insulin: 
DRG Instruments GmbH, Marburg, Germany; C-peptide: EZHCP-20K, 
Millipore, US) according to the manufacturer’s protocol. 
4.3.5.3 Testosterone Assay (ELISA): 
Venous blood samples were collected into EDTA-coated tubes intermittently 
during the study i.e., before injections and prior to individual RE sessions in 
the mornings to measure fluctuations in total T concentrations. Blood samples 
were immediately cold centrifuged at 1750 g, with resulting plasma fractions 
aliquoted and frozen at –80°C until further analysis. An enzyme-linked 
immunosorbent assay (ELISA; ab108666, Abcam, United Kingdom) 
competitive technique was used to assess the abundance of total T in the 
plasma of all participants the intra-assay coefficient of variation was <5%, and 
the assay sensitivity was 70 ng·dl-1; the detection range was 20-1600 ng·dl-1. 
 
 




4.3.5.4 Calculation of insulin resistance/sensitivity: 
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                                        (Ohkura et al., 2013) 
Where. G0 is fasting glucose level, I0 is fasting insulin level, G mean or I mean 
are mean of glucose or insulin levels during the OGTT, C-peptide0 is fasting 
C-peptide level, HOMA-IR is Homeostatic model assessment-insulin resistant, 
HOMA-β is Homeostatic model assessment-β cell function, Matsuda and 
Cederholm are indices of insulin sensitivity, GIR-index is glucose infusion rate-
index. In HOMA-IR, insulin levels is used to determine the resistance to insulin 
action and in HOMA-β C-peptide is used to determine pancreatic insulin 
secretion (β-cell function) (Matsuda and DeFronzo, 1999). 





Physiological characteristics of participants are shown in Table 4-1. In 
accordance, only the OT study group significantly increased weight (P=0.006) 
and BMI (P=0.006) after 6-weeks of RET; primarily through significant gains 
in FFM in the OT group vs. baseline (see body composition section below). 
Further, total T concentrations in the OT therapy group were significantly 
higher and in YZ group were significantly lower than in the corresponding P 
group at all time-points after baseline (P<0.05). Plasma T concentrations 
during the study are shown in Figure 4-2. 
Table 4-1: Physiological characteristics of participants 
 
YZ(n=8) YP(n=8) OT(n=9) OP(n=9) 
 
Baseline Week 6 Baseline Week6 Baseline Week6 Baseline Week6 


















23.1(1.1) 23.4(1.1) 22.9(1.4) 23.2(1.4) 25.7 (1) 26.2 (1)a 26.5(1.1) 26.7 
(1.1) 
   Values are means (SEM). 





Figure 4-2: Time course of changes in total T in young (A) and older (B) groups 
4.4.1 Body Composition: 
Total FFM increased significantly following 6-weeks RET in OT (53.0±1.7 to 
56.0±5.2 kg, 5.8%, P<0.0001, Figure 4-3 C), but not in OP (54.1±6.3 kg to 
54.8±5.8 kg, 1.46%). Further, TFM (22.5±2.0 kg to 21.3±1.8kg vs. 24.7±2.8kg 
to 24.5±2.7kg, P=0.01) decreased significantly in OT, but not in OP (Figure 
4-3 D). Additionally, FFM increased significantly to a greater extent following 
the 6-week RET in YP (55.9±1.7kg to 57.4±1.7kg, 2.7%, P=0.006, Figure 4-3 
A) than YZ (55.4±2.8kg to 55.8±3.1kg, 0.65%). However, YP study group 
showed a trend in decrease in TFM (19.1±3.4kg to 18.5±3.3kg, P=0.4) vs. YZ 
(16.7±1.9 kg to 17.4±2.1 kg, P=0.2, Figure 4-3 B). 
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Figure 4-3: changes in fat free mass (FFM) and total fat mass (TFM) in younger and older groups. 
Values are means ± SEM.  a- Significantly different from baseline 
4.4.2 Glucose, insulin and C-peptide levels: 
Over the RET, both the YP and OT subjects decreased AUC insulin, YP 
decreasing 2381 ± 1013 mU-1.2h-1, P = 0.009 and OT 1367 ± 572 mU-1.2h-1, 
P =0.03.  Further, measures of C-Peptide showed decreases in OT compared 
to OP (OT: 601±46 ng.ml-1.2h-1vs. OP: 830±77 ng.ml-1.2h-1, P=0.02), with a 
trend in YP compared to YZ (551±57 vs. 789±116, P=0.08). However, by 6 
weeks of RET there was no changes in glucose AUC of all groups (Figure 4-4). 
















Figure 4-4   changes in insulin, glucose and C-peptide (A-F). Values are means ± SEM.  a Significantly different from baseline, P<0.05; b significantly different between two 
groups, P<0.05. AUC: area under curve. 




4.4.3 Insulin resistance and sensitivity: 
Over the RET, HOMA-β and HOMA-IR did not change significantly (P<0.05).  
However, GIR-Index and Matsuda increased significantly in YP (P<0.05) and 
Cederholm index increased significantly in both YP and OT groups (P<0.05, 
Table 4-2) 
Table 4-2 Glycaemic control-related calculations.  
a significantly different from OGTT1, b significantly different from OGTT2, c significantly different based 
on fold changes, d significantly different between groups. HOMA-IR: homeostasis model assessment for 
insulin resistance; HOMA-B: homeostasis model assessment for beta cell function; GIR-index: Glucose 
infusion rate index. 
 
 
Index Group OGTT1 OGTT2 OGTT3  Group OGTT1 OGTT2 OGTT3 
HOMA-β YP(n=8) ---------- ----------- 27.8±10.5  OP(n=9) ---------- ----------- 36.7±5.1 
YZ(n=8) ----------- ----------- 48.9±8.5  OT(n=9) ----------- ----------- 27.1±4.8 
HOMA-IR YP(n=8) 1.28±0.3 1.27±0.2 0.99±0.1  OP(n=9) 1.33±0.2 1.37±0.2 1.03±0.2 
YZ(n=8) 0.91±0.2 1.36±0.4 1.36±0.3  OT(n=9) 0.89±0.1 0.88±0.2 0.78±0.1 
GIR-Index YP(n=8) ---------- ----------- 8.2±2.5d  OP(n=9) ---------- ----------- 2.4±0.6 
YZ(n=8) ----------- ----------- 2.5±0.4  OT(n=9) ----------- ----------- 2.7±0.3 
Matsuda YP(n=8) 9.9±2.4 7.6±1.2 12.8±3.2C  OP(n=9) 8.4±2.4 8.1±2.1 10.1±2.6 
YZ(n=8) 12.4±2.6 10.1±1.7 8.4±1.1  OT(n=9) 12.2±2.8 13.4±2.5 15.3±2.6 
Cederholm YP(n=8) 68.1±5.1 61.7±4.7 74.5±3.7b  OP(n=9) 49.1±3.7 49.8±3.7 57.1±5.1 
YZ(n=8) 65.7±6.1 66.1±6.9 68.1±5.3  OT(n=9) 57.3±5.1 60.1±3.5 68.6±5.3a 





4.4.4 Correlations and ratios: 
Increase in FFM was correlated with increase in glucose levels in YZ and OP 
groups with lower T levels (Figure 4-6A); however, increase in FFM was 
negatively correlated with increase in insulin levels in OT group with higher T 
levels (Figure 4-6.B). Moreover, insulin levels were negatively correlated with 
T levels in OT (Figure 4-6.D). Nevertheless, there was no correlation between 
insulin and TFM (Figure 4-6.C). In addition, in line with moderately further 
decrease in glucose levels per unit of FFM in OT group (Figure 4-5.A), insulin 
levels per unit of FFM decreased in YP and OT with higher T levels during 6-
weeks RET, compared to YZ group (Figure 4-5.B). To support, insulin to 
glucose ratio decreased in YP and OT groups significantly in comparison with 
YZ (Figure 4-5.C). 





Figure 4-5: Ratios (A-D). Values are means +/- SEM. a Significantly different from YP, P<0.05; d 
Significantly different from OT, P<0.05. AUC: Area under curve 





Figure 4-6: Correlations (A-E). Values are means ±SEM. 





There is plethora of evidence suggesting low endogenous testosterone (T) 
levels are associated with development of insulin- resistant states and type 2 
diabetes (Ottarsdottir et al., 2018). However, there is still a paucity of evidence 
looking at the role of endogenous T and interventions that will alter glucose 
metabolism in a positive way with ageing (Muraleedharan and Jones, 2010) 
and anabolic hormonal therapy. Hence, in this study, in line with gaining FFM, 
with 6 weeks of RET coupled with the suppression of endogenous T (YZ) and 
provision of exogenous T (OT) showed significant effects particularly YZ was 
associated with blunted decrease in AUC insulin and on the other hand OT 
showed attenuated AUC insulin, when compared to baseline measures 
respectively.  
The role of FFM changes in relation to RET and various metabolic diseases in 
altering glycemic control has been contentious recently (Lagacé, Brochu and 
Dionne, 2020). Further, a recent meta-analysis of studies investigating the 
effects of 8 weeks of RET in older Type 2 diabetics showed that, altogether 
improvement in glycaemia control assessed with HbA1c were independent of 
variation in FFM (Lee, Kim and Kim, 2017). Interestingly, Baldi et al., reported 
inverse relationship of HbA1c with variation of FFM with 10 weeks of RET in 
individuals with T2DM (Baldi and Snowling, 2003). In addition, Shaibi et al., 
reported 16 week of RET (twice per week) significantly insulin sensitivity in 
overweight Latino males independent of changes in body composition (Shaibi 




et al., 2006). Supporting the above argument, it is reported that 20 weeks 
(Smutok et al., 1993) and 3 months (Eriksson et al., 1997) of RET augmented 
insulin sensitivity similar to those observed following endurance training. In line 
with majority of studies as discussed above, this study with 6 weeks of RET in 
YP and OT observed significant increase in FFM and positive effects on 
glycemic control. Indeed, increased FFM enhanced availability of glucose 
storage area in total resulting in efficient clearance of circulating glucose and 
therein facilitating normal glucose tolerance (Ibañez et al., 2005; Misra et al., 
2008). Accordingly, augmented FFM seems to positively associated with 
improvement in glycaemia control in men after RET (Eriksson et al., 1997) 
although it appears to be independent of alteration in intrinsic capacity of 
muscle to respond to insulin (Miller, Sherman and Ivy, 1984; ET et al., 2000). 
In the present study, we showed that the groups that had augmented FFM 
gain (i.e., YP and OT) represented attenuated insulin levels and augmented 
insulin sensitivity after 6-weeks RET. However, in line with previous studies 
(Takala et al., 1999), RET did not change insulin-stimulated glucose uptake 
per kilogram of FFM after 6-weeks RET, and as increased glycaemia control 
represents a true long-term adaptation to RET (Ebeling et al., 1993); hence, it 
seems failure to show increase in insulin sensitivity in YZ and OP was probably 
due to short-term (6-weeks) RET (Takala et al., 1999). Though, 12-weeks 
combined RET and aerobic training had no effect on glycaemia control (i.e. 
glucose and insulin levels) in men with prostate cancer undergoing androgen 
deprivation therapy (>2-months) (Galvão et al., 2010). In addition, 16-weeks 




heavy RET with/without growth hormone provision increased FFM but did not 
change glucose, insulin, and C-peptide levels in healthy older men (Zachwieja 
et al., 1996). Consequently, considering a positive correlation between FFM 
gain (YZ: 0.6% vs. OP: 1.4%) and glucose levels in both YZ and OP groups, 
and negative correlation between T and insulin in OT group, the positive 
effects of RET on glycaemia control in YP and OT cannot be attributed to a 
mere increase in FFM (Andersen et al., 2003) and likely via factors 
independent of changes in FFM (Shaibi et al., 2006).   
Furthermore, the interplay between hypogonadism and the development of the 
metabolic syndrome is still unclear (Laaksonen et al., 2004), low testosterone 
per se is associated with metabolic syndrome (i.e. decreased insulin sensitivity 
(Keating, O’Malley and Smith, 2006), increased insulin resistance 
(Grossmann, 2014; Wang et al., 2016) and type 2 diabetes (Wang et al., 
2016), likely via decrease in FFM and increase in TFM (Wang et al., 2016). In 
fact, to support this argument, our results showed higher T levels in OT group 
during RET was associated with attenuated insulin level, it is postulated that 
higher T levels and FFM were associated with up-regulated glucose 
metabolism in healthy men (Pitteloud, Mootha, et al., 2005; Hou et al., 2015). 
Interestingly, T therapy seems to counter act glycaemia control deficiency 
during ageing/ illnesses (Grossmann, Gianatti and Zajac, 2010); e.g. provision 
of exogenous T (200mg, every 2-weeks for 3-months (Kapoor et al., 2006) or 
oral 160mg/d for 6-months (Emmelot-Vonk et al., 2008)) has shown to reduce 
insulin resistance and improves glycaemia control in hypogonadal men with 




type 2 diabetes and healthy older men, respectively. On the contrary, T 
therapy alone for 40-weeks (1000 mg injection, every ~2 months) did not 
improve insulin resistance and glycaemia control in hypogonadal men with 
type 2 diabetes, albeit increased in FFM and decrease in TFM (Gianatti et al., 
2014); suggesting the greater benefits of T therapy adjuvant to RET in our 
study. Moreover, short-term (12-weeks) (Smith, Lee and Nathan, 2006) and 
long term (24-months) (Haidar et al., 2007) androgen deprivation therapy in 
men with prostatic cancer decreased insulin sensitivity and increased TFM 
which were associated with an increased risk of developing type 2 diabetes 
(Kintzel et al., 2008). Furthermore, lower endogenous T levels were 
associated with increase C-peptide levels, in turn suggesting impaired 
pancreatic ß-cell function and increased insulin secretion in older men (Tsai et 
al., 2000). In our study, we assessed C-peptide levels to measure endogenous 
insulin secretion, GIR and ß-cell function (Jones and Hattersley, 2013). Both 
C-peptide and insulin are secreted in equimolar amounts from the ß-cells as 
the reliable surrogate marker for assessing pancreatic ß-cell function and GIR 
(Chailurkit et al., 2007; Ohkura et al., 2013). Further, C-peptide is only 
minimally removed and metabolised by the liver and has longer half-life when 
compared to insulin 20-30 min vs. 3-5 min) (Jones and Hattersley, 2013). In 
our study, both younger group with higher endogenous T and older group with 
exogenous T provision had lower levels of C-peptide after 6-weeks of RET, 
demonstrating decreased secretion of endogenous T in both groups with 
higher peripheral insulin sensitivity and GIR. Henceforth, T had permissive role 




in improvement of glycemic control during short-term RET and T provision 
coupled to RET seems to be an effective strategy to combat andropause-
related metabolic disorders. Interestingly, some previous studies have 
reported debatable results about the effects of long term RET on glycemic 
control in older men with lower endogenous T; 16- weeks (Zachwieja et al., 
1996) RET showed no improvement in glycemic control (measuring c-peptide 
levels) in older men, nevertheless 12-weeks (Iglay et al., 2007) and 4-months 
(Hansen et al., 2012) of RET decreased fasting c-peptide but, those studies 
did not estimate insulin sensitivity and insulin levels in older and middle aged 
healthy men, respectively. In our study, we showed only 6-weeks of RET 
adjuvant to T therapy (vs. RET alone) augmented glycaemia control in older 
men; furthermore, T deprivation during RET blunted glycaemia control 
improvement in younger men (vs. RET with normal T levels). However, it 
appears RET eliminated worsened glycemic control induced T suppression 
(Smith, Lee and Nathan, 2006).  
To conclude, T therapy (OT) and non-suppressed endogenous T (YP), 
enhanced insulin sensitivity (supported by reduced C-peptide) in older and 
young men, respectively, coupled with RET, suggesting endogenous T is a 
permissive mediator of RET-induced augmentation of insulin sensitivity; and T 
therapy adjuvant to pre/re-habilitation RET may be of value to overcome the 
burgeoning trend of worsening glycaemia control with ageing. 
  




Chapter 5: Effects of Beta-Hydroxy-Beta-Methylbutyrate (HMB) 
on Carbohydrate Metabolism in young and old healthy men: 
5.1 Overview: 
Insulin resistance remains a principal component in development of various 
metabolic diseases. The main basis of treatment of insulin resistance until now 
remains diet and exercise but complicated by poor adherence to these 
measures. Beta-hydroxy beta-methylbutyrate (HMB) is a nutraceutical 
supplement with controversial effects on insulin sensitivity in animal models 
and poor understanding in humans. The aim of this study is to evaluate the 
impact of acute supplementation of HMB on insulin sensitivity in humans 
during an oral glucose tolerance test.  
Methods: Ten young (18-35y) and 10 older (65-85y) males underwent two 
75g oral glucose tolerance test.  
Results: HMB significantly reduced the insulin area-under-the-curve (AUC) 
with no difference in glucose AUC, resulting in a trend towards an increase in 
the Cederholm index of insulin sensitivity in younger men. In older men, HMB 
had no effect on insulin or glucose responses.  
Conclusions: Acute HMB supplementation may improve insulin sensitivity 
following a single oral glucose load in young men; however, this does not 
appear to be sustained into older age. 





5.2 Aim of the study: 
The aim of this study was to evaluate the acute impact of a novel nutraceutical, 
a metabolite of amino acid leucine termed HMB supplementation, on 
glycaemic control during an oral glucose tolerance test in young and older 
humans. 
5.3 Materials and Methods: 
Institutional research ethics approval (University of Nottingham Faculty of 
Medicine and Health Sciences Research Ethics Committee) was obtained 
(A12092016 SoM MS GEM) to recruit 10 healthy young (aged 18-35 y) and 10 
healthy older (aged 65-85 y) male subjects by local advertising. 
Exclusion criteria included extremes of BMI (<18 or >32 kg/m2) and diagnosis 
of metabolic disorders. The study was registered with clinicaltrials.gov 
(NCT03018496) and complied with the 1964 Declaration of Helsinki. 
After providing written informed consent to participate in the study, all subjects 
underwent a clinical examination involving measurements of height, weight 
and resting blood pressure (OMRON M3, Omron Healthcare, UK) before being 
enrolled. Each subject performed two, 3 h 75g oral glucose tolerance tests 
(OGTT)(FM et al., 2007; Wopereis et al., 2009), spaced 2-weeks apart. During 
one OGTT, the glucose was administered with 3g HMB-FA (a dose previously 




shown to produce a measurable effect on protein metabolism (Dj et al., 2013)), 
with glucose alone administered during the alternate OGTT. The order in 
which the subjects completed the two studies was randomised via a computer-
generated randomisation tool (sealedenvelope.com). 
On each study day, subjects presented to the laboratory at 0900h fasted from 
2100h the preceding evening. On arrival, a 22G retrograde intravenous 
cannula was inserted into a vein in the dorsum of a hand to facilitate blood 
sampling (using the hot-hand method (heated to 55 oC)(Liu et al., 1992)).  
Blood was drawn for real-time quantification of blood glucose concentrations 
with aliquoted plasma frozen for later quantification of insulin concentrations. 
After baseline measures, participants drank 75g oral dextrose (Myprotein, 
Northwich, UK) dissolved in 200mL of water, with or without 3g HMB-FA gel 
(Metabolic Technologies Inc., Ames, Iowa, USA) provided immediately after 
the glucose. Blood samples were drawn at baseline then 15, 30, 45, 60, 107 
80, 100, 120, 140, 160 and 180 minutes after the dextrose drink. 
Leg blood flow was measured as a potential mechanism by which HMB could 
affect glucose and insulin kinetics. Measurements were made of the common 
femoral artery of the right leg at three time points during each study visit 
(baseline, 60 and 120 minutes after dextrose) using Doppler ultrasound (iU22, 
Phillips Healthcare, Guildford, UK) and a 9-3mHz probe. Blood flow was 




calculated as the product of the artery cross sectional area and the mean blood 
velocity over 3 cardiac cycles (Phillips et al., 2012). 
Blood glucose concentrations were determined using a near patient glucose 
analyser (YSI Life sciences, Ohio, USA). Plasma insulin concentrations were 
determined using an ultrasensitive enzyme linked immunosorbent assay 
(ELISA) (Mercodia Ultrasensitive Insulin ELISA, Mercodia, Uppsala, Sweden). 
Area-under-the-curve (AUC) analyses were performed for both glucose and 
insulin concentrations facilitating calculation of the Cederholm and Matsuda 
indices of insulin sensitivity, with the homeostatic model of insulin resistance 
(HOMA-IR) calculated from fasting values (Patarrão, Wayne Lautt and Paula 
Macedo, 2014). 
β-hydroxy-β-methylbutyric acid (HMB-FA, CAS# 625-08-1; Formula: 
C5H10O3) was manufactured by TSI Co., Ltd (Shanghai, China) for Metabolic 
Technologies, Inc. (Ames, IA, USA) and purity were 98% as measured by high 
performance liquid chromatography (HPLC). 
Area under curve (AUC) analyses were performed for both glucose and insulin 
concentrations enabling calculation of Cederholm (Cederholm and Wibell, 
1990) and Matsuda indices (Matsuda and DeFronzo, 1999) of insulin 
sensitivity. Further, Homeostatic model of insulin resistance (HOMA-IR) was 
calculated form fasting values (Patarrão, Wayne Lautt and Paula Macedo, 
2014) 




HOMA-IR was calculated using formula: 
 
All statistical analyses were performed using Graphpad Prism Version 7.02 
(California, USA) with data presented as mean (SD). After conformation of 
normality, analysis was performed using 2-way ANOVA by age and treatment 
with Sidak’s multiple comparison post-hoc testing. Significance was set at 
p<0.05. 
  





Ten young and ten older subjects were recruited to study with all subjects 
completing both OGTT’s. Definition of impaired fasting glucose (IFG- if fasting 
plasma glucose 6.1 to 6.9mmol/l and 2-h post ingestion of 75g oral glucose 
<7.8mmol/l) and Impaired glucose tolerance (IGT- if fasting plasma glucose 
<7.0mmol/l and 2-h post ingestion of 75g oral glucose ≥7.8 and 
<11.1mmol/l)(WHO, 2006). Subject characteristics are displayed in Table 5-1. 
HMB did not alter leg blood flow responses to glucose in either the young or 
older participants at any time point, although there was a main effect of age at 
all three time points (Table 5-2). 
There was a main effect of time of insulin and glucose in both young and older 
subjects. (all P<0.0001).  
HMB significantly reduced the insulin AUC (4158 (2753) vs. 5836 (4451) 
mU/Lx180min; p=0.02) in younger subjects (Figure 5-1C), with no difference 
in glucose total AUC (1127 (147) vs. (1142 (122) mmol/Lx180min; p=0.8) 
(Figure 5-1D). This led to a trend towards an increase in the Cederholm index 
of insulin sensitivity (62.7 (13.9) vs. 55.1 (11.0); p=0.08))(Figure 5-1E). There 
was no change in the Matsuda index of insulin sensitivity (10.3 (4.9) vs. 8.9 
(4.4); p=0.19) (Figure 5-1F, respectively).  
 




Table 5-1- Subject characteristics (Mean (SD)) 




Age (years) 22 (4) 72 (3)1 
Height (cm) 179 (6) 176 (6) 
Weight (Kg) 81 (10) 82 (7) 
BMI (Kg/m2) 25.4 (2.5) 26.5 (2.7) 
Systolic blood Pressure (mmhg) 129 (8) 143 (19)2 
Diastolic blood pressure (mmhg) 76 (9) 83 (15) 
HOMA-IR 1.2 (0.9) 1.3 (0.6) 
Impaired fasting glucose (6.1-6.9 mmol/l) 
(n) 
0 0 
Impaired glucose tolerance 120min 
sample (≥ 7.8 and <11.1mmol/l (n) 
0 7 
1p<0.001 vs. young participants, 2p<0.05 vs. young participants 




Table 5-2- Leg blood flow (ml/min) 
Time Young  Older  
 HMB No HMB p HMB No HMB p 
Baseline 510 (148) 440 (147) 0.37 275 (97) 281 (121) 0.99 
60 min 478 (168) 534 (180) 0.74 334 (134) 371 (150) 0.79 
120 min 572 (183) 518 (148) 0.69 343 (119) 302 (113) 0.81 
 





Figure 5-1- Insulin (A) and glucose (B) concentrations before (time 0) and after a 75g glucose challenge.  
Area-under-the-curve (AUC) for Glucose (C) and insulin (D), and Cederholm (E) and Matsuda indices 
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In older subjects, HMB had no effect on the insulin (5712 (2488) vs. 5980 
(2854) mU/Lx180min; p=0.88) (Figure 5-2C) or total glucose AUC (1426 (194) 
vs. (1409 (180) mmol/Lx180min; p=0.84) (Figure 5-2D), with no resultant 
difference in either their Cederholm (57.9 (14.2) vs. 55.6 (10.7); p=0.72) or 
Matsuda index (9.2(4.3) vs. 8.8(5.2); p=0.88) (Figure 5-2E and Figure 5-2F, 
respectively). There was a main effect of age on total glucose AUC, which was 
not present for insulin AUC or either index of insulin sensitivity. All of the 
statistical findings reported for total glucose AUC were also apparent for 
incremental glucose AUC.  
  





Figure 5-2- Insulin (A) and glucose (B) concentrations before (time 0) and after a 75g glucose challenge.  
Area-under-the-curve (AUC) for Glucose (C) and insulin (D), and Cederholm (E) and Matsuda indices 















































































































































































































































There is ongoing intensive effort amongst scientific community towards 
identifying novel nutraceutical approach to treat insulin resistance (IR) 
particularly with ageing, given IR is a major factor in Type 2 diabetes and also, 
associated with many maladies such as obesity, essential hypertension, 
dyslipidaemia, non-alcoholic fatty liver disease, obstructive sleep apnoea and 
cancer (Evans and Goldfine, 2013). 
This study has demonstrated a single 3g dose of HMB can reduce acute 
insulin response to an oral glucose load in younger men indicating a possible 
role in improving insulin sensitivity, however same was not observed in older 
men suggesting this effect is not persistent as you get older. This observation 
dampens the potential of HMB to be used as a nutraceutical to improve insulin 
sensitivity, as insulin resistance is prevalent in old age (Ryan, 2012). 
Given, emerging evidence suggests that HMB has been positively associated 
with acute anabolic responses (Wilkinson et al., 2013, 2018) it can be 
postulated that, HMB may lead to improvement in insulin sensitivity allowing 
for the fact that insulin plays an important role in anabolic processes (Wilkes 
et al., 2009; Abdulla, Smith, Philip J Atherton, et al., 2015). Furthermore, 
despite clear evidence suggesting anabolic effect of HMB in older adults 
(Holeček, 2017) what is not clear is, why there is no improvement in insulin 
sensitivity in older adults.  




Recently a review showed that, in healthy as well as in overweight and type 2 
diabetic subjects, the short term energy balanced high protein diet only 
showed limited and minor effects on insulin sensitivity concluding the results 
were equivocal (Rietman et al., 2014). However, Harber et al reported that 
acute (24 h average insulin concentration was 50% lower, p<0.001, after 2 and 
7 d) low carbohydrate and high protein diet caused as immediate postprandial 
reduction in daily plasma insulin (Harber et al., 2005). Conversely, Chen et al 
reported negative effect of high protein diet on insulin sensitivity (Chen et al., 
2020). So, our data herein suggests that specific amino acid metabolites (HMB 
and their precursor amino acids) may enhance insulin sensitivity under certain 
conditions. We postulate, one potential mechanism for this improvement in 
insulin resistance in our study could be improvement in leg blood flow leading 
to increase in peripheral glucose uptake, however this was not the case in this 
study. It may be noted that, given leg blood flow was only recorded at specific 
time points (baseline, 60 min and 120 min), an earlier or later improvement in 
leg blood flow may have been missed. Further in our study, there was main 
effects of age on leg blood flow at all 3 time points (baseline, 60min and 
120min) further supporting the notion that basal whole-leg blood flow and 
vascular conductance decrease progressively with advancing ageing in 
healthy men (Dinenno et al., 1999) and this may in turn explain the lack of 
improvement in insulin sensitivity in older men. 
HMB predominantly available in calcium salts (CaHMB) and a study by Fuller 
et al reported that Free acid gel form of HMB resulted in quicker and greater 




concentration (+185%) and improved clearance (+25%) of HMB form plasma, 
concluding that gel form of HMB could improve HMB availability and efficacy 
to tissues both in health and pathological state (Fuller et al., 2011). Intriguingly, 
Vukovich et al reported that acute HMB supplementation in young men had 
not effect on plasma glucose and insulin concentrations (Vukovich et al., 
2001a). This was contrary to what is observed in this study and one possible 
explanation for above observation could be the gel form of HMB used in this 
study. Also, Vukovich et al, in their study used different method of 
quantification of insulin (Radioimmunoassay, RIA) compared to ELISA method 
used in this study. Further, a reduced blood sampling frequency was reported 
(large differences were reported at 45and 140 minutes in this study, time 
points which were not measured by Vukovich et al.,). So, HMB in gel form 
(used in this study) seems to enhance insulin sensitivity in young men contrary 
to what is reported in literature in certain condition. 
In this study, HMB elicited a trend for increasing Cederholm index of insulin 
sensitivity (predominantly peripheral) in our young subjects, whilst having no 
effects on Matsuda index (both hepatic and peripheral) suggesting HMB is 
affecting predominantly peripheral rather than hepatic element of insulin 
sensitivity (Gutch et al., 2015). This is conflicting to the observation which has 
previously been shown in a chronic study of HMB in rodents where an 
improvement in hepatic insulin sensitivity mediated via GLUT2 was noted 
(Sharawy et al., 2015). A separate chronic HMB rodent study did however 
show a potential reduction in GLUT4 mediated peripheral  insulin sensitivity 




(Yonamine et al., 2014), a finding which may be more in keeping with the 
results of this study. Per se, further investigation of the mechanistic basis 
behind the differential effects of HMB on acute glucose handling and changes 
in insulin sensitivity with advancing age should be concentrated on looking at 
peripheral mechanisms of insulin sensitivity, including a more detailed analysis 
of vascular responses. Furthermore, chronic supplementation studies 
measuring longer-term changes in insulin sensitivity will be required before 
HMB could be considered as a potential nutraceutical therapeutic agent for 
improving insulin sensitivity in humans.  Finally, although the results herein 
suggest that the detrimental impact of HMB on insulin sensitivity seen in some 
rodent studies (Yonamine et al., 2014) does not translate to humans, further 
clinical trials are required to confirm this. 
Two limitations of this study were noted; firstly, no detailed food and physical 
activity diary were recorded between the study visits. However, to prevent any 
confounders, all subjects were advised to replicate their dietary and physical 
activity behaviours for 24 h period before each visit. Further, each subject 
fasted for 12 h preceding each study visit which is likely to negate the impact 
of this limitation. Secondly, only male subjects were recruited which limits the 
generalisability of the finding to wider population group, particularly female 
population.  
In conclusion, acute HMB supplementation can significantly reduce plasma 
insulin concentrations in young men in response to glucose challenge without 




changing blood glucose concentrations, leading towards a trend for 
improvement in insulin sensitivity. This is not the case in older men. Future 
trials particularly looking at acute (with detailed consideration to vascular 
responses) and chronic supplementation with HMB on insulin sensitivity with 
a through consideration of age (e.g., middle-aged adults) and gender is 
needed. 
  




Chapter 6: Conclusions: 
6.1 Overview of studies and general conclusion: 
In this thesis, we demonstrated that human skeletal muscle disuse causes 
many undesirable complications with emphasis placed on development of 
peripheral insulin resistance. The underlying processes seem to be very 
complex and have numerous interplays between different mechanisms. We 
report that, during skeletal muscle disuse, both post absorptive and post 
prandial MPS is suppressed, with some evidence albeit controversial 
supporting increase in protein MPB. In our short term (4 d) single leg 
immobilisation study showed significant loss of skeletal muscle mainly driven 
by sustained reduction in MPS. Indirect measures of MPB using validated 
calculations to derive FBR showed no significant increase. Also, a lack of 
increase in markers of MPB point towards a minor role, if any, of MPB in short 
term disuse muscle atrophy. Further, we showed that integrated MPS driven 
by blunting of anabolic resistance to protein intake (both fasted and fed state) 
was reduced in short term (4 d) single leg immobilisation. Given, muscle 
disuse results in development of whole body and muscle specific IR and 
supporting this argument, our study showed reduced GLUT4 activity in 
immobilised leg possibly leading to significant elevation of plasma insulin 
levels. It is also suggested that muscle insulin resistance (IR) secondary to 
disuse appears to drive the procession of disuse muscle atrophy independent 
of other mechanisms known to cause muscle IR. Thus, our data suggests 




findings consistent with widely reported notion that human skeletal muscle 
disuse causes peripheral (muscle IR) insulin resistance and hence the search 
for targeted strategies (to improve basal MPS and anabolic response to 
feeding) to prevent the setting of muscle atrophy is paramount.  
Leading on from above discussion, in search for therapeutic intervention, we 
postulated that short-term testosterone suppression augments peripheral IR 
in young men coupled with 6 weeks of RET. In accordance, we also showed 
poor glycaemic control (blunted decrease in AUC insulin vs. baseline). 
Suggesting that endogenous testosterone plays a major role in maintaining 
glycaemic control (improve insulin resistance). On the contrary, in the same 
study, we also showed that 6 weeks of RET coupled with the exogenous 
provision of testosterone had significant positive effect on peripheral 
glycaemic control (attenuated insulin levels and augmented insulin sensitivity) 
via net protein accretion through anabolic pathways in older men. Collectively, 
we demonstrated that just 6 weeks of whole body RET coupled with 
unsuppressed endogenous testosterone (young men) and provision of 
exogenous testosterone (older men) had positive effects on peripheral 
glycaemic control via improving net protein accumulation through anabolic 
pathways. So, we demonstrated the potential of testosterone in reversing the 
ageing-induced muscle wasting and in turn having a positive effect on 
glycaemic control. Thus, we argue long-term testosterone supplementation 
may be an effective strategy to overcome sarcopenia, an unwanted 
accompaniment of ageing and the potential benefits in glucose metabolism 




and potential reductions in the risks of developing type 2 diabetes. However 
further studies to establish its safety and efficacy over long term is warranted.  
In addition, we also postulated Beta-hydroxy beta-methylbutrate (HMB) a 
nutraceutical supplement with contentious effects on insulin sensitivity in 
animal models has a positive effect on insulin sensitivity in humans during an 
oral glucose tolerance test. In accordance, we showed that the 
supplementation of 3g of HMB during a OGTT in young men significantly 
reduced the insulin area-under-the-curve (AUC) with no difference in glucose 
AUC, resulting in a trend towards an increase in the Cederholm index of insulin 
sensitivity. Interestingly, similar observation was not noted in older men when 
given HMB. Suggesting, acute HMB supplementation may improve insulin 
sensitivity following a single glucose load in young men; however, this does 
not appear to be sustained into older age. 
Cumulatively, we can conclude that a multitudinous approach may be needed 
to overcome the burgeoning burden of worsening insulin resistance and 
development of persistent IR states such as Type 2 diabetes associated with 
loss of skeletal muscle: sarcopenia (disuse, disease, ageing etc.) and anabolic 
hormone resistance (ageing). So, our studies try to approach this complex 
area and it may be possible to address this by combining pre/re-habilitation 
(combined with RET) post muscle disuse, combined with anabolic hormone 
replacement (testosterone) and with nutraceuticals (HMB) supplementation.  




6.2 Limitations of studies and future directions: 
This thesis aims to draw conclusions and attempts to find intervention 
strategies (from 3 experimental studies) to address major conundrum the 
current scientific society is facing particularly sarcopenia and ever-increasing 
burden of metabolic syndrome. We recognise that there were some limitations 
with the studies, this and future directions are discussed here.  
The immobilisation study looked at short-term (4 d disuse) effects on muscle 
mass, MPS, MPB and glycaemic control, so may not be capturing full picture 
of all muscle related metabolic and molecular adaptions as changes may be 
temporal. So, studies looking at long-term muscle disuse model may be 
needed. We initially planned to conduct both 3 d and 14 d immobilisation but 
due to disruption in supply of amino acid tracer we could only complete 4 d 
immobilisation study in time for this thesis. Also, further research in to 
establishing direct measure of MPB instead of indirect measure (as used in 
our study) may offer more in-depth knowledge of the actual catabolic 
processes.  
We recognise that there were number of limitations in relation to our study into 
effects of testosterone in men coupled with RET. Whilst, in non-hypogonadal 
men, testosterone both unsuppressed endogenous in young men and 
exogenous supplementation in older men has shown to improve glycaemic 
control. But same cannot be assumed for women. The clinical relevance of 
testosterone in women over 65yrs is not clearly known and high testosterone 




level may be associated with insulin resistance, metabolic syndrome and 
cardiovascular disease (Patel et al., 2009). Further, in women, the effects of 
testosterone on all insulin-targeted tissues is tightly regulated by circulating 
hormone levels with a narrow window and accumulating evidence suggest any 
excess (mainly reported in setting of polycystic ovarian syndrome) contributes 
to insulin resistance (Diamanti-Kandarakis, Pappalou and Kandaraki, 2019). 
Given this concern regarding development of IR in women with testosterone 
supplementation our findings from this study cannot be generalised to entire 
population. Hence, further studies are needed to investigate the effects of 
testosterone therapy with or without RET in pre/ post-menopausal women to 
investigate this controversial area. Also, further studies are needed to 
investigate the effects of physiological vs. supra-physiological doses of 
testosterone on the aforementioned end points, including efficacy and safety.  
Though our study showed acute HMB-FA can significantly reduce plasma 
insulin concentration in young men in response to oral glucose load and 
indicated a possible trend towards improved insulin sensitivity, further 
investigation of the mechanistic basis of this using glucose clamp techniques 
(deemed as a gold standard in studying insulin sensitivity) may be warranted. 
In addition, chronic supplementation studies measuring longer-term changes 
in insulin sensitivity may be required before HMB-FA could be considered as 
a therapeutic agent for improving insulin sensitivity. 
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You are being invited to participate in this research study investigating the 
impact of single leg immobilization on skeletal muscle mass. Before deciding 
whether or not you would like to participate in this research study, you should 
be aware of what is involved as well as the possible health risks present. This 
form will provide you with a detailed explanation about the research study, 
which will also be discussed with you in person. Please take your time to make 
your decision. Feel free to discuss it with your friends and family. The decision 
to take part in the study is completely up to you. McMaster University and 
Professor Stuart Phillips have received a grant from the Canadian Institutes of 
Health Research (CIHR) to cover the costs of conducting the study. 
PURPOSE OF THE STUDY 
Periods of muscle disuse are commonly experienced in young and elderly 
individuals as a result of short-term hospitalization or leg casting after injury. 
Periods of immobilization result in a profound loss of muscle mass and 
strength. Aside from skeletal muscle’s central role in movement, the muscle 
also plays a large role in general health. For example, skeletal muscle is the 
largest ‘sink’ into which blood sugar (glucose) is taken up following a meal. 
Leg immobilization results in an impairment in the body’s ability to take up 
glucose into skeletal muscle tissue, which can eventually result in insulin 
resistance. In our study, we are interested in looking at the regulation of 
muscle mass during and after a short period of leg immobilization. We will 
measure the rate of muscle growth and breakdown as well as the rate of 
glucose uptake by the muscle. Understanding the underlying mechanisms 
causing muscle loss after immobilization will help us to create interventions to 
prevent the loss of muscle mass and function during periods of disuse. 
INCLUSION AND EXCLUSION REQUIREMENTS 
How many people will be recruited for this study? 
If you consent to participate in this study, you will be one of 8 participants. One 
of your legs will be immobilized for the 4-day duration of the study, with the 
other leg acting as a control. We will randomly select which leg will be 
immobilized, such that 4 participants will have their dominant leg immobilized 
and 4 participants will have their non-dominant leg immobilized. 
Inclusion criteria 
We will only include males in this study, who are between the age of 18 and 
30 year. In order to participate in this study, you need to be healthy and not 
smoke. 
Exclusion criteria 




1) The use of anti-inflammatory and/or analgesic medication, whether it is 
prescription or not 
2) A history of neuromuscular disorders or muscle/bone wasting diseases 
3) Any acute or chronic illness, cardiac, pulmonary, liver, or kidney 
abnormalities, uncontrolled hypertension, insulin-dependent or insulin-
independent diabetes, or the presence of any other metabolic disease – all of 
which will be determined via a medical history screening questionnaire 
4) The use of any medications known to affect protein metabolism 
(glucocorticoids, non- steroidal anti-inflammatory medication, or prescription 
strength acne medication, etc.) 
5) A (family) history of thrombosis 
6) The use of anticoagulant medications 
PROCEDURES INVOLVED IN THE RESEARCH 
Time Commitment 
Your time commitment during the study will be a continuous period of 5 days. 
Prior to the start of the study, we will plan an introductory meeting (screening). 
During this visit the investigators will determine if you match the criteria 
required for your participation and will answer any questions that you may 
have at that time. If you consent to participate in the study following this visit, 
we will schedule a date for you to start the trial. Over the course of the study 
duration, you will visit McMaster University two times for testing. The first 
testing day (day 0) will last roughly 3 hours, whereas the infusion day will last 
roughly 8 hours. While outside of the laboratory (day 1-3) you will be asked to 
leave the knee brace in position at all times, as applied by the investigators of 
the study. 
Screening 
During the screening you will be asked to complete a medical questionnaire. 
Moreover, body height, weight, and blood pressure will be taken by an 
investigator of the study. Finally, we will familiarize you to the strength testing 
machine that you will be asked to use during the study. 
Study Days 
Day 0 
You will be asked to visit McMaster University for baseline testing. During this 
visit you will come to the laboratory in the fasted state (not having eaten 
anything for a period of at least 10 hour). Upon arrival to the laboratory, you 




will undergo a body scan to assess your body composition including total body 
weight, lean mass, and fat mass, etc. We will then place a 
  
catheter in both of your arms; one for blood sampling and one for infusion of 
amino acids. You will be asked to saturate a cotton swab with your saliva, and 
we will take a blood sample, then ingest the ‘heavy water’ that we will provide 
you with (explained below). Subsequently, we will start the amino acid infusion, 
which will continue for 2 hours. Every 15 minutes we will take another blood 
sample. Two hours after ingestion of the heavy water you will be asked to 
saturate another cotton swab. During the infusion you will undergo an 
ultrasound scan on your mid-thigh region of both of your legs for the 
assessment of muscle thickness. Following the infusion, you will also be asked 
to perform three leg extension contractions for the measurement of maximal 
leg strength. Before leaving McMaster University, one of the investigators will 
apply a knee brace to one of your legs to start the immobilization period. Once 
the knee brace is in place, we kindly ask that you do not tamper with the 
positioning of the knee brace at all. Following application of the knee brace 
you will be sent home. 
Day 1 - 3 
During this day you will not be visiting McMaster University. You must ensure 
that the knee brace is still in place and you will receive a phone call from one 
of the investigators to ensure no problems have arisen overnight or over the 
course of the day. You will be asked to obtain another saliva sample upon 
waking. 
Day 4 (see Figure 2 for an overview of this day) 
During this day you will visit McMaster University in the fasted state. Upon 
arrival an investigator will remove the knee brace and you will be asked to lie 
on your back on one of our laboratory beds for commencement of the infusion 
trial. A catheter will be placed in both arms to allow us to perform the infusion 
trial. Before beginning the infusion, we will obtain a baseline blood sample. 
Following the collection of baseline blood, we will begin the first infusion via 
one of the catheters, which will be continued for the entire duration of the trial. 
Periodically the investigators will collect blood samples from the other catheter. 
The catheter allows us to take multiple blood samples without having to use a 
needle every time. After 1.5 hours, muscle biopsies are collected under local 
anaesthesia from both legs. Another muscle biopsy will be taken from the 
immobilized and control leg 2 hours later, signifying the end of the fasted state 
measurements. 
Next, to simulate conditions after a meal, we will start the second infusion 
containing a mixture of amino acids (building blocks of dietary protein) and 




dextrose (sugar). Additional muscle biopsies will be collected from both legs 
at 90 and 180 minutes of the amino acid/dextrose infusion. The last muscle 
biopsy marks the end of the infusion trial. After ending the infusion trial, the 
investigators will measure your body composition, muscle thickness, muscle 
cross sectional area, and muscular strength as previously described. 
Following this testing the investigators will send you home. 
 
Figure 1. Study Schematic. Heavy water will be provided on day 0. You will 
consume the heavy water after you take the saliva sample while at the lab, 
under investigator supervision. Heavy water is similar chemically and behaves 
like regular drinking water. 
 
Figure 2. Schematic overview of the infusion trial (day 4). We will be infusing 
stable tracers to track the rate of muscle growth and breakdown and how this 
process may be impacted by the period of disuse. We will also infuse nutrients 
to mimic the state that your body would be in if you had just eaten a meal. At 
the beginning of the trial (8:00 am) we will place a catheter in each arm, one 
for the infusions and one to perform serial blood sampling every 10 minutes. 
STUDY MEASURES 
Muscle mass and function 
Dual energy X-ray absorptiometry (DXA) scan 




In this study we will perform two DXA scans, which will take place before (day 
0) and following immobilization (day 4). A DXA scan is generally used to 
determine bone mineral density and diagnose osteoporosis, a condition in 
which the bones are extremely fragile. However, DXA scan also provides 
information on body fat percentage and lean body mass. The DXA procedure 
uses a very small dose of radiation which is not harmful for your body (see 
risks below). The procedure takes approximately 7 minutes and involves lying 
still on a bed while the scan arm passes over your body. 
Ultrasound 
Ultrasound will be used on 2 occasions (before and after immobilization) to 
measure the size of your thigh muscles. During the ultrasound test a probe 
with gel on the tip will be applied to the middle region of your thigh to allow for 
the measurement of muscle thickness. Ultrasound works by emitting sound 
waves through the skin. When the sound wave comes into contact with an 
object, such as an organ or bone, it is reflected back. The reflected signal is 
then picked up by the ultrasound probe which is able to produce an image of 
your skin, muscle and bone in your leg. 
Muscle strength 
Leg muscle strength will be measured on 2 occasions (before and after 
immobilization) using a Biodex dynamometer, which is a chair fitted with an 
arm to which your leg is strapped. In order to determine muscle strength, you 
will be asked to repeatedly kick your leg out against the arm of the machine. 
The force produced by your leg will be recorded by the force transducer in the 
arm of the machine. 
Heavy water and saliva sampling 
On one occasion (day 0) you will consume approximately 200 mL of heavy 
water. Heavy water contains deuterium, which is a form of hydrogen that is 
naturally occurring at a very low concentration of approximately 0.01% in the 
human body. We provide deuterium-labelled water that is 70% enriched, which 
allows us to detect and trace deuterium in your body. We will measure 
deuterium in the saliva samples as well as the muscle biopsies to be able to 
calculate the rate of muscle growth during the 3 days of immobilization. 
Infusions and blood sampling 
During the infusion trial we apply various infusions that allow us to measure 
muscle growth and breakdown as well as muscle glucose (sugar) uptake. We 
would like to measure these processes in both the fasted state as well as after 
meal intake. In this study, we will simulate meal intake by infusing nutrients 
directly into the bloodstream. All infusions will be applied through one catheter 
which will be placed in one of the veins in your arm. In the other arm, we will 




also place a catheter for regular blood sampling. Placement of the 2 catheters 
is not painful and could be compared to the sting from a single blood draw. 
 Muscle biopsies 
During this study, muscle biopsies will be obtained from both legs at 4 time 
points (all during day 4). The muscle biopsy procedure will be performed by 
trained and qualified personnel. Muscle biopsies are obtained from the middle 
region of the thigh muscle under local anaesthesia. First, the skin as well as 
the sheet surrounding the muscle (fascia) will be frozen (anesthetized) using 
an injection of lidocaine. Second, a small incision in the skin and fascia 
(approximately 5 mm) will be made using a scalpel. Through the incision in the 
skin and fascia, a muscle biopsy needle will be inserted into your muscle. 
Using this biopsy needle, a small piece of muscle tissue (50-100 mg; about 
the size of a match head) will be cut off. The biopsy needle will then 
immediately be removed from your leg. The incision will be stitched or glued 
and wrapped with a tensor bandage. 
POTENTIAL HARMS, RISKS, AND DISCOMFORTS 
DXA scan 
The radiation dose from one DXA scan is approximately 10 microsievert (μSv), 
which is about the amount of radiation an average person receives every 24 
hours from natural radiation in our environment (i.e. from the sun, television 
and computer screens, etc.). This procedure is painless and non-invasive. 
Heavy water 
Heavy water contains deuterium, which is a hydrogen isotope, yet non-
radioactive and is in fact already present in small amounts in the water we 
drink daily (i.e., 0.01%). In very large amounts, deuterium-labelled water can 
have adverse effects. A very high dose (more than 40 cups consumed in a 
very short time period for a person weighing about 150 pounds) may cause a 
toxic response. In this study you will receive 60 times less than this amount. 
In previous research studies using heavy water, very few people who drank 
deuterium-labelled water reported temporary dizziness or vertigo. There is a 
3.3% chance of encountering these side effects and only upon the first- or 
second-time heavy water is ingested. If it does occur, the side effects may last 
up to two hours and will go away on their own. If this occurs, we ask you that 
you rest quietly and refrain from driving or operating heavy machinery. About 
half the water in your body is replaced every week. Once you stop drinking 
heavy water, deuterium will return to its normal concentration in 20-30 days. 
Single leg immobilization 




One leg will be immobilized for 3.5 days using a knee brace. The knee brace 
will be placed in a fixed flexion position and sealed with a plastic strap. In case 
of emergency, you can break the 
  
seal and remove the knee brace. The knee brace may cause some itching or 
discomfort. There is also a potential risk of deep vein thrombosis (DVT; blood 
clot). A DVT occurs in 1.2 per 1,000 patients per year. The incidence increases 
with age: from 0.2 (15 to 24 years) to 6.5 (over 75 years) per 1,000 patients 
per year. Immobilization is a risk factor for DVT, but the exact increased risk 
is unknown. As women have a higher risk of DVT, we will include men only. 
Moreover, the incidence strongly increases above the age of 75 years. To limit 
the risk of DVT we will exclude individuals with a (family) history DVT or blood 
clotting disorders. Symptoms are not always apparent but may include 
swelling of the calf, ankle, foot, or thigh; increased warmth of the leg; pain in 
the leg; and red or bluish discoloration of the skin on the leg, foot, or toes. If 
you experience one of these symptoms, please contact the study investigators 
(Dr. Stefan Gorissen, Tanner Stokes, or Dr. Stuart Phillips) immediately. 
Muscle biopsy procedure 
The muscle biopsy technique is routinely used in research, and complications 
are rare provided that proper precautions are taken. During the time that the 
biopsy sample is being taken (approximately 5 sec), you may feel the 
sensation of deep pressure in your thigh and, on some occasions, this is 
moderately painful. However, the discomfort very quickly passes, and you are 
immediately capable of performing exercise and daily activities. You should 
not do strenuous exercise for the rest of the day. However, low-intensity 
exercise such as walking, or cycling may help to accelerate the healing 
process. Once the anaesthetic wears off, your leg may feel tight and often 
there is the sensation of a deep bruise or "Charlie Horse". Analgesics (pain 
killers) such as Acetaminophen (Tylenol) or Ibuprofen (Motrin) can be taken if 
you experience pain associated with the biopsy. It is also beneficial to 
periodically apply an ice pack to the biopsy site the following day, as this will 
help to reduce any swelling and any residual soreness. The following day your 
leg may feel uncomfortable when going downstairs. The tightness in the 
muscle usually disappears within 2 days and subjects routinely begin 
exercising at normal capacity within a day. 
There is a risk of internal bleeding at the site of the biopsy, which can result in 
bruising and temporary discoloration of the skin. On occasion a small lump 
may form under the site of the incision, but this normally disappears within 2-
3 weeks. As with any incision there is also a risk of infection. However, this 
risk is virtually eliminated through proper cleansing of the area and daily 
changing of wound coverings. In order to allow the incisions to heal properly 
and minimize any risk of infection, you should avoid prolonged submersion in 




water for 2-3 days. Daily showers are acceptable, but baths, swimming, 
saunas, etc. should be avoided for at least 4 days following the biopsy 
procedure. If the incision does not heal within a few days or you are in any way 
concerned about inflammation or infection (usually this means that the incision 
site is red, hot, swollen, and/or itchy), please clean the incision and contact us 
immediately. In very rare occasions, there can be damage to a superficial 
sensory nerve, which will result in temporary numbness in the area. There is 
also an extremely small chance that you will be allergic to the local anaesthetic 
(lidocaine); the real incidence of lidocaine allergy is unknown. 
In past experience with healthy young subjects, 1 in 2,200 have experienced 
a local skin infection; 1 in 500 have experienced a small lump at the site of the 
biopsy (in all cases this disappeared within approximately 2-3 weeks by 
rubbing the area); 1 in 1,500 have experienced a temporary loss of sensation 
in the skin at the site of incision (an area of numbness about the size of a 
quarter which lasted up to 3-4 months), and 1 in 30 have experienced bruising 
around the site of incision which lasted for approximately 4-5 days. To the best 
of our knowledge, older subjects who have undergone the muscle biopsy 
procedure have reported no adverse reactions. While there is also a 
theoretical risk of damage to a small motor nerve branch (these allow your 
muscle to move) of the medial vastus lateralis muscle, this has never been 
seen in over 9,500 biopsies performed by the investigators at McMaster 
University and the risk of damaging a small motor nerve branch is considered 
small. 
Venous blood sampling 
A soft plastic catheter will be inserted into a forearm vein by a physician or a 
medically trained and certified member of the laboratory group, and a blood 
sample will be drawn (~5 mL or 1 teaspoons). The discomfort of this procedure 
is transient and is very similar to having an injection by a needle, e.g., when 
donating blood. Upon removal of the needle or catheter any discomfort should 
subside. During the course of the experiment, four separate catheters will be 
inserted into your arm (2 on each occasion). In this experiment the total blood 
taken is ~250 mL, which is half of the blood removed during a donation to a 
blood bank. This amount of blood loss is not enough to affect your physical 
performance in any way. After each blood sample has been taken pressure 
will be placed on the site in order to minimize bleeding and facilitate healing. 
The insertion of a needle or catheter for blood sampling is a common medical 
practice and involves few risks if proper precautions are taken. The needles 
are inserted under completely sterile conditions; however, there is a theoretical 
risk of infection. There is a chance of internal bleeding if adequate pressure is 
not maintained upon removal of the needle. This may cause some minor 
discomfort and could result in bruising/skin discoloration, which could last up 
to a few weeks. In very rare occasions, trauma to the vessel wall could result 




in the formation of a small blood clot, which could travel through the 
bloodstream and become lodged in a smaller vessel. However, we have never 
experienced such a complication after several thousand blood draws. 
RESEARCH RELATED INJURY 
If you are injured as a direct result of taking part in this study, all necessary 
medical treatment will be made available to you at no cost. Financial 
compensation for such things as lost wages, disability or discomfort due to this 
type of injury is not routinely available. However, if you sign this consent form 
it does not mean that you waive any legal rights you may have under the law, 
nor does it mean that you are releasing the investigator(s), institution(s), and/or 
sponsor(s) from their legal and professional responsibilities. 
POTENTIAL BENEFITS 
There are no direct benefits for you to participate in this study. However, the 
findings of this study may contribute to the development of nutritional 
interventions that prevent or attenuate the loss of skeletal muscle mass with 
disuse, aging, or in various clinical settings. Moreover, you will receive 
information about your own health as we perform a DXA scan. 
PAYMENT OR REMUNERATION 
If you participate in this study, you realize that there are no direct benefits to 
you. You will receive an honorarium of $400 upon the completion of the study 
to compensate you for your time commitment. Should you wish/be required to 
withdraw from the study at any point, we will reimburse you on a pro rata basis 
for the time you have spent on the study (i.e., half of the study completed = 
$200). 
PLEASE NOTE: Remuneration will be in the form of a cheque issued by 
McMaster University. The cheque for the full amount will be mailed to you at 
the completion of the study. While we will attempt to have the remuneration 
forwarded to you as soon as possible, it may take at least four weeks following 
the completion of the study for the cheque to be processed and the 
remuneration received. 
In addition to the remuneration, we will also cover your on-campus parking 
during the experimental phases. 
CONFIDENTIALITY 
Muscle biopsies will be stored for up to 15 years after completion of the study 
for analyses. All data collected during this study will remain confidential and 
stored in offices and on computers to which only the investigators have 
access. Any identifying information will be coded, with corresponding code-




identifiers to be kept stored in a locked filing cabinet under the supervision of 
Professor Stuart Phillips, Dr. Stefan Gorissen, and Tanner Stokes. Information 
kept on a computer will be protected by a password. All data will be stored in 
the locked filing cabinet under the supervision of Professor Stuart Phillips. 
Professor Phillips, Dr. Gorissen, and Tanner Stokes will have access to the 
data and will supervise access to other researchers within the group. 
Information about you will not be released to any other person for any reason. 
If the results of the study are published, your identity will remain confidential. 
The data for this research study will be retained for 15 years. 
For the purposes of ensuring the proper monitoring of the research study, it is 
possible that a member of the Hamilton Integrated Research Ethics Board 
(HiREB) may consult your research data. However, no records which identify 
you by name or initials will be allowed to leave the university/hospital. By 
signing this consent form you authorize such access. 
You should be aware that the results of this study will be made available to the 
scientific community through publication in a scientific journal, although neither 
your name nor any reference to you will be used in compiling or publishing 
these results. Upon completion of the study, we are able to provide a 
personalized report of our findings at your request, as well as direct you 
towards all publications resulting from this study. 
PARTICIPATION AND WITHDRAWAL 
At any time, you can choose whether to participate in this study or not. You 
may remove yourself or your data from the study at any time if you wish. You 
may also refuse to answer any questions posed to you during the study and 
still remain a subject in the study. The investigators reserve the right to 
withdraw you from the study if they believe that circumstances have arisen 
that warrant doing so. 
You will receive a completed (i.e., signed) copy of this ethics form. You may 
withdraw your consent to participate in this study at any time, and you may 
also discontinue participation at any time without penalty. In signing this 
consent form or in participating in this study you are not waiving any legal 
claims or remedies. 
QUESTIONS ABOUT THE STUDY 
For any questions related to this study, please contact Tanner Stokes at 289-
680-1900 or Dr. Stefan Gorissen at 905-730-5894. You can also contact them 
if you have concerns about your health or any of the procedures occurring 
during the study. 
In the event of an emergency please contact Professor Stuart Phillips at 905-
525-9140 ext. 24465 (office), Dr. Stefan Gorissen at 905-730-5894, or Tanner 




Stokes at 289-680-1900. As with any medical emergency, you should proceed 
to the urgent care/emergency department of the closest hospital if an 
emergency should arise during the course of the study. 
This study has been reviewed by the Hamilton Integrated Research Ethics 
Board (HiREB). The HiREB is responsible for ensuring that participants are 
informed of the risks associated with the research, and that participants are 
free to decide if participation is right for them. If you have any questions about 
your rights as a research participant, please call the HIREB office at 905- 521-
2100 ext. 42013. 
CONSENT STATEMENT 
Signature of research participant 
I have read the preceding information thoroughly. I have had the opportunity 
to ask questions, and all of my questions have been answered to my 
satisfaction. I agree to participate in this study. I understand that I will receive 
a signed copy of this form. 
Name of Participant…………………………………………………………………. 
Signature of Participant………………… Date (mm/dd/yyyy)………………….. 
Consent form administered and explained in person by:………………………. 
Name and title……………………………………………………………………….. 
Signature…………………………………. Date (mm/dd/yyyy)………………….. 
Signature of investigator……………………………………………………………. 
In my judgment, the participant is voluntarily and knowingly giving informed 
consent and possesses the legal capacity to give informed consent to 
participate in this study. 
Signature of Investigator…………………….. Date (mm/dd/yyyy)………….. 
  




8.2 Appendix 2 
Healthy Older Volunteer’s Information Sheet 
Clinical, Metabolic and Molecular Physiology Research Group 
 
Title of Project: The regulation of skeletal muscle protein synthesis by 
systemic hormones and its influence on ageing and anabolic resistance 
Names of Investigators: 
Dr Daniel Wilkinson  Dr Iskandar Idris, 
Dr Phil Atherton  Dr Haitham Abdullah, 
Dr Ken Smith   Dr Supreeth Rudrappa 
Dr Bethan Phillips 
  
You have been invited to take part in a research study. Before you decide whether to 
take part it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with friends and relatives if you wish to. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. If you decide to take part, you will be given a copy of your 




Muscles represent the largest organ in the body, making up over 50% of total body 
weight. Most people know that skeletal muscles are important for movement and to 
support the skeleton, but not everyone is aware of how important muscles are for 
whole-body health. For example, muscles represent a vast protein store containing 
amino acids (the building blocks of protein) which can be broken down in times of 
fasting, infection and disease in order to provide energy to help other vital organs. 
Hormones can play an important role in the regulation of muscle mass throughout 
adult life, with reductions in hormones levels due to illness or disease leading to a 
reduction in muscle mass and strength. It however still remains unclear how these 




hormones regulate these changes in muscle mass. This knowledge could be key in 
developing future pharmaceuticals for treatment of muscle wasting disease. Further 
to this, most people will have noticed that with age people become frail. This is 
principally due to the wasting of skeletal muscle known as “sarcopenia”. Crucially, 
sarcopenia is more than just a symptom of weakness and poor functional capacity; it 
exposes people to an increased risk of falls and fractures, impacting quality of life, 
independence, health status and ultimately lifespan. It is because of these detrimental 
effects on health, and the associated health costs that sarcopenia is of grave concern. 
Interestingly, with ageing there is also an associated reduction in hormone levels and 
a lower stimulation of hormonal release in response to things like exercise. This 
association leads to the possibility that reductions in hormone levels with age could 
contribute to the frailty and sarcopenia associated with normal ageing, and therefore 
there is a significant clinical need to identify whether this is a significant contributing 
factor to this muscle loss so that it can be specifically targeted for intervention (i.e., 
hormonal therapies).   
What does the study involve? 
 
Screening Visit 
Before you formally enter the study, you will be asked to attend our facility (the 
Medical School, Royal Derby Hospital), without having eaten anything (from 2000h 
the night before), a screening visit to ensure that you are eligible for participation in 
this study. During this visit (approximately 60 minutes), we will explain the study in full 
and answer any questions you may have, then (i) ask you to sign a consent form for 
the study, (ii) take a blood sample (10-20ml), and (iii) conduct a health assessment - 
including measuring your height and weight and a trace of your heart’s electrical 




Once we have received the results of your blood tests from screening, we will contact 
you to inform you of your results and confirm your inclusion into the study.  If you are 
happy to proceed with the study, we will organise a mutually convenient day on which 
you will attend our facility to begin the study. The study period will last a total of 8 
weeks in duration, and over this period you will be asked to attend our exercise suite 
3 times a week for supervised exercise training and for collection of samples.   
On the initial lab visit a DXA scan and ultrasound will be performed to measure your 
body composition, your leg muscle mass and muscle architecture (fibre length and 
thickness). The ultrasound is similar to the scan carried out to image babies during 
pregnancy and involves some jelly and a probe being placed on your thigh. A leaflet 
describing the DXA scan in more detail is attached. In brief, this is a whole-body low 




dose X-ray scan that provides us with information about the tissue under your skin. 
The radiation exposure from this scan is very low, equivalent to ~3 days background 
exposure and significantly less than a flight to America. A test called an oral glucose 
tolerance test (OGTT) will also be performed. This test assesses your body’s 
response to a single glucose drink and is commonly used by GPs to assess a person’s 
health. This test involves a small 75g glucose drink followed by regular 15 min blood 
samples over the following two hours, this sampling will be performed via the 
placement of a small tube in a vein in your arm (the OGTT will be repeated again at 
the start and end of the exercise training period). Following this your strength will be 
assessed and you will be familiarised with the exercise protocol to be performed 
during the study period. Your 1 repetition maximum (1-RM) will then be determined 
for six muscles (this is the highest amount of weight you can lift once with one leg) so 
we can determine your workload during the exercise training. Following completion 
of the exercise test a muscle biopsy will be collected from the vastus lateralis muscle 
(i.e., a region in the front of the thigh muscle) after an injection of local anaesthetic to 
numb the area. After the local anaesthetic a trained clinician will make a small (0.5 
cm) cut through the skin and underlying muscle sheath then take the biopsy (a small 
piece about the size of an orange pip) with a special set of forceps. With the local 
anaesthetic you may feel pushing during this procedure but no pain. A stitch is placed 
in the skin afterwards to aid healing. A tight bandage will be placed around the thigh 
after the biopsy and should remain in place for ~12h to speed healing. You will then 
provide a saliva sample and be provided with a drink of ‘heavy water’ (~250 ml) to 
consume.  This water contains a stable isotope tracer (deuterium in place of 
hydrogen, but is not radioactive), which is slightly different from normal water, but it 
is perfectly safe. We will ask you to provide a small sample of saliva 3-4 hours later, 
(which you can store refrigerated in sealed tubes we will provide). We will also ask 
you to collect samples of saliva daily around midday and at least an hour after food 
or drink for the first week. You will be provided with a small volume (~10 ml) of 
additional heavy water to consume daily for the remainder of the study period. This 
tracer is what allows us to measure rates of muscle growth and metabolism. In 
addition to the heavy water, we will provide you with a small drink of labelled creatine 
and 3-methylhistidine tracers (as with the heavy water, these are not radioactive and 
are perfectly safe, both creatine and 3-methylhistidine occur naturally in your 
muscles), we will then ask you to collect urine samples over the next 72h, before 
returning at 72h for a series of small blood samples. These samples will provide us 
with a measure of your muscle weight and how quickly your muscle is breaking down 
and will be repeated at 3 and 6 weeks into the exercise period to assess for any 
changes related to the testing. 
You will then be randomly assigned to one of two testing groups, either: 1) a placebo 
group, or 2) a testosterone supplemented group (Sustanon 250: 250mg intramuscular 
injection every 2-3wks). The testosterone intervention is aimed at increasing levels of 
testosterone in your blood, which are known to be lower in ageing populations and 
are anticipated to contribute to reduced muscle mass with ageing and in response to 
exercise training.  
Following an initial lead in period of one week, where you will perform no exercise, 
you will return to the lab 3 x week for 6-weeks for a whole body progressive 
supervised resistance exercise training programme. You will be asked to perform 3 
sets of 10 repetitions of both upper and lower body exercises at a weight equivalent 




to 80% of your 1-RM. At the start of the exercise period (designated week 0 on the 
attached diagram), and every 1.5 weeks up to the end of the exercise period (at 1.5, 
3, 4.5 and 6 weeks as highlighted in the diagram, you will be asked to return to the 
lab for muscle biopsies. As well as using the biopsies to assess changes in 
metabolism due to the interventions, biopsies will also be used for cell-culture work 
to explore important mechanisms regulating the numerous roles of muscle. 
 
During the intervention period, you will also have repeat ultrasound measurements, 
muscle function and strength tests every 1.5 weeks. An additional small patellar 
tendon biopsy will also be obtained at 6 weeks – this is the tendon that attaches the 
bottom of your kneecap (patellar) to the top of your shinbone (tibia). This biopsy will 
be taken using a microneedle technique, guided by ultrasound. This procedure has 
been conducted regularly within our labs without any reports of discomfort (average 
discomfort reported during and following the procedure was 2 out of 10; with 1 being 
no discomfort and 10 being maximal discomfort). Prior to each muscle biopsy an 
ultrasound scan of the muscle will be performed (with a repeat DXA scan) to monitor 
any changes in muscle structure due to the training regime. Following the training 
regime the intervention will be stopped and you will be monitored for one additional 
week to ensure hormonal levels have returned to normal. Following this a final muscle 
biopsy will be obtained. A diagram of the study protocol is provided below.  
 



















Primarily because you have expressed an interest in taking part in the study 
and you have met with the entry criteria and do not have on-going medical 




Do you have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part, you are still free to withdraw at any time and without giving a 
reason. 
 
What do I have to do? 
 
You are requested to fast on the night before and avoiding heavy exercise for 48h 
prior to your visits to the laboratory. We will provide you with a recommended dietary 
intake for the study period that we would like you to adhere to where possible. This 
will follow a standard balanced diet according to current recommended daily 
allowances for carbohydrates, fats and proteins, and will help us to limit the impact of 
dietary intake upon the outcomes of study. 
  
What is the drug or procedure that is being tested? 
 
One group of individuals will receive slow-release testosterone (the other a placebo), 
which provides increases in testosterone levels, it is safe to use in healthy humans 
and similar testosterone products have been previously used in studies within our 
research group and is regularly used as a treatment in humans. Testosterone (or 
placebo) will be administered via intramuscular injection every 2-3wks. You will be 
provided with all necessary information regarding this compound and any potential 
side effects (see below) and will be continually monitored by our researchers. 
 




What are the side effects of any treatment or procedures received when taking 
part? 
 
Research studies often involve some risks, not all of which may be currently known. 
In the light of our experience, muscle and tendon biopsies are well tolerated by all our 
volunteers. Scarring is hardly perceptible and fades with time. However, the 
procedure may cause mild pain in some volunteers, but with appropriate local 
analgesia this is minimal; indeed data from a previous audit of the procedure 
demonstrated that 83% of our participants experienced less than or the expected 
discomfort during the muscle biopsy and all respondents said that they would or may 
be willing to participate in a similar study in the future. Some discomfort (muscle 
tenderness and stiffness) may be felt for 2-3 days afterwards but mild painkillers will 
usually effectively abolish this. There is a slight risk of infection at biopsy sites, 
however all procedures are performed under sterile conditions to minimize any risk of 
infection. Damage to small nerves of the skin during the biopsy is possible; however 
these nerves grow back with restoration of normal sensation, without difficulty.  
 
We will provide you with a short, anonymized questionnaire about your experience of 
the biopsy procedures during this study should you wish to respond.  
 
The risks involved in venous blood sampling are very small. Occasionally, however 
there may be bruising due to leakage from a blood vessel on withdrawal of the needle, 
but this is uncommon with good practice. The loss of 60 ml of blood has no ill effects 
in healthy persons and is much less than if you donate blood. 
 
As with any pharmacological intervention there may be some side effects associated 
with the administration of the Testosterone, however these are uncommon and are 
generally only associated with prolonged administration over periods longer than 
what is being performed in the current study. Those side effects which may be 
encountered are mild and include headache, increased hypertension, acne, 
increased blood count and skin irritation at the gel site (a full list of all potential side 
effects associated with testosterone are attached with this information sheet). If you 
are randomized into a testosterone (vs. placebo) group, you will be given the chance 
to discuss these with any of the clinicians if unsure. 
 
What are the exclusion criteria for this study? 
 




We are recruiting healthy men between the ages of 65 to 75 years, who are of normal 
weight or slightly overweight. If you have been a subject in any other research study 
in the last three months which involved: taking a drug, being paid a disturbance 
allowance or having an invasive procedure (e.g. blood sample >50ml) you would not 
be eligible to take part. 
 
You would also be unsuitable if you have particular medical conditions or are taking 
certain medications. If you are interested in this study, please discuss these further 
with the study doctor.  
 
What are the possible disadvantages and risks of taking part? 
 
Healthy volunteers have been chosen for this study; however, it is possible that the 
routine tests could detect unknown health problems. Should this be the case you will 
be informed and advised to attend your GP practice for further management. Your 
GP will be notified. Be advised, however, that future insurance status e.g. for life 
insurance or private medical insurance, could be affected by these diagnoses. 
 
What if something goes wrong? 
 
In the unlikely event of a complication following the study or that you should wish to 
voice grievances, in the first instance please contact the clinician involved in the 
execution of the study or the lead investigator, Dr Phil Atherton (T: 01332 724725; E: 
philip.atherton@nottingham.ac.uk). If you remain unhappy and wish to complain 
formally, you should then contact the FMHS Research Ethics Committee 
Administrator, c/o The University of Nottingham, School of Medicine Education 
Centre, B Floor, Medical School, Queen’s Medical Centre Campus, Nottingham 
University Hospitals, Nottingham, NG7 2UH.  E-mail:  louise.sabir@nottingham.ac.uk. 
 
Will my taking part in this study be kept confidential? 
We respect your right to privacy, and we will take measures to safeguard 
confidentiality. A single form, on which you are asked to sign to give consent for 
involvement will carry details of your name and address, but no health-related details. 
This is kept securely in a locked cabinet within the Medical School. Access to this 




cabinet is restricted to personnel directly involved in the study and to University staff 
with direct responsibility for ensuring the study is conducted appropriately.  
 
We will follow current ethical and legal practice and all information about you will be 
handled in confidence. If you join the study, some parts of the data collected about 
you will be looked at by authorised persons from the University of Nottingham who 
are organising the research. They may also be looked at by people authorised to 
check that the study is being carried out correctly. All will have a duty of confidentiality 
to you as a research participant and we will do our best to meet this duty.  
 
All information which is collected about you during the course of the research will be 
kept strictly confidential, stored in a secure and locked office, and on a password 
protected database. Any information about you that leaves the University will have 
your name and address removed (anonymised) and a unique code will be used so 
that you cannot be recognised from it, with the exception of a letter sent to your GP 
advising of your participation in this study. 
 
Your personal data (address, telephone number) will be kept for 5 years after the end 
of the study so that we are able to contact you about the findings of the study and 
possible follow-up studies. All other data (research data) will be kept securely for 7 
years. After this time your data will be disposed of securely. During this time all 
precautions will be taken by all those involved to maintain your confidentiality and 
only direct members of the research team will have access to your personal data. 
 
What will happen to any samples I give? 
We will use the tendon and biopsy samples to see how your muscle and tendons 
respond to exercise and/ or the effect of age or hormones. We may also use your 
muscle samples to generate cell-culture samples so that we can further investigate 
mechanisms involved in muscle health and disease outside of the human body. We 
will also seek your consent for any samples remaining after analysis for this study has 
been completed, to be stored and used in future research. This is optional and you 
will be asked to give separate consent for this. The samples will be securely stored 
with a code unique to you at the University of Nottingham under the Universities 
Human Tissue Research Licence (No. 12265). 
 
Some of these future studies may be carried out by researchers other than the current 
research team. This may include researchers working for commercial companies. 
Any samples or data used will be anonymised so that you could not be identified in 




any way. If you do not agree to this, any remaining samples will be disposed of in 
accordance with the Human Tissue Authorities code of practice. 
 
Will any genetic tests be done? 
In the current study we will collect a blood sample that can be used to obtain 
information about your genes (RNA and DNA), however this analysis will not give us 
information on disease prognosis and samples will not be subject to genetic 
manipulation.  
 
Who is funding the research? 
 
This research is funded by The University of Nottingham. 
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the University of Nottingham Medical 
School Ethics Committee.  
Contact for Further Information 
 
Thank you for taking part in the study. For further information you can contact Mr 
Nima Gharahdaghi on 01332 724685 or at mzxng@nottingham.ac.uk, or Dr Daniel 
Wilkinson (Research Fellow) on 01332 724850 or at d.wilkinson@nottingham.ac.uk, 
both are alternatively contactable at Clinical, Metabolic and Molecular Physiology, 
University of Nottingham, School of Medicine, Division of Graduate Entry Medicine 
and Health, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT. 
 
 
Testosterone Reported Adverse Reactions 




(taken from http://www.medicines.org.uk/emc/medicine/22159)  
 
Adverse Drug Reactions terminology used for the classification of incidence: Very 
common ≥10% - Common ≥1% to <10% - Uncommon ≥0.1% to <1% - Rare ≥0.01% 
to <0.1% - Very rare <0.01% - Not known (can not be estimated from the available 
data). 
The cumulative safety experience of testosterone is derived from Phase I to Phase III 
clinical trials and post-marketing experience. 
The adverse reactions listed in the table below have been observed in clinical studies 




Adverse Reaction Frequency 
Nervous disorders Headache Common 
Vascular disorders Hypertension worsened Common 







and breast disorders 




Application site reaction (including 
erythema, rash and pruritus) 
Common 
Peripheral oedema Uncommon 




Investigations PSA increased, haematocrit 
increased, haemoglobin increased, 
red blood cell count increased 
Common 
Uncommonly, gynaecomastia may develop and persist in patients being 
treated for hypogonadism with testosterone. 
  




8.3 Appendix 3 
Healthy Younger Volunteer’s Information Sheet 
Clinical, Metabolic and Molecular Physiology Research Group 
 
Title of Project: The regulation of skeletal muscle protein synthesis by 
systemic hormones and its influence on ageing and anabolic resistance 
Names of Investigators: 
Dr Daniel Wilkinson  Dr Iskandar Idris, 
Dr Phil Atherton  Dr Haitham Abdullah, 
Dr Ken Smith   Dr Supreeth Rudrappa 
Dr Bethan Phillips 
  
You have been invited to take part in a research study. Before you decide whether to 
take part it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with friends and relatives if you wish to. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. If you decide to take part, you will be given a copy of your 
consent form and this leaflet. 
Background 
 
Muscles represent the largest organ in the body, making up over 50% of total body 
weight. Most people know that skeletal muscles are important for movement and to 
support the skeleton, but not everyone is aware of how important muscles are for 
whole-body health. For example, muscles represent a vast protein store containing 
amino acids (the building blocks of protein) which can be broken down in times of 
fasting, infection and disease in order to provide energy to help other vital organs. 
Hormones can play an important role in the regulation of muscle mass throughout 
adult life, with reductions in hormones levels due to illness or disease leading to a 
reduction in muscle mass and strength. It however still remains unclear how these 
hormones regulate these changes in muscle mass. This knowledge could be key in 
developing future pharmaceuticals for treatment of muscle wasting disease. Further 




to this, most people will have noticed that with age people become frail. This is 
principally due to the wasting of skeletal muscle known as “sarcopenia”. Crucially, 
sarcopenia is more than just a symptom of weakness and poor functional capacity; it 
exposes people to an increased risk of falls and fractures, impacting quality of life, 
independence, health status and ultimately lifespan. It is because of these detrimental 
effects on health, and the associated health costs that sarcopenia is of grave concern. 
Interestingly, with ageing there is also an associated reduction in hormone levels and 
a lower stimulation of hormonal release in response to things like exercise. This 
association leads to the possibility that reductions in hormone levels with age could 
contribute to the frailty and sarcopenia associated with normal ageing, and therefore 
there is a significant clinical need to identify whether this is a significant contributing 
factor to this muscle loss so that it can be specifically targeted for intervention (i.e., 
hormonal therapies).   
What does the study involve? 
Screening Visit 
 
Before you formally enter the study, you will be asked to attend our facility (the 
Medical School, Royal Derby Hospital), without having eaten anything (from 2000h 
the night before), a screening visit to ensure that you are eligible for participation in 
this study. During this visit (approximately 60 minutes), we will explain the study in full 
and answer any questions you may have, then (i) ask you to sign a consent form for 
the study, (ii) take a blood sample (10-20ml), and (iii) conduct a health assessment - 
including measuring your height and weight and a trace of your heart’s electrical 
activity (an ECG). 
Main Study 
 
Once we have received the results of your blood tests from screening, we will contact 
you to inform you of your results and confirm your inclusion into the study.  If you are 
happy to proceed with the study, we will organise a mutually convenient day on which 
you will attend our facility to begin the study. The study period will last a total of 8 
weeks in duration, and over this period you will be asked to attend our exercise suite 
3 times a week for supervised exercise training and for collection of samples.   
On the initial lab visit a DXA scan and ultrasound will be performed to measure your 
body composition, your leg muscle mass and muscle architecture (fibre length and 
thickness). The ultrasound is similar to the scan carried out to image babies during 
pregnancy and involves some jelly and a probe being placed on your thigh. A leaflet 
describing the DXA scan in more detail is attached. In brief, this is a whole-body low 
dose X-ray scan that provides us with information about the tissue under your skin. 
The radiation exposure from this scan is very low, equivalent to ~3 days background 
exposure and significantly less than a flight to America. A test called an oral glucose 




tolerance test (OGTT) will also be performed. This test assesses your body’s 
response to a single glucose drink and is commonly used by GPs to assess a person’s 
health. This test involves a small 75g glucose drink followed by regular 15 min blood 
samples over the following two hours, this sampling will be performed via the 
placement of a small tube in a vein in your arm (the OGTT will be repeated again at 
the start and end of the exercise training period). Following this, your strength will be 
assessed, and you will be familiarised with the exercise protocol to be performed 
during the study period. Your 1 repetition maximum (1-RM) will then be determined 
for six muscles (this is the highest amount of weight you can lift once) so we can 
determine your workload during the exercise training. Following completion of the 
exercise test a muscle biopsy will be collected from the vastus lateralis muscle (i.e., 
a region in the front of the thigh muscle) after an injection of local anaesthetic to numb 
the area. After the local anaesthetic a trained clinician will make a small (0.5 cm) cut 
through the skin and underlying muscle sheath then take the biopsy (a small piece 
about the size of an orange pip) with a special set of forceps. With the local 
anaesthetic you may feel pushing during this procedure but no pain. A stitch is placed 
in the skin afterwards to aid healing. A tight bandage will be placed around the thigh 
after the biopsy and should remain in place for ~12h to speed healing.  You will then 
provide a saliva sample and be provided with a drink of ‘heavy water’ (~250 ml) to 
consume.  This water contains a stable isotope tracer (deuterium in place of 
hydrogen, but is not radioactive), which is slightly different from normal water, but it 
is perfectly safe. We will ask you to provide a small sample of saliva 3-4 hours later, 
(which you can store refrigerated in sealed tubes we will provide). We will also ask 
you to collect samples of saliva daily around midday and at least an hour after food 
or drink for the first week. You will be provided with a small volume (~10 ml) of 
additional heavy water to consume daily for the remainder of the study period. This 
tracer is what allows us to measure rates of muscle growth and metabolism. In 
addition to the heavy water, we will provide you with a small drink of labelled creatine 
and 3-methylhistidine tracers (as with the heavy water, these are not radioactive and 
are perfectly safe, both creatine and 3-methylhistidine occur naturally in your 
muscles), we will then ask you to collect urine samples over the next 72h, before 
returning at 72h for a series of small blood samples. These samples will provide us 
with a measure of your muscle weight and how quickly your muscle is breaking down 
and will be repeated at 3 and 6 weeks into the exercise period to assess for any 
changes related to the testing. 
You will then be assigned to one of two testing groups, either: 1) a placebo group or 
2) a testosterone lowering group (Zoladex: 3.6mg/4weeks). Each of these 
interventions will be provided via an injection just under your skin. The testosterone 
lowering intervention is aimed at determining the influence of testosterone levels in 
your blood on muscle mass gains due to exercise training.  
Following an initial lead in period of one week, where you will perform no exercise, 
you will return to the lab 3 x wk for 6-weeks for a whole body progressive supervised 
resistance exercise training programme. You will be asked to perform 4 sets of 8 
repetitions of both upper and lower body exercises at a weight equivalent to 80% of 
your 1-RM. At the start of the exercise period (designated week 0 on the attached 
diagram), and every 1.5 weeks up to the end of the exercise period (at 1.5, 3, 4.5 and 
6 weeks as highlighted in the diagram), you will be asked to return to the lab for 
additional muscle biopsies. As well as using the biopsies to assess changes in 




metabolism due to the interventions, biopsies will also be used for cell-culture work 
to explore important mechanisms regulating the numerous roles of muscle. 
 
During the intervention period, you will also have repeat ultrasound measurements, 
muscle function and strength tests every 1.5 weeks. An additional small patellar 
tendon biopsy will also be obtained at 6 weeks – this is the tendon that attaches the 
bottom of your kneecap (patellar) to the top of your shinbone (tibia). This biopsy will 
be taken using a microneedle technique, guided by ultrasound. This procedure has 
been conducted regularly within our labs without any reports of discomfort (average 
discomfort reported during and following the procedure was 2 out of 10; with 1 being 
no discomfort and 10 being maximal discomfort). Prior to each muscle biopsy an 
ultrasound scan of the muscle will be performed (with a repeat DXA scan) to monitor 
any changes in muscle structure due to the training regime. Following the training 
regime the intervention will be stopped and you will be monitored for one additional 
week to ensure hormonal levels have returned to normal. Following this a final muscle 
biopsy will be obtained. A diagram of the study protocol is provided below.  
Why have you been chosen? 
 
Primarily because you have expressed an interest in taking part in the study and you 
have met with the entry criteria and do not have on-going medical problems. We will 
be recruiting healthy, recreationally active males aged 18-30y. 



















It is up to you to decide whether or not to take part. If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part, you are still free to withdraw at any time and without giving a 
reason. 
What do I have to do? 
 
You are requested to fast on the night before and avoiding heavy exercise for 48h 
prior to your visits to the laboratory. We will provide you with a recommended dietary 
intake for the study period that we would like you to adhere to where possible. This 
will follow a standard balanced diet according to current recommended daily 
allowances for carbohydrates, fats and proteins, and will help us to limit the impact of 
dietary intake upon the outcomes of study. 
What is the drug or procedure that is being tested? 
 
One group of individuals will receive a drug named Zoladex, a gonadotropin releasing 
hormone analogue. This is a licensed drug that reduces the production of 
testosterone within the body. It is safe to use in healthy humans and has been 
previously used in a number of similar studies to assess testosterone metabolism in 
humans. This will be administered by a small injection into soft tissue of the abdomen 
every 4 weeks. You will be provided with all necessary information regarding this drug 
and any potential side effects (see below) and will be continually monitored by our 
researchers.  
What are the side effects of any treatment or procedures received when taking 
part? 
 
Research studies often involve some risks, not all of which may be currently known. 
In the light of our experience, muscle and tendon biopsies are well tolerated by all our 
volunteers. Scarring is hardly perceptible and fades with time. However, the 
procedure may cause mild pain in some volunteers, but with appropriate local 
analgesia this is minimal; indeed data from a previous audit of the procedure 
demonstrated that 83% of our participants experienced less than or the expected 
discomfort during the muscle biopsy and all respondents said that they would or may 
be willing to participate in a similar study in the future. Some discomfort (muscle 
tenderness and stiffness) may be felt for 2-3 days afterwards but mild painkillers will 
usually effectively abolish this. There is a slight risk of infection at biopsy sites, 
however all procedures are performed under sterile conditions to minimize any risk of 
infection. Damage to small nerves of the skin during the biopsy is possible; however, 
these nerves grow back with restoration of normal sensation, without difficulty.  





We will provide you with a short, anonymized questionnaire about your experience of 
the biopsy procedures during this study should you wish to respond.  
 
The risks involved in venous blood sampling are very small. Occasionally, however 
there may be bruising due to leakage from a blood vessel on withdrawal of the needle, 
but this is uncommon with good practice. The loss of 60 ml of blood has no ill effects 
in healthy persons and is much less than if you donate blood. 
 
As with any pharmacological intervention there may be some side effects associated 
with Zoladex administration, however these are uncommon and are generally only 
associated with prolonged administration over periods longer than what is being 
performed in the current study. Those side effects which may be encountered over 
the proposed study period are generally mild and include Acne, hot flushes, erectile 
dysfunction, altered blood sugar, mood changes and irritation at injection site (a full 
list of all potential side effects associated with testosterone are attached with this 
information sheet). If you are randomized into a Zoladex (vs. placebo) group, you will 
be given the chance to discuss these with any of the clinicians if unsure. 
What are the exclusion criteria for this study? 
 
We are recruiting healthy men between the ages of 18 to 30 years, who are of normal 
weight or slightly overweight. If you have been a subject in any other research study 
in the last three months which involved: taking a drug, being paid a disturbance 
allowance or having an invasive procedure (e.g., blood sample >50ml) you would not 
be eligible to take part. 
 
You would also be unsuitable if you have particular medical conditions or are taking 
certain medications. If you are interested in this study, please discuss these further 
with the study doctor.  
What are the possible disadvantages and risks of taking part? 
 
Healthy volunteers have been chosen for this study; however, it is possible that the 
routine tests could detect unknown health problems. Should this be the case you will 
be informed and advised to attend your GP practice for further management. Your 
GP will be notified. Be advised, however, that future insurance status e.g., for life 
insurance or private medical insurance, could be affected by these diagnoses. 




What if something goes wrong? 
 
In the unlikely event of a complication following the study or that you should wish to 
voice grievances, in the first instance please contact the clinician involved in the 
execution of the study or the lead investigator, Dr Phil Atherton (T: 01332 724725; E: 
philip.atherton@nottingham.ac.uk). If you remain unhappy and wish to complain 
formally, you should then contact the FMHS Research Ethics Committee 
Administrator, c/o The University of Nottingham, School of Medicine Education 
Centre, B Floor, Medical School, Queen’s Medical Centre Campus, Nottingham 
University Hospitals, Nottingham, NG7 2UH.  E-mail:  louise.sabir@nottingham.ac.uk. 
Will my taking part in this study be kept confidential? 
We respect your right to privacy, and we will take measures to safeguard 
confidentiality. A single form, on which you are asked to sign to give consent for 
involvement will carry details of your name and address, but no health-related details. 
This is kept securely in a locked cabinet within the Medical School. Access to this 
cabinet is restricted to personnel directly involved in the study and to University staff 
with direct responsibility for ensuring the study is conducted appropriately.  
 
We will follow current ethical and legal practice and all information about you will be 
handled in confidence. If you join the study, some parts of the data collected about 
you will be looked at by authorised persons from the University of Nottingham who 
are organising the research. They may also be looked at by people authorised to 
check that the study is being carried out correctly. All will have a duty of confidentiality 
to you as a research participant and we will do our best to meet this duty.  
 
All information which is collected about you during the course of the research will be 
kept strictly confidential, stored in a secure and locked office, and on a password 
protected database. Any information about you that leaves the University will have 
your name and address removed (anonymised) and a unique code will be used so 
that you cannot be recognised from it, with the exception of a letter sent to your GP 
advising of your participation in this study. 
 
Your personal data (address, telephone number) will be kept for 5 years after the end 
of the study so that we are able to contact you about the findings of the study and 
possible follow-up studies. All other data (research data) will be kept securely for 7 
years. After this time your data will be disposed of securely. During this time all 
precautions will be taken by all those involved to maintain your confidentiality and 
only direct members of the research team will have access to your personal data. 




What will happen to any samples I give? 
We will use the tendon and biopsy samples to see how your muscle and tendons 
respond to exercise and/ or the effect of age or hormones. We may also use your 
muscle samples to generate cell-culture samples so that we can further investigate 
mechanisms involved in muscle health and disease outside of the human body. We 
will also seek your consent for any samples remaining after analysis for this study has 
been completed, to be stored and used in future research. This is optional and you 
will be asked to give separate consent for this. The samples will be securely stored 
with a code unique to you at the University of Nottingham under the Universities 
Human Tissue Research Licence (No. 12265). 
 
Some of these future studies may be carried out by researchers other than the current 
research team. This may include researchers working for commercial companies. 
Any samples or data used will be anonymised so that you could not be identified in 
any way. If you do not agree to this, any remaining samples will be disposed of in 
accordance with the Human Tissue Authorities code of practice. 
Will any genetic tests be done? 
In the current study we will collect a blood sample that can be used to obtain 
information about your genes (RNA and DNA), however this analysis will not give us 
information on disease prognosis and samples will not be subject to genetic 
manipulation. 
Who is funding the research? 
 
This research is funded by The University of Nottingham. 
Who has reviewed the study? 
 
This study has been reviewed and approved by the University of Nottingham Medical 
School Ethics Committee.  
Contact for Further Information 
 
Thank you for taking part in the study. For further information you can contact Mr 
Nima Gharahdaghi on 01332 724685 or at mzxng@nottingham.ac.uk, or Dr Daniel 
Wilkinson (Research Fellow) on 01332 724850 or at d.wilkinson@nottingham.ac.uk, 
both are alternatively contactable at Clinical, Metabolic and Molecular Physiology, 




University of Nottingham, School of Medicine, Division of Graduate Entry Medicine 
and Health, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT. 
 
Zoladex reported Undesirable effects (taken from 
http://www.medicines.org.uk/emc/document.aspx?documentid=7855)  
 
Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), 
Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000) and Not known (cannot be 
estimated from the available data). – These are associated with chronic administration 
  




8.4 Appendix 4: 
Division of Medical Sciences and Graduate Entry 
Medicine 
School of Medicine 
 
Healthy Volunteers Information Sheet 
 
Study Title: Exploring time-efficient strategies to improve fitness for surgery in older 
adults 
 
Name of Investigators: 
Mr Philip Herrod       
Dr Beth Phillips  
Mr Jon Lund  
 
You have been invited to take part in a research study.  Before you decide whether 
to take part it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with friends and relatives if you wish to. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. If you decide to take part, you will be given a copy of your 
consent form and this leaflet. 
 
Background: 
One change associated with human aging is a reduction in “fitness”, both in terms 
of how far or quickly a person can run/cycle/swim and also in how well their blood 
vessels work. Additionally, a person’s metabolic fitness decreases; this is how well 
the body copes with nutrition and is why, for example, older people have a higher 
risk of diseases like type 2 diabetes. Previous studies have shown that as people 




become less fit, they are at increased risk of suffering a complication whilst 
undergoing surgery. We also know that measuring how fit someone is, is better at 
predicting the risk of a surgical complication than purely using a person’s age alone. 
Lots of research has shown that exercise can potentially reverse some of the age-
related declines in fitness, however, most has used long sessions of continuous 
exercise over a long period of time. We have recently shown that high-intensity 
interval training (HIT), whereby people cycle on an exercise bike very hard for a 
minute, followed by a short rest, repeated over the course of 15 minutes can rapidly 
improve a person’s fitness. However not everyone will be able to, or indeed want 
to participate in exercise this strenuous; therefore, we would like to explore if other 
options, such as dietary supplements can improve aspects of fitness 
 
We intend to examine the effect of giving a dietary supplement on the way a 
person’s body handles the glucose (from carbohydrates/ sugars) in a meal. Previous 
work has shown that taking a beta-hydroxy beta-methyl butyrate (HMB) 
supplement may improve a patient’s response to glucose; however, the evidence is 
not clear. HMB is a commercially available nutritional supplement (sold in, for 
example Holland and Barrett) providing a compound that your body produces each 




We aim to recruit 8 younger (18-35) and 8 older (age 65-85) male volunteers to 
study the effect of 1 dose of HMB on the body’s response to a sugary drink over 3 
hours. Volunteers will be asked to return 1 week later to undergo the same 
procedure but with a placebo in place of HMB. The order in which the two tests are 
carried out will be at random, so you will not know on which day you have been 
given the placebo and which day you are given the HMB. 
 
Why have you been chosen? 
In order for this study to be successful, volunteers have been chosen who fit the entry 
criteria and do not have significant on-going medical problems. We are inviting 8 
younger participants and 8 older participants to take part. 
 
Do you have to take part? 




It is up to you to decide whether or not to take part.  If you do decide to take part, 
you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part, you are still free to withdraw at any time and without giving 
a reason. 
 
Would an inconvenience allowance be paid? 
No inconvenience allowances are available for this study. 
 
What does the study involve? 
The location for this study is The Medical School at the Royal Derby Hospital. The 
study consists of a screening visit (~1 hour) and 2 acute study visits (one week apart) 
each of which should last approximately 4 hours.  
 
Screening Visit  
Prior to being enrolled onto the study you will be asked to attend the Medical School 
at the Royal Derby Hospital for a screening visit to assess your suitability for the 
study, give you the opportunity to ask questions about the study and ask you to 
provide written consent for your participation in the study. This visit will last approx. 
60 min and we will ask you to arrive in the morning (~9am) fasted (free to drink 
water) from (~9pm) the night before. During this visit we will: 
 
i. take a small amount of blood to measure health parameters, including 
fasting glucose, liver and kidney function 
ii. measure your height and weight 
iii. conduct a health assessment, including an ECG to monitor your heart, a 
blood pressure check and conducts an assessment of previous medical 
history 
 
Study Day 1 




Once we have the received the results of your blood tests and on the premise that 
all of your results are within normal range, we will enrol you on to the study.  
 
On your first study day we will ask you to attend at ~9am, again fasted from ~9pm 
the night before. At the start of this visit we will take measures to estimate your body 
composition using a specialist set of scales that give us an estimate of your muscle 
and fat mass. You will then take part in an oral glucose tolerance test (OGTT). This 
test will give us information about how your body produces insulin and manages the 
sugar within your body. Firstly, a small cannula (a fine, flexible plastic tube) will be 
inserted into a vein in your hand or forearm to allow us to take blood samples. This 
cannula will then be connected to a drip of saline (sterile water) in order to keep it 
working. Your hand will be placed in a warm box and will remain here for the duration 
of the test. After an initial blood sample is taken from the cannula, you will then be 
asked to consume a sugary drink plus either the HMB or the placebo. Over the 
following 3 hours small samples of blood will be taken regularly (~every 15 minutes) 
from the cannula. In addition, before the drink and 3 points after (15 min, 60 min and 
120 min) the blood flow in a large vein at the top of your leg will be measured. This 
will be done using ultrasound. Similar to how babies are viewed during pregnancy 
cool ultrasound gel will be placed in your groin region and an ultrasound probe will 
be placed on the gel to measure blood flow. At the end of the test, we will provide 
you with a drink and light snack and monitor your blood sugar for a further 30 
minutes. 
 
Study Day 2 
We will ask you to attend the following week to undergo the same procedures as 
outlined above but with the alternate drink (HMB or placebo). 
 
What do I have to do? 
We are studying the effects of a single dose of a dietary supplement on the way your 
body processes a sugary drink. We are studying these aspects in healthy young and 
older adults, so we need volunteers who are eating and exercising as they would 
normally. We ask you to fast on the nights before your screening and study day visits, 
and we also request that you try and eat the same foods on the day before each 
study day visit.  With these exceptions please do not modify your usual diet or activity 
levels for this study. 
 




What is the drug or procedure that is being tested? 
The study is testing the effects of beta-hydroxy beta-methyl butyrate, a commercially 
available nutritional supplement on glucose handling in older adults. 
 
What are the side effects or risk of any treatment or procedures received when 
taking part? 
Research studies often involve some risks, not all of which may be currently known. 
Blood tests and the insertion of cannula can result in bruising around site, however 
with good practice this bruising should be minimal. Pressure will be applied to the 
cannula site at the end of each study day visit to minimise the risk of bruising. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you directly, but you will receive information 
on your blood test results and blood pressure check. In addition, the information we 
get from this study will give us a better understanding of the effects of HMB 
supplementation which may improve glucose handling in older people and 
potentially help improve a patient’s fitness to undergo surgery. Finally, if you would 
like a copy of any findings arising from this research please let a member of the 
research team know. 
 
What are the possible disadvantages and risks of taking part? 
Healthy volunteers have been chosen for this study; however, it is possible that the 
routine tests could detect unknown health problems. Examples of these include 
diabetes and high blood pressure, as they are common and often undiagnosed. 
Should this be the case, you will be informed and advised to attend your GP practice 
for further management. Your GP will also be notified. 
 
What are the exclusion criteria for this study? 
We are recruiting healthy volunteers between the ages of 18- 35 and 65 to 85 years, 
who are of normal weight or slightly overweight. If you have been a subject in any 
other research study in the last three months which involved: taking a drug; being 
paid a disturbance allowance or having an invasive procedure (e.g., blood sample 
>50ml) you would not be eligible to take part. 





You would also be unsuitable if you have particular medical conditions or are taking 
certain medications. If you are interested in this study, please discuss these further 
with the research team.  
 
What if something goes wrong? 
If you suffer any symptoms or side effects, you should report them immediately to 
the research team (see end of sheet for contact details). If you have a concern about 
any aspect of this study, you should ask to speak to the research team who will do 
their best to answer your questions.  The researchers contact details are given at the 
end of this information sheet. If you have a complaint on your treatment by a 
member of staff or anything to do with the study, you can initially approach the lead 
investigator Dr B Phillips. If this achieves no satisfactory outcome, you should then 
contact the Ethics Committee Secretary, Mrs Louise Sabir, University of Nottingham, 
Faculty of Medicine & Health Sciences Research Ethics Committee c/o School of 
Medicine Education Centre, B Floor, Medical School, QMC Campus, Nottingham 
University Hospitals, NG7 2UH. E-mail: louise.sabir@nottingham.ac.uk.  
 
Will my taking part in this study be kept confidential? 
We respect your right to privacy, and we will take measures to safeguard 
confidentiality. A single form, on which you are asked to sign to give consent for 
involvement will carry details of your name and address, but no health-related 
details. This is kept securely in a locked cabinet within the Medical School. Access to 
this cabinet is restricted to personnel directly involved in the study and to University 
staff with direct responsibility for ensuring the study is conducted appropriately.  
 
We will follow current ethical and legal practice and all information about you will be 
handled in confidence. If you join the study, some parts of the data collected about 
you will be looked at by authorised persons from the University of Nottingham who 
are organising the research. They may also be looked at by people authorised to 
check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant and we will do our best to meet this 
duty.  
 




All information which is collected about you during the course of the research will be 
kept strictly confidential, stored in a secure and locked office, and on a password 
protected database. Any information about you which leaves the hospital will have 
your name and address removed (anonymised) and a unique code will be used so 
that you cannot be recognised from it, with the exception of a letter sent to your GP 
advising of your participation in this study (if applicable). 
 
Your personal data (address, telephone number) will be kept for 5 years after the end 
of the study so that we are able to contact you about the findings of the study and 
possible follow-up studies. All other data (research data) will be kept securely for 7 
years.  After this time your data will be disposed of securely. During this time all 
precautions will be taken by all those involved to maintain your confidentiality and 
only direct members of the research team will have access to your personal data. 
 
What will happen to any samples I give? 
We would also like to seek your consent for any samples remaining after analysis for 
this study has been completed, to be stored and used in future research. This is 
optional and you will be asked to give separate consent for this. The samples will be 
securely stored with a code unique to you at the University of Nottingham under the 
Universities Human Tissue Research Licence (No. 12265). 
 
Some of these future studies may be carried out by researchers other than the 
current research team. This may include researchers working for commercial 
companies. Any samples or data used will be anonymised so that you could not be 
identified in any way. If you do not agree to this, any remaining samples will be 
disposed of in accordance with the Human Tissue Authorities code of practice. 
 
Will any genetic tests be done? 
In the current study we will not be using your samples for genetic testing. 
 
What will happen to the results of the research study? 
Data collected during the study will be published in the scientific literature enabling 
other health professionals and scientists to use the information. You will not be 




identified in any publication. There is usually a delay of at least one year from the 
study completion before this occurs. Should you wish to be informed of publications 
resulting from this study, please inform the study team. 
 
Who is funding the research? 
This study is funded by the Royal College of Surgeons of England and the Dunhill 
Medical Trust. 
 
Who has reviewed the study? 
This study has been reviewed and approved by the University of Nottingham Medical 
School Ethics Committee. 
 
Contact for Further Information 
Thank you for your interest in this study. For further information please contact Dr 
Phil Herrod on 01332 724731/ pherrod@nhs.net or the principal investigator, Dr 
Beth Phillips. Both of these researchers are alternatively contactable at The 
University of Nottingham, Division of Medical Sciences and Graduate Entry Medicine, 
School of Medicine, Royal Derby Hospital, Derby, DE22 3DT. 
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